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All men dream but not equally. Those who dream by night in the dusty recesses of their 
minds wake in the day to find that it was vanity; but the dreamers of the day are dangerous 
men, for they may act their dreams with open eyes, to make it possible. 
T. E. Lawrence, Seven Pillars of Wisdom, a Triumph 
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Abstract 
Cancer, which is characterized by uncontrolled cell division and proliferation, is the second 
leading cause of death in the United States. Of these deaths, approximately 30% are the result 
of mutations in Ras protein. When activated, Ras propagates multiple signal transduction 
cascades and induces cell proliferation, differentiation, and apoptosis. Within the Ras 
subfamily, there are several isoforms of Ras which differ in their posttranslational 
modifications. The modifications include proteolytic cleavage of the CAAX box, 
farnesylation, and palmitoylation which act as plasma membrane anchors where most signal 
transduction takes place. 
This dissertation demonstrates that Ras endocytosis takes place through a novel vesicular 
mechanism before being recycled. On the contrary, during exocytosis, Ras does not 
predominantly use the vesicular trafficking to reach the plasma membrane. Finally, work 
presented here will show the importance of the Ras hypervariable region and how this region 
directs membrane localization and trafficking. Together this body of work offers valuable 
insight into intracellular trafficking and provides a new direction toward developing more 
effective cancer therapies. 
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Chapter 1 
General Introduction 
The ultimate goal behind studying Ras signal transduction is to understand Ras-mediated 
biological activity. Ras is a molecular switch that causes cell proliferation, differentiation, 
and apoptosis. [1-4] Overexpression of activated Ras frequently causes cells to ignore contact 
inhibition and grow in small clusters called foci. Formation of foci often is an indicator of 
cells’ oncogenecity, the cells potential for becoming a type of cancer. [5-7] Mutations in Ras 
are very common among many types of cancers (~30% of all human cancers). More 
specifically, Ras mutations can be attributed to 90% of pancreatic, 35% of lung [8], and 60% 
of thyroid cancers. [9] Although not specifically named, many other types of cancers also 
have been linked to Ras mutations. [10] 
As a disease, cancer is the second most common cause of death in the U.S. The American 
Cancer Society estimates that approximately 1.4 million new cases of cancer were diagnosed 
in the U.S. in 2006 alone. [11] Currently, multiple treatments for cancers are available. Some 
of these treatments target Ras lipid modifications and vesicular trafficking from the Golgi to 
the plasma membrane. [12-14] Increasing our understanding about Ras intracellular 
trafficking and signal transduction cascades may well lead to the development of more 
effective cancer treatments with minimal side effects and, ultimately, the elimination of 
cancer. This goal, however, cannot be accomplished without understanding cancer at the 
molecular and cellular levels. At a molecular level, Ras can interact with multiple 
downstream signal transducers and transcription factors. A mutation in Ras that causes 
constant activation of the downstream effectors results in constitutive activation of Ras-
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mediated signal transduction cascades. These signal transduction cascades result in biological 
responses at the cellular level which attack cancer at the cellular level. [15, 16] 
Molecular responses 
Ras is a GTP binding protein. GTP binding proteins (GTPases) are members of a 
superfamily of proteins that can act as molecular switches. As their name indicates, the 
functions of GTPase proteins depend on an ability to exchange GDP (inactive) for GTP 
(active) and visa versa. The exchange between GTP and GDP often requires interaction with 
other proteins. For example, GDP Exchange Factor (GEF) is needed for GDP to GTP 
exchange and GAP (GTPase Activating Protein) proteins are needed for GTP hydrolysis to 
GDP. [17] 
Ras is perhaps one of the most extensively studied members of the G-protein family and 
belongs to the monomeric subcategory. Much like its family members, Ras operates also by 
GTP/GDP exchange. Ras is universally expressed in all eukaryotes and it shares 
approximately 40–50% sequence homology with other family members. [18] To date, four 
major isoforms of Ras have been identified: HRas, KRas A, KRas B, and NRas. These 
isoforms are highly conserved with one another (approximately 85%) and most of the 
isoform variations occur at the carboxy terminus. [19] 
In order for Ras to become fully functional, newly synthesized proteins must be 
posttranslationally modified with lipid moieties that later serve as membrane anchors. More 
specifically, the carboxy terminus of Ras is described as the CAAX box, where C represents 
cysteine, AA represents aliphatic amino acids, and X represents any amino acid. The 
posttranslational modification process begins when —AAX of the CAAX box is cleaved. 
Then a farnesyl group is added to the terminal cysteine (C) at the newly exposed carboxy 
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terminus. [20] In the case of KRas, this farnesyl group along with upstream poly-lysine 
residues are sufficient to anchor the protein to the cytoplasmic leaflet of the plasma 
membrane. For NRas and HRas, which lack upstream poly-lysine residues, upstream 
cysteines acquire additional palmitate groups—one and two groups respectively. [21] 
Once securely attached to the plasma membrane, activated Ras can produce multiple 
responses at both the molecular and cellular levels. [2, 22-24] On a molecular level, Ras is 
able to interact with multiple downstream effectors and activate signal transduction cascades. 
Some of the more commonly studied Ras downstream effectors are: c-RAF (Receptor 
Associated Factor), Phosphotidyl Inositol-3 Kinase (PI3K) [25], and JNK. [26] At a cellular 
level, examples of Ras-induced responses include proliferation, differentiation, and 
apoptosis. Expressions of Ras in different kinds of cells result in different biological 
responses. For instance, when Ras is activated in a mouse fibroblast (NIH 3T3), it causes cell 
proliferation and, if Ras activation is prolonged, the cells lose their ability to regulate their 
growth by contact inhibition. [27] In contrast, if Ras is activated in neuronal cells like PC-12 
(pheochromocytoma), cells begin to grow neurites and differentiate. [28] 
Cellular responses 
Contrary to the traditional school of thought, recent findings indicate that subcellular Ras 
localization is also important in Ras signal transduction cascades. [29] Ras isoforms are often 
retained in endomembranous structures such as the Golgi apparatus, Endoplasmic Reticulum 
[30], and even mitochondria. [31] Signal transduction cascades activated from these 
endomembranes seem to have longer lifespans than if they were activated at the plasma 
membrane [29, 32-34] More specifically, when KRas is activated from the mitochondria, it 
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stimulates apoptosis [31], whereas KRas activated at the plasma membrane results in cell 
proliferation and differentiation. [35] 
Because proper membrane recognition and binding are vital for Ras to interact with its 
downstream effectors, it is not hard to imagine that Ras trafficking also plays a crucial role in 
Ras-mediated signal transduction and subsequent cellular response. [36] Until recently, the 
common understanding has been that the primary mode for Ras trafficking—or at least HRas 
and NRas—is through vesicles. [37-41] Vesicular trafficking begins at the Endoplasmic 
Reticulum (ER). Vesicles begin to form in the ER by aggregation of Coat Protein Complex II 
(COP II) protein complexes [42-44], while COP II complexes are activated by another small 
GTPase, Sec-related, Ras-related protein 1 (Sar1). [45] COP II complex aggregations recruit 
cargo proteins and vesicles are released into the ER Golgi Intermediate Compartment 
(ERGIC). Once at the ERGIC, cargo proteins and vesicles move to the Golgi. Then from the 
Golgi, the vesicles containing Ras travel on microtubule tracks to reach the plasma 
membrane. [46] (Figure 1) Also at the Golgi, a small fraction of proteins retreat back to ER. 
The reverse trafficking from Golgi to ER is mediated by Coat Protein Complex I (COP I) 
protein complexes. [42, 47, 48] 
Once at the plasma membrane, Ras attaches to the cytoplasmic leaflet by HRas—lipid 
modifications—or by KRas—lipid modification and polylysine residues. [39] Membrane 
adhesion of Ras molecules is brief and dynamic. After activating its downstream partners, 
some Ras molecules are removed from the plasma membrane via endocytosis. [49] 
Generally, endocytosis implies an inward trafficking with aid of vesicles. To date, several 
different types of vesicles have been known to facilitate Ras endocytosis, but the vast 
majority of inward-bound Ras were thought to be located on the clathrin-coated vesicles. [50] 
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Recent discoveries [51, 52] suggest that it is possible for Ras to maintain its ability to signal 
and utilize non-clathrin vesicles to reach the Endosomal Recycling Center (ERC)—a final 
destination for endocytic vesicles. 
Thesis Organization 
This dissertation, which follows the three-article structure set out by the Iowa State 
University Graduate College, is organized into five chapters. This first chapter offers an 
overview of the basic premises of the Ras family of molecular and cellular mechanisms and 
provides an overview of each of the three articles submitted for publication resulting from 
research I conducted in Dr. Janice E. Buss’s laboratory at Iowa State University between 
2002 and 2007; my specific contributions to the research and the articles are also noted.  
A general literature review closes this chapter, and the final chapter offers general 
conclusions. 
HRas does not need COP I- or COP II-dependent vesicular transport to reach 
the plasma membrane 
The first manuscript, “HRas does not need COP I- or COP II-dependent vesicular 
transport to reach the plasma membrane,” presents a new exocytosis mechanism for HRas. 
This manuscript, which has been accepted for publication by the Journal of Biological 
Chemistry, suggests that HRas can reach the plasma membrane by a non-vesicular, Golgi-
independent mechanism. 
I am the second author on this paper; Hui Zheng is the first author of this work and Dr. 
Buss is the third author. My specific contribution involved demonstrating that not every cell 
expressing HRas in a population shows Golgi accumulation and investigating how HRas 
moves from the ER to the plasma membrane in a microtubule–independent pathway. 
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Golgi–independent trafficking requires the conservation of HRas 
hypervariable region 
The manuscript, “Golgi–independent trafficking requires the conservation of HRas 
hypervariable region,” will be submitted to the Journal of Cell Biology. This manuscript 
expands upon findings that were established in “HRas does not need COP I- or COP II-
dependent vesicular transport to reach the plasma membrane,” the third of three articles 
presented in this dissertation. Specifically, I examined whether Golgi-independent trafficking 
of HRas was available across multiple cell types., I also investigated what role(s), if any, the 
HRas hypervariable region plays on trafficking and membrane localization. 
I am the sole author of this paper; I conducted the research and prepared the results 
reported here. 
Internalization of HRas via Arf6-associated endosomal pathway 
In the manuscript, “Internalization of HRas via Arf6-associated endosomal pathway,” a 
clathrin-independent endocytosis pathway for HRas was examined. The study presents the 
possibility that HRas can be activated even during transit. I investigated how both HRas and 
KRas are removed from the plasma membrane via vesicular endocytosis. I found that HRas-
containing ARF6 endosomes merge, then localize to the Endosomal Recycling Center 
(ERC). Finally, in this article, I demonstrate that the terminal 10 amino acids of HRas contain 
enough trafficking signals to move the Green Fluorescent Protein (GFP) from and to the 
plasma membrane and re-localize the GFP to the ERC. 
Along with Xing Wang, I am the co-first author of this article. Under the supervision of 
Dr. Buss, I conducted a significant portion of the laboratory work, including designing and 
carrying out experiments, arranging for required materials, and recording the research 
process. 
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Chapter 5 General conclusions 
Chapter 5 summarizes the work presented in this dissertation and reports the major 
insights into HRas trafficking, lipid modification, and signal transduction derived from this 
work. Further, this chapter discusses the biological implications of this work and offers 
suggestions for future research in the areas of HRas trafficking and signal transduction. 
General Literature Review 
Rat Sarcoma protein, Ras, is a major player in signal transduction that regulates cell 
proliferation, differentiation, and apoptosis. [53] In the past few decades, interest in Ras has 
grown among the scientists because [54] of its oncogenic ability. Although Ras is 
ubiquitously expressed, the isoforms differ from one another in their abilities to trigger 
different forms of carcinomas. For instance, KRas mutants are responsible for approximately 
15–20% of small cell lung cancers and 95% of pancreatic adenocarcinomas. [54] Malignant 
thyroid cancers, on the other hand, could have HRas, KRas, or NRas mutations. Taken 
together, approximately 30% of all human cancers contain Ras gene mutations. [10] This 
kind of oncogenic ability in conjunction with its complex signal transduction activation 
capabilities makes Ras not only a great tool for better understanding tumorigenesis but also a 
potential candidate for cancer drug development. 
Ras is a member of the small or monomeric GTPase superfamily. To date, there are 
approximately 150 known members in this family. [55] Like many of its fellow family 
members, Ras acts as a molecular switch that resonates between its active, GTP-bound form 
and its inactive GDP-bound form. [19] In simple terms, as a molecular switch, Ras acts to 
either turn on or off cell divisions. When activated by its upstream signal transducer, Guanine 
nucleotide Exchange Factor (GEF), Ras is recruited to a membranous platform where it 
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releases the GDP and binds a GTP in its switch regions. [18] This exchange then causes a 
conformational change that will allow activation of downstream effectors. 
In humans, there are four major isoforms of Ras: HRas, KRas 4A, KRas 4B, and NRas. 
Alternative splicing of the fourth exon results in the two KRas isoforms, KRas 4A and 
KRas 4B. [39] Conservation and sequence identity among these four isoforms of Ras is very 
high—about 85% within the first 165 residues at the N–terminus—while the remaining 20-
odd amino acids at the C-terminus vary greatly from isoform to isoform. [55] Figure 2 shows 
switch regions, domains, and Ras C-terminus variations between isoforms. 
Posttranslational modification 
For a molecule to successfully act as a molecular switch, it must be able to relay—
localize—information from the extracellular matrix into the cytoplasm and often to the 
nucleus. For Ras, localization to the cytoplasmic leaflet of a cellular membrane is essential 
for activation of the downstream effectors. [56] However, without any lipid attachments, Ras 
molecules are hydrophilic and cytosolic in nature. So, for Ras molecules to succeed in 
membrane localization, they must first be posttranslationally modified at the C-terminus. [57] 
Following C-terminus modifications, Ras are inserted into the hydrophobic tails of the 
phospholipid bilayer. [58] 
The C-terminus of Ras is often described as the CAAX box, which consists of a cysteine 
and two aliphatic residues followed by any amino acid, respectively. Creating mature Ras 
molecules requires a four-step series that modifies each of the amino acids in the CAAX box. 
These steps are: 1) farnesylation, 2) proteolysis, 3) methylation, and 4) palmitoylation. First, 
a farnesyl is added to the cysteine by a farnesyl transferase which located in the cytoplasm. 
[59] This leads to cleaving or proteolysis of the –AAX by Ras Converting Enzyme 1 
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(RCE 1). Next the newly exposed C–terminus is methylated by Isoprenylcysteine Carboxyl 
Methyl Transferase (Icmt). [60, 61] HRas, NRas, and KRas 4A are further modified by a 
palmitoyl transferase that attaches a palmitate to the two cysteines just upstream of the 
CAAX box. [62-67] These modifications now create a hydrophobic C–terminus and, 
ultimately, permit membrane binding of Ras upon activation of the signal transduction 
cascade. [56] Figure 3 shows the four steps of Ras posttranslational modification. 
KRas 4B, the most abundant form of KRas, lacks these palmitoylation sites. Instead the 
farnesyl is sufficient enough to localize KRas 4B to the membrane and then the positive 
charges on the polybasic residues (-KKKKKKSKTK) help insert KRas 4B into the cytoplasmic 
face of the membrane. [2] This unique polybasic region allows KRas 4B to behave 
differently than other Ras isoforms. KRas localizes to the membrane in an unknown 
mechanism whereas other Ras are traditionally thought to localize to the plasma membrane 
via vesicular trafficking. [68-70] 
Ras signal transduction 
Ras, like many other small GTPase family members, is activated by its GTP and GDP 
bound state. [71] GTP binding increases Ras’ affinity for the down stream effectors through 
conformational changes in the switch 1 and switch 2 regions. (Figure 1) GTP binding is a 
very transient phenomenon that is facilitated by Guanine Nucleotide Exchange Factor (GEF). 
A GEF releases the GDP already bound to Ras which allows Ras to exchange GDP for a 
GTP. [72] The reverse is facilitated by GTPase Activating Protein (GAP), which acts by 
releasing the terminal phosphate group from the GTP and returns the Ras once again to its 
GDP bound form. [10] Amino acid changes in the switch regions that hinder this exchange 
often result in dominant negative and constitutively active mutants. Also, the ability of Ras to 
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behave as a GTPase is the primary difference between Ras and its oncogenic counterparts—
activity decreases up to 300 fold in transformed cells. [4] 
Because Ras activation results in various cellular responses, Ras signal transduction is a 
complicated process that requires specificity and precision. [73] Of all Ras signal 
transduction cascades, perhaps the best studied is the Mitogen Activating Protein Kinase 
(MAPK) cascade. In this cascade, an extracellular growth factor, such as Epidermal Growth 
Factors (EGF), binds to its receptor (EGFR), which causes dimerization and phosphorylation. 
[74] In response to the phosphorylation, Growth Factor Receptor Binding Protein (Grb), an 
adaptor protein, binds to Son of Sevenless (SOS), becomes a GEF/adapter complex, and 
localizes to the plasma membrane. [75] Once at the plasma membrane, this GEF/adapter 
complex activates Ras which, in turn, recruits and activates the serine/theronine kinase 
named RAF. [76] RAF is then phosphorylated and activates MAPK/ERK Kinase (MEK), 
then MEK activates Extracellular signal-Regulated Kinase (ERK). After phosphorylation, 
ERK is dimerized and that complex will move to the nucleus. Once in the nucleus, ERK 
activates transcription factors. [77] (Figure 4) 
Ras mediated signal transduction from endomembranes 
Traditionally, the final destination for activated Ras is thought to be the plasma 
membrane. [78] Any other localization on endomembranes was considered a temporary 
occurrence where pools of proteins had not yet been trafficked to the plasma membrane. [36] 
Although the plasma membrane may not be the only membrane platform, the plasma 
membrane is still the most prominent place where Ras signal transduction occurs. In fact, up 
to now, conventional thinking has been that Ras C–terminus mutants that improperly direct 
Ras to endomembranes (e.g., Golgi and ER) are less likely to be oncogenic. [79, 80] 
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However, recent studies have also shown that Ras can localize to other membranous 
organelles such as Golgi apparatus, endoplasmic reticulum (ER), and even mitochondria. 
[31] A study by Chiu et al. shows that Ras can be activated from both Golgi and the plasma 
membrane when stimulated. [52] Interestingly, while signaling was rapid and transient at the 
plasma membrane, signaling at the Golgi was slower and long lasting. [81] 
In addition to the Golgi, the ER can also serve as a signaling platform for Ras. [82, 83] 
When Ras is mutated such that its farnesylation sites are retained but not its palmitoylation 
sites, the vast majority of the Ras protein localizes to the ER and cytosol. When these ER-
bound proteins are expressed in conjunction with the Green Fluorescent Protein-Ras Binding 
Domain of RAF (GFP-RBD) and stimulated with growth factors, rapid accumulation of Ras 
on the ER has been observed. [84] This kind of Ras colocalization experiment with GFP-
RBD demonstrates that not only have the ER-redirected Ras molecules retained their GTPase 
activity but they also maintain their signal transduction capabilities. 
There is strong evidence that the plasma membrane is not the only platform for Ras-
mediated signal transduction cascade. Ras farnesyl inhibitors that are developed to prevent 
only Ras plasma membrane localization might be inadequate in terms of Ras localization at 
other endomembrane structures. 
Vesicular endocytosis 
Once the Ras signaling cascade is transmitted at the plasma membrane, Ras is 
endocytosed then it is either recycled back out to the plasma membrane  or degraded. [85, 86] 
This vesicular trafficking process provides a method for desensitization and down regulation 
which is essential for cell survival. [87-89] There are two basic modes of endocytosis—
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phagocytosis and pinocytosis. Endocytic vesicles converge at the lysosome where they can 
be degraded or at the endosomal recycling center. [90] (Figure 5) 
PHAGOCYTOSIS 
Phagocytosis generally occurs in specialized cells that interact with large cellular debris 
and/or pathogens. Phagocytosis might be also responsible for how eukaryotic cells first 
obtained mitochondria and chloroplasts. 
PINOCYTOSIS 
Pinocytosis is responsible for the cell’s fluid and small nutrient uptake. Pinocytosis can 
be further divided into four categories: 1) clathrin-mediated, dynamin-dependent, 
2) caveolin-mediated, dynamin-dependent, 3) clathrin/caveolin-independent but dynamin-
dependent, and 4) clathrin-, caveolin-, and dynamin-independent.  
Figure 6 shows phagocytosis and the four categories of smaller pinocytosis vesicles. 
1.  Clathrin-mediated, dynamin-dependent endocytosis. Among the four categories of 
pinocytosis, perhaps the clathrin-mediated endocytosis (CME) is the best understood. 
Endocytosis is initiated when the Adaptor Protein complex2 (AP2) is recruited to the plasma 
membrane after the ligand binds to its receptor. This allows the clathrin triskelia to form a 
lattice around the AP2/ligand/receptor complex. [91-93] The clathrin lattices create plasma 
membrane curvatures that eventually become external phases of the vesicles. In order for 
these budding vesicles to completely separate from the plasma membrane, they require 
dynamin, yet another GTPase,. Dynamin forms a necklace around the neck of the budding 
vesicle and pinches off the nascent vesicle from the plasma membrane. [92, 93] Both 
Epidermal Growth Factor Receptor (EGFR) and transferrin are thought to be endocytosed 
through this pathway. 
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2.  Caveolin-mediated, dynamin-dependent. The caveolin-mediated, dynamin-dependent 
category of pinocytosis results in caveolae vesicles. These coated, endocytic vesicles are 
lined with caveolin, which dimerizes and binds to cholesterol, and inserts the caveolae into 
the cytoplasmic side of the plasma membrane. Caveolae are tightly regulated by endocytosis 
pathways. 
3.  Clathrin/caveolin-independent but dynamin dependent. The third type of pinocytosis 
vesicles are clathrin and caveolin independent, but require dynamin, a small GTPase. Unlike 
clathrin, dynamin does not coat the endocytic vesicles but activates a budding off mechanism 
that releases vesicles from the plasma membrane. A dynamin-dominant-negative mutant that 
cannot exchange its GDP for GTP inhibits vesicular endocytosis. 
4.  Clathrin/caveolin/dynamin-independent. The final pinocytosis category is independent 
of dynamin, clathrin, and caveolin. [94] This pathway is thought to be mediated via ARF 
(ADP Ribosylation Factor). [95] ARF is a small GTPase that is no stranger to vesicular 
trafficking. [96] ARF contains six family members—ARF1, ARF2, ARF3, ARF4, ARF5, 
and ARF6. Of the six, ARF1 and ARF6 have been well studied. ARF1 is a Golgi-localized 
protein that directly interacts with COP I in Ras exocytosis. On the other hand, ARF6 is 
thought to regulate endocytosis and trafficking to the ERC which is embedded within the 
Golgi complex. [97] (Figure 6) 
ENDOSOMAL RECYCLING CENTER 
Regardless of the vesicular coating or lack thereof, once separated from the plasma 
membrane, vesicles travel toward the cytosol and cluster together to form the Early 
Endosomal Compartment (EEC). [98] From the EEC, cargo-containing vesicles can either 
join the late-endosome, or eventually localize to the lysosome where the proteins can be 
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degraded or the cargo vesicles can be localized to the ERC where cargos such as EGFR are 
redirected toward the plasma membrane. [85] Even though Ras signaling and trafficking out 
to the plasma membrane are well known, the fate of Ras after signaling has been elusive. In 
addition, because vesicular membranes are derived from the plasma membrane, it is 
reasonable to speculate that Ras can continue to signal while bound to a vesicular membrane 
as long as all of its signaling partners are present. [99] Furthermore, even if Ras effectors are 
not present in the exact same vesicle as Ras, and because several vesicles merge to form 
early endosomes (EE), Ras can encounter its downstream effectors and use EE as a signaling 
platform. Finally, because some proteins can be localized to the ERC [52], HRas-mediated 
signal transduction can also occur there as long as Ras and its effectors are both located in 
the ERC. (Figure 5) 
Vesicular exocytosis 
Generally, exocytosis describes movement of vesicles from inside the cell toward the 
plasma membrane and out into the extracellular matrix. Currently we recognize two kinds of 
protein trafficking, ER to Golgi and Golgi to ER. 
CARGO TRANSPORT FROM ER TO GOLGI 
Trafficking between ER and Golgi has been well documented. [38, 39, 100, 101] 
Trafficking between these two membranes is interesting because both anterograde trafficking 
(ER to Golgi) and retrograde trafficking (Golgi to ER) occur simultaneously. [102, 103] For 
example, ER to Golgi anterograde trafficking requires small GTPases such as Sec-related and 
Ras-related protein 1 (Sar1). [45] To initiate anterograde trafficking between ER and Golgi, 
GTP binds to Sar1 and allows the COP II complex of proteins to accumulate. [44] These 
aggregations of COP II proteins complexes now mark the ER exit sites. [104] It is here, in 
these ER exit sites, that the cargo-containing vesicles will begin to form. The GTP binding of 
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Sar1 serves as an initiation signal for other GTPases such as ARF 1 [105, 106], which is 
required for vesicle maturation and, eventually, their release from ER. [107-110] Once 
formed, the cargo-containing vesicles are exported to the vesiculo-tubular intermediate 
compartment called Endoplasmic Reticulum Intermediate Compartment (ERGIC) before 
arriving at the Golgi. [107] From Golgi, the vesicles will continue to move toward the plasma 
membrane by using microtubules. [111, 112] 
CARGO TRANSPORT FROM GOLGI TO ER 
Golgi is a dynamic tubular structure that is used for cargo sorting and trafficking. One of 
the unique attributes of Golgi is its ability to distinguish between outward bound vesicles 
headed toward the plasma membrane and other vesicles that are headed toward other 
endomembranes, including ER. [113] Golgi is primarily formed by accumulating vesicles 
from the ER. [114-116] As with the ER, the Golgi apparatus has its own set of resident 
proteins (e.g., giantin), but they are not tightly bound to the membrane. [114] Golgi residents 
can often cycle back and forth between ER and Golgi. Thus, Golgi’s structural integrity and 
its ability to maintain a steady pool of resident proteins are highly dependent on the 
continuous fusion of ER derived vesicles to the existing Golgi. [42-45, 48] In some cases, if 
Golgi and its residents are not replenished by constant forward and backward trafficking, it 
will disassemble. The retrograde trafficking from Golgi back to ER is facilitated by the COP 
I machinery. [117] 
One of the commonly used pharmacological reagents in protein trafficking studies which 
targets this constant exchange of vesicles between ER and Golgi, is Brefeldin A (BFA), a 
fungal reagent that the COP I coated vesicles are especially sensitive to. [118, 119] More 
specifically, BFA prevents GTP binding of ARF 1. When ARF 1 activation is inhibited, COP 
   16
I machinery is prevented from forming and designating ER export sites. [120] Ultimately, 
exposure to BFA will arrest vesicular budding from ER. Even though this does not prevent 
Golgi-to-ER anterograde trafficking. Upon prolonged BFA treatment, the Golgi membranes 
retreat quickly back into the ER and are not replenished. So, in time, the Golgi completely 
collapses. [119, 121] 
Microtubules and intracellular trafficking 
Microtubules are filamentous structures that are part of cytoskeletons and are important 
for maintaining cell structure, polarity, motility, and division. [112, 122] Microtubules are 
polymers made of heterodimer units that consist of α and β subunits. Although both subunits 
bind to GTP, only the β subunit is able to exchange GTP for GDP. 
Microtubular polarity allows cargo to travel in only one direction. [123] The growing end 
of the microtubule, where elongation takes place, is called the plus end, and the shrinking end 
of the microtubule is called the minus end. Microtubules are regulated by the members of the 
GTPase family like Rho and Ran. Like Ras, Rho and Ran are also activated by GTP binding 
and inactivated by GDP binding. Expression of the dominant negative forms of Rho or Ran 
proteins—when the proteins cannot release the GDP—prevents microtubule polymerization. 
This effect can also be created by using pharmacological reagents like nocodazole. [124] 
Powered by GTP, microtubules constantly cycle between elongation and shrinkage. [124] 
This cycling makes microtubules very unstable structures, but cycling also allows new tracks 
to be laid quickly so they can help healthy cells move and traffic vesicles. [125] 
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Concluding Remarks 
Ras signals determine whether cell proliferation is regulated or is not regulated, in which 
case, cells become oncogenic, so study into Ras signaling offers insights into tumorigenesis, 
the focus of the three papers that make up the core of this dissertation. 
The studies discussed here present evidence that suggests that Ras signals from multiple 
locations at multiple times and with multiple signaling partners. This adds more complexity 
to what was already a complex system, but because Ras can signal from multiple locations, 
understanding Ras signal transduction in relation to its trafficking pattern moves us closer to 
understanding oncogenesis at the cellular and molecular levels. 
References 
1. Johnson, L., et al. Somatic activation of the K-ras oncogene causes early onset lung 
cancer in mice. Nature, 2001. 410: p 1111–1116. 
2. Johnson, L., et al. K-Ras is an essential gene in the mouse with partial functional 
Overlap with N-Ras. Genes and Developement, 1997. 11: p 2468–2481. 
3. Jura, N., et al. differential modification of Ras proteins by ubiquitination. Molecular 
Cell, 2006. 21: p 679–687. 
4. Malumbres, M. and M. Barbacid. Ras oncogens: the first 30 years. Nature Reviews, 
2002. 3: p 7–14. 
5. Wang, Y., et al. Endosomal signaling of epidermal growth factor receptor stimulates 
signal transduction pathways leading to cell survival. Molecular and Cellular Biology, 
2002. 22: p 7279–7290. 
6. Hanahan, D. and R.A. Weinberg. The hallmark of cancer. Cell, 2000. 100: p 57–70. 
7. Laird, D.A. and D. Shalloway. Oncoprotein signaling and mitosis. Cell Signaling, 
1997. 9: p 249–255. 
8. Mitsuuchi, Y. and J.R. Testa. Cytogenetics and molecular genetics of lung cancer. 
American Journal of Medical Genetics, 2002. 115: p 183–188. 
   18
9. Garcia-Rostan, G., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R.,. Carcangiu, 
M. L , Costa, J., Tallini, G. Ras mutations are associated with aggressive tumor 
phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology, 2003. 
21: p 3226–3235. 
10. Lowy, D.R. and Willumsen, B.M. Function and regulation of Ras. Annual Review of 
Biochemestry, 1993. 62: p 851–891. 
11. Cancer Statistics 2006: A presentation from the American Cancer Society. Cancer 
Statistic 2006 [Power point Presentation] 2006 [cited 2006. 
12. Bianco, R., et al. Key Cancer signal transduction pathway as therapeutic targets. 
European Journal of Cancer, 2006. 42: p 290–294. 
13. Sridhar, S.S., Hedley, D., and Siu, L.L. Raf kinase as a target for anticancer 
therapeutics. Molecular Cancer Therapy, 2005. 4: p 681–690. 
14. Buss, J. and Marsters, J.C.J. Farnesyl Transferase inhibitors: the successes and 
surprises of a new class of potential cancer chemotherapeutics. Chemistry and Biology, 
1995. 2: p 787–791. 
15. Hamad, N.M., et al. Distinct requirements for Ras oncogenesis in human versus mouse 
cells. Genes & Development, 2002. 16: p 2045–2057. 
16. Gupta, S., et al. Binding of Ras to Phosphoinositide 3-Kinase p110 is required for Ras-
driven tumorigenesis in Mice. Cell, 2007. 129: p 957–068. 
17. Colicelli, J. Human Ras superfamily proteins and related GTPases. Science, 2004. 250: 
p 1–31. 
18. Ehrhardt, A., et al. Ras and relatives-job sharing and networking keep an old family 
together. Experimental Hematology, 2002. 30: p 1089–1106. 
19. Mor, A. and M.R. Philips. Compartmentalized Ras/MAPK signaling. Annual Review of 
Immunology, 2006. 24: p 771–800. 
20. Silvius, J.R. Mechanisms of Ras protein targeting in mammalian cells. Journal of 
Membrane Biology, 2002. 190: p 83–92. 
21. Hancock, J.F., et al. All Ras Proteins are polyisoprenylated but only some are 
palmitoylated. Cell, 1989. 57: p 1167–1177. 
   19
22. Koera, K., et al. K-Ras is essential for the development of the mouse embryo. 
Oncogene, 1997. 15: p 1151–1159. 
23. Esteban, L.M., et al. Targeted genomic disruption of H-ras and N-ras, individually or in 
combination, reveals the dispensability of both loci for mouse growth and 
development. Molecular Cell. Biology, 2001. 21: p 1444–1452. 
24. Voice, J., et al. Four human ras homologs differ in their abilities to activate Raf-1, 
induce transformation, and stimulate cell motility. Journal of Biological Chemistry, 
1999. 274: p 17164–17170. 
25. Akagi, T., et al. v-Crk activates the Phosphoinositide 3-Kinase/AKT pathway by 
utilizing focal adhesion kinase and H-Ras. Molecular and Cellular Biology, 2002. 22: p 
7015–7023. 
26. Vojtek, A.B., S.M. Hollenberg, and J.A. Cooper. Mammalian Ras interacts directly 
with the serine/threonine kinase Raf. Cell, 1993. 74: p 205–214. 
27. Stacey, D.W., L.A. Feig, and J.B. Gibbs. Dominant inhibitory Ras mutants selectively 
inhibit the activity of either cellular or oncogenic Ras. Molecular Cell Biology, 1991. 
11: p 4053–4064. 
28. Bar-Sagi, D. and J.R. Feramisco. Microinjection of the ras oncogene protein into PC12 
cells induces morphological differentiation. Cell, 1985. 42: p 841–848. 
29. Bivona, T.G. and M.R. Philips. Ras pathway signaling on endomembranes. Current 
Opinions in Cell Biology, 2003. 15: p 136–142. 
30. Hammond, A.T. and B.S. Glick. Dynamics of transitional endoplasmic reticulum sites 
in vertebrate cells. Molecular Biology of Cell, 2000. 11: p 3013–3030. 
31. Dong, S., et al. Palmitoylation and plasma membrane localization of Ras2p by a 
nonclassical trafficking pathway in Saccharomyces cerevisiae. Molecular and Cellular 
Biology, 2003. 23: p 6574–6578. 
32. Chiu, Y.L. and T.M. Rana. RNAi in human cells: basic structural and functional 
features of small interfering RNA. Molecular Cell, 2002. 10: p 549–561. 
   20
33. Castro, I.P.d., et al. Ras Activation in Jurkat T cells following low-grade stimulation of 
the T-Cell receptor Is specific to N-Ras and occurs only on the Golgi Apparatus. 
Molecular and Cellular Biology, 2004: p 3485–3496. 
34. Rocks, O., et al. An acylation cycle regulates localization and activity of palmitoylated 
Ras isoforms. Science Express, 2005: p 10.1126/science.1105654. 
35. Bivona, T.G., et al. PKC regulates farnesyl-electrostatic switch in K-Ras that promotes 
its association with Bcl-XL on mitochondria and induces apoptosis. Molecular Cell, 
2006. 21: p 481–493. 
36. Philips, M.R. Compartmentalized signaling of Ras. Biochemical Society, 2005: p 657–
661. 
37. Hancock, J.F., et al. A CAAX or a CAAL motif and a second signal are sufficient for 
plasma membrane targeting of ras proteins. EMBO Journal, 1991. 10: p 4033–4039. 
38. Choy, E., et al. Endomembrane trafficking of Ras: the CaaX motif targets proteins to 
the ER and Golgi. Cell, 1999. 98: p 69–80. 
39. Apolloni A, p I., Lindsay M, Parton RG, Hancock JF. H-ras but not K-ras traffics to the 
plasma membrane through the exocytic pathway. Molecular Cell Biology 2000. 20: p 
2475–2487. 
40. Schroeder, H., et al. S-acylation and plasma membrane targeting of the farnesylated 
carboxy-terminal peptide of N-ras in mammalian fibroblasts. Biochemistry, 1997. 30: p 
13102–13109. 
41. Hancock, J.F., H. Paterson, and C.J. Marshall. A polybasic domain or palmitoylation is 
required in addition to the CAAX motif to localize p21ras to the plasma membrane. 
Cell, 1990. 63: p 133–139. 
42. Ward, T.H., et al. Maintenance of Golgi structure and function depends on the integrity 
of ER export. Journal of Cell Biology, 2001. 155: p 557–570. 
43. Miles S, M.H., Forsten K.E, Storrie B. Evidence that the entire Golgi apparatus cycles 
in interphase HeLa cells: sensitivity of Golgi matrix proteins to an ER exit block. 
Journal of Cell Biology, 2001. 155(4): p 543–55. 
   21
44. Stroud W.J, Shu, Jiang, Jack, G., Storrie B. Persistence of Golgi matrix distribution 
exhibits the same dependence on Sar1p activity as a Golgi glycosyltransferase. Traffic, 
2003. 4(9): p 631–41. 
45. Kuge O, D.C., Orci L, Rowe T, Amherdt M, Plutner H, Ravazzola M, Tanigawa G, 
Rothman JE, Balch W.E. Sar1 promotes vesicle budding from the endoplasmic 
reticulum but not Golgi compartments. Journal of Cell Biology, 1994. 125(1): p 51–65. 
46. Sannerud, R., et al. Rab 1 Defines novel pathway connecting the pre-Golgi 
intermediate compartment with the cell periphery. Molecular Biology of the Cell, 2006. 
17: p 1514–1526. 
47. Presley, J., et al. ER-to-Golgi transport visualized in living cells. Nature, 1997. 389: p 
81–85. 
48. Cole NB, S.C., Sciaky N, Terasaki M, Edidin M, Lippincott-Schwartz J. Diffusional 
mobility of Golgi proteins in membranes of living cells. Science, 1996. 273(5276): p 
797–801. 
49. Fivaz M.T. Reversible intracellular translocation of KRas but not HRas in hippocampal 
neurons regulated by Ca2+/calmodulin. Journal of Cell Biology, 2005. 170(3): p 429–
41. 
50. Roy, S., B. Wyse, and J.F. Hancock. H-Ras signaling and K-Ras signaling are 
differentially dependent on endocytosis. Molecular Cell. Biology, 2002. 22: p 5128–
5140. 
51. LeRoy, C. and J.L. Wrana. Clathrin- and non-clathrin-mediated endocytic regulation of 
cell signaling. Nature Reviews in Molecular and Cellular Biology, 2005. 6: p 112–126. 
52. Gomez GA, D.J. H-Ras dynamically interacts with recycling endosomes in CHO-K1 
cells: involvement of Rab5 and Rab11 in the trafficking of H-Ras to this pericentriolar 
endocytic compartment. Journal of Biological Chemistry, 2005. 280(41): p 34997–
5010. 
53. Harvey, J.J. An unidentified virus which cause the rapid production of tumours in mice. 
Nature, 1964. 204: p 1104–1105. 
   22
54. Mitsuchi, Y. and J.R. Testa. Cytogenetics and molecular genetics of lung cancer. 
American Journal of Medical Genetics, 2002. 115: p 183–188. 
55. Hancock, J.F. Ras Proteins: Different Signals From Different Locations. Nature, 2003. 
4: p 373–384. 
56. Cox, A.D. and C.J. Der, Protein prenylation: more than just glue? Current Opinions in 
Cell Biology, 1992. 4: p 1008–1016. 
57. Kenworthy, A.K., et al. Dynamics of putative raft-associated proteins at the cell 
surface. Journal of Cell Biology, 2004. 165(5): p 735–746. 
58. Cox, A.D., Mutation and analysis of prenylation signal sequences. Methods in 
Enzymology, 1995. 250: p 105–121. 
59. Tschantz, W.R., E.S. Furfine, and p J. Casey. Substrate binding is required for release 
of product from mammalian protein farnesyl transferase. Journal of Biological 
Chemistry, 1997. 272(15): p 9989–9993. 
60. Dai, Q., et al. Mammalian prenylcysteine carboxyl methyltransferase is in the 
endoplasmic reticulum. Journal of Biological Chemistry, 1998. 273: p 15030–15034. 
61. Schmidt, W.K., Tam, A., Fujimura-Kamada, K., and Michaelis, S. Endoplasmic 
reticulum membrane localization of Rce1p and Ste24p, yeast proteases involved in 
carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. 
Proceedings of the National Academy of Science, USA, 1998. 95: p 11175–11180. 
62. Swarthout, J.T., et al. DHHC9 and GCP16 constitute a human protein fatty 
acyltransferase with specificity for H- and N-Ras. Journal of Biological Chemistry, 
2005. 280(35): p 31141–8. 
63. Linder, M. and R.J. Deschenes. Model organisms lead the way to protein 
palmitoytransferase. Journal of Cell Science, 2004. 117: p 521–526. 
64. Linder, M. and R.J. Deschenes. Palmitoylation: policing protein stability and traffic. 
Nature, 2007. 8: p 74–85. 
65. Lobo, S., et al. Identification of a Ras palmitoyltransferase in Saccharomyces 
cerevisiae. Journal of Biological Chemistry, 2002. 277(43): p 41268–41273. 
   23
66. Petaja-Repo, U.E., et al. Ligands act as a pharmacological chaperones and increase the 
efficiency of δ opiod receptor maturation. EMBO Journal, 2002. 21: p 1628–1637. 
67. Smotrys, J.E. and M.E. Linder. Palmitoylation of intracellular signaling proteins: 
regulation and function. Annual Review of Biochemestry, 2004. 73: p 559–587. 
68. Figueroa, C., J. Taylor, and Vojtek, A.B. Prenylated Rab acceptor protein is a receptor 
for prenylated small GTPases. Journal of Biological Chemistry, 2001. 276: p 28219–
28225. 
69. Ghomashchi, F., et al. Binding of prenylated and polybasic peptides to membranes: 
affinities and intervesicle exchange. Biochemistry, 1995. 34: p 11910–11918. 
70. Roy, M.-O., R. Leventis, and J.R. Silvius. Mutational and biochemical analysis of 
plasma membrane targeting mediated by the farnesylated, polybasic carboxy terminus 
of K-ras4B. Biochemistry, 2000. 39: p 8298–8307. 
71. Stone, J.C. Regulation of Ras in lymphocytes: Get a GRP. Biochemical Society 
Transduction, 2006. 34: p 858–862. 
72. Meder, D. and J. Simons. Ras on the roundabout. Science, 2005 307: p 1731–1733. 
73. Kelley-Spratt, K.S., et al. P19Arf suppresses growth, progression, and metastasis of H-
Ras driven carcinoma through p53-dependent and -independent pathways. PLoS 
Biology, 2004. 2(8): p 242–254. 
74. Zhao, C., et al. Phospholipase D2-generated phosphotidic acid couples EGFR 
stimulation to Ras activation by Sos. Nature Cell Biology, 2007. 9: p 706–715. 
75. Kholodenko, B.N., J.B. Hoek, and H.V. Westerhoff. Why cytoplasmic signaling 
proteins should be recruited to cell membranes. Trends in Cell Biology, 2000. 10: p 
173–178. 
76. Baccarini, M. An old kinase on a new path: Raf and apoptosis. Nature, 2002. 9: p 783–
785. 
77. Cano, E. and L.C. Mahadevan. Parallel signalp Processing among mammalian MAPKs. 
Science, 1995. 20: p 117–122. 
   24
78. Augsten M, p R., Biskup C, Rennert K, Wittig U, Beyer K, Blume A, Wetzker R, 
Friedrich K, Rubio I. Live-cell imaging of endogenous Ras-GTP illustrates 
predominant Ras activation at the plasma membrane. EMBO Journal, 2006. 7(1): p 46–
51. 
79. Kato, K., et al. Isoprenoid addition to Ras protein is the critical modification for its 
membrane association and transforming activity. Proceedings of the National Academy 
of Science (USA), 1992. 89: p 6403–6407. 
80. Kato, K., C.J. Der, and J.E. Buss. Prenoids and palmitate: lipids that control the 
biological activity of Ras proteins. Seminars in Cancer Biology, 1992. 3: p 179–188. 
81. Eungdamrong, N.J. and R. Iyengar. Compartment-specific feedback loop and regulated 
trafficking can result in sustained activation of Ras at the Golgi. Biophysical Journal, 
2007. 92: p 806–815. 
82. Quatela, S., G. and M.R. Philips. Ras signaling on the Golgi. Current Opinions in 
Biology, 200618: p 162–167. 
83. Baldwin, T.A. and H.L. Ostergaard. The Protein-tyrosine phosphatase CD45 reaches 
the cell surface via Golgi-dependent and -independent pathways. 2002. 
84. Bivona, T.G. and M.R. Philips. Analysis of Ras and Rap activation in living cells using 
fluorescent Ras binding domains. Methods, 2005. 37: p 138–145. 
85. Barbieri, M.A., et al. The Src Homology 2 Domain of Rin1 mediates its binding to the 
epidermal growth factor receptor and regulates receptor endocytosis. Journal of 
Biological Chemistry, 2003. 278(34): p 32027–32036. 
86. Lefkowitz, R., J. and E. Whalen. Beta -arrestins: traffic cops of cell signaling. Current 
Opinions in Cell Biology, 2004. 16: p 162–168. 
87. Miaczynska, M., L. Pelkmans, and M. Zerial. Not just a sink: endosomes in control of 
signal transduction. Current Opinion in Cell Biology, 2004. 16: p 400–406. 
88. Donaldson, J.G., A. Honda, and R. Weigert. Multiple activities for Arf 1 at the Golgi 
complex. Biochimica et Biophysica Acta, 2005. 1744: p 364–373. 
89. Miaczynska, M., L. Pelkmans, and M. Zerial, Not just a sink: endosomes in control of 
Signal Transduction. Current Opinions in Cell Biology, 2004. 16: p 400–406. 
   25
90. Conner, S.D. and S.L. Schmid. Regulated portals of entry into the cell. Nature, 2003. 
422: p 37–45. 
91. Houndolo, T., P.L. Boulay, and A. Claing. G protein-coupled receptor endocytosis in 
Arf6-depleted cells. Journal of Biological Chemistry, 2005. in press. 
92. Sorkin, A. Cargo recognition during clathrin-mediated endocytosis: a team effort. 
Current Opinion in Cell Biology, 2004. 16: p 392–399. 
93. Sorkin, A. and M. von Zastrow. Signal transduction and endocytosis: close encounters 
of many kinds. Nature, 2002. 3: p 600–614. 
94. Glebov, O.O. and B.J. Nichols. Lipid raft proteins have a random distribution during 
localized activation of the T-cell receptor. Nature Cel 
95. l Biology, 2004. 6: p 238–243. 
95. Aikawa, R., et al.. Oxidative stress activates extracellular signal-regulated kinases 
through Src and Ras in cultured cardiac myocytes of neonatal rats. Journal of Clinical 
Investigations, 1997. 100: p 1813–1821. 
96. Grodnitzky, J.A., et al. Somatostatin receptors signal hrough EFA6A-ARF6 to activate 
phospholipase D in clonal B-cells. Journal of Biological Chemistry, 2007. 281: p 
13410–13418. 
97. Vitale, N., et al. Calcium-regulated exocytosis of dense-core vesicles requires the 
activation of ADP-ribosylation factor (ARF6) by ARF nucleotide binding site opener at 
the plasma membrane. Journal of Cell Biology, 2002. 159: p 79–89. 
98. Bonazzi, M., et al. CtBP3/BARS drives membrane fission in dynamin-independent 
transport pathways. Nature Cell Biology, 2005. 7: p 570–585. 
99. Robertson, S., E., et al. Extracellular signal-regulated kinase regulates clathrin-
independent endosomal trafficking. Molecular Biology of Cell  2006. 17:645–657. 
100. Roy S, Rotblat B,. Prior I.A., Muncke C,. Grainger S., Parton R.G., Henis YI, Kloog 
Y., Hancock J.F. Individual palmitoyl residues serve distinct roles in H-ras trafficking, 
microlocalization, and signaling. Molecular Cell Biology, 2005. 25(15): p 6722–33. 
101. Apolloni, A., et al. H-ras but not K-ras traffics to the plasma membrane through the 
exocytic pathway. Molecular Cell. Biology, 2000. 20: p 2475–2487. 
   26
102. Lam, K.K.Y., et al. Palmitoylation by the DHHC protein Pfa4 regulates the ER exit of 
Chs3. Journal of Cell Biology, 2006. 174: p 19–25. 
103. Shorter, J. and G. Warren. Golgi architecture and inheritance. Annual Review of Cell 
Development Biology, 2002. 18: p 379–420. 
104. Duden, R. ER-to-Golgi transport: COP I and COP II function. Molecular Membrane 
Biology, 2003. 20: p 197–207. 
105. Donaldson, J.G. and C.L. Jackson. Regulators and effectors of the ARF GTPases. 
Current Opinion in Cell Biology, 2000. 12: p 475–482. 
106. Altan-Bonnet, N., et al. A role for Arf1 in mitotic Golgi disassembly, chromosome 
segregation, and cytokinesis. PNAS, 2003. 100(23): p 13314–13319. 
107. Altan-Bonnet, N., R. Sougrat, and J. Lippincott-Schwartz. Molecular basis for Golgi 
maintenance and biogenesis. Current Opinion in Cell Biology, 2006. 16: p 364–372. 
108. Pathre, P., et al. Activation of phospholipase D by the small GTPase Sar1p is required 
to support COP II assembly and ER export. EMBO Journal., 2003. 22: p 4059–4069. 
109. Shimoi, W., et al. p125 Is Localized in Endoplasmic Reticulum Exit Sites and Involved 
in Their Organization. Journal of Biological Chemistry, 2005. 280(11): p 10141–
10148. 
110. Aridor, M., et al. The Sar1 GTPase coordinates biosynthetic cargo selection with 
endoplasmic reticulum export site assembly. Journal of Cell Biology, 2001. 152: p 
213–229. 
111. Thyberg, J. and S. Moskalewski. Role of microtubules in the organization of the golgi. 
Experimental Cell Research, 1999. 246: p 263–279. 
112. Ho, J. and A. Bretscher. Ras regulates the polarity of the yeast actin cytoskeleton 
through the stress response pathway. Molecular Biology of the Cell, 2001. 12: p 1541–
1555. 
113. Magee, A.I., et al. Dynamic fatty acylation pf p21N-ras. EMBO Journal, 1987. 6: p 
3353–3357. 
   27
114. Mironov, A.A., et al. ER-to-Golgi carriers arise through direct en bloc protrusion and 
multistage maturation of specialized ER exit domains. Development of Cell, 2003. 5(4): 
p 583–94. 
115. Nebenfuhr, A., Ritzenhaler, C.  and D.G. Robinson. Brefeldin A: Deciphering an 
Enigmatic Inhibitor of Secretion. Plant Physiology 2002. 130: p 1102–1108. 
116. Lee, M.C.S., et al. Bi-directional protein transport between the ER and Golgi. Annual 
Review of Cell Developmental Biology, 2006. 20: p 87–128. 
117. Elsner, M., et al. Spatiotemporal dynamics of the COP I vesicle machinery. EMBO 
Journal, 2003. 4: p 1000–1005. 
118. Bannykh S.I., Matteson, J., Balch W.E. The role of ARF1 and Rab GTPases in 
polarization of the Golgi stack. Traffic, 2005. 6(9): p 803–19. 
119. Watson, R., T., et al. The exocytic trafficking of TC10 occurs through both classical 
and non-classical secretory transport pathways in 3T3L1 adipocytes. Molecular Cell 
Biology, 2003. 23: p 961–974. 
120. Sciaky, N., et al. Golgi tubule traffic and the effects of Brefeldin A visualized in living 
cells. Journal of Cell Biology, 1997. 139: p 1137–1155. 
121. Klausner, R.D., J.G. Donaldson, and J. Lippincott-Schwartz, Brefeldin A: insights into 
the control of membrane traffic and organelle structure. Journal of Cell Biology, 1992. 
116: p 1071–1080. 
122. Desai, A. and T.J. Mitchison. Microtubule polymerization dynamics. Annual Review of 
Cell Development Biology, 1997. 13: p 87–117. 
123. Hunter, A.W., and L. Wordeman. How motor protein influences microtubule 
polymerization dynamics. Journal of Cell Science, 2000. 113: p 4379–4389. 
124. Zheng, Y. G. Protein control of microtubule assembly. Annual Review of Cell 
Developmental Biology, 2004. 20: p 867–894. 
125. Kadama, A., T. Lechler, and E. Fuchs. Coordinating cytoskeletal tracks to polarize 
cellular movements. Journal of Cell Biology, 2004. 167: p 203–207. 
   28
Figure Legends 
Figure 1. Ras exocytosis 
A newly made Ras protein is located in the cytosol. Ras posttranslational modification 
begins with addition of a farnesyl group by the farnesyl transferase. This lipid 
modification kinetically traps HRas on the cytosolic surface of the ER membrane. 
Here the CAAX box is cleaved and two palmitates are added, so HRas 
posttranslational modification is complete. A mature HRas can move out to the 
plasma membrane by a vesicular trafficking mechanism, which includes passage 
through ERGIC and Golgi. Ras can also traffic to the plasma membrane directly from 
ER in a non-vesicular trafficking mechanism. KRas, which only contains a farnesyl 
group, localizes to the plasma membrane from ER in an unknown trafficking 
mechanism. 
Figure 2  Ras domains 
Structurally Ras proteins are divided into conserved domains and hypervariable regions. 
The conserved domain begins at the N-terminus and extends to residue 165. This 
domain is well conserved all Ras isoforms. Within the conserved domain there are 
two switch regions (switch 1 and switch 2) where GTP/GDP exchange occurs. 
Mutations in the switch regions can result in constitutively active or dominant 
negative mutants. The hypervariable region begins at the residue 166 and ends at the 
C-terminus. This region is posttranslationally modified with lipid groups. KRas 4 B 
acquires a farnesyl group at the CAAX box, whereas KRas A and NRas acquire an 
additional palmitate just upstream. HRas acquires two palmitates in addition to the 
farnesyl. 
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Figure 3  HRas C-terminus modifications 
A newly synthesized HRas must be posttranslationally modified at the C-terminus before 
acting as a molecular switch. HRas posttranslational modification begins with the 
addition of a farnesyl group at the C of the CAAX box by the farnesyl transferase. 
Then the —AAX of the CAAX box is cleaved by the Ras Converting Enzyme 1 
(RCE 1), and the newly exposed C-terminus is methylated by the Isoprenyl cystein 
Carboxy Methyl Transferase (Icmt). Finally, two additional palmitates are added to 
the upstream cysteines by palmitoyl transferase and complete HRas C-terminus 
modifications. 
Figure 4  Ras-mediated MAPK signal transduction pathway 
The best studied Ras-mediated signal transduction is the Mitogen Activating Protein 
Kinase Pathway (MAPK). To begin the signal transduction cascade by activating Ras, 
a GEF exchanges a GDP for a GTP, then the Ras downstream effectors RAF, MEK 
and ERK activated by addition of phosphate groups. Activation of this signal cascade 
leads to cell proliferation, differentiation, and apoptosis. After initiating the MAPK 
signal transduction pathway, Ras becomes inactive by exchanging its GTP for a GDP. 
This exchange is facilitated by GAP enzymes. 
Figure 5  Endocytic vesicle trafficking 
There are two major endocytic vesicle trafficking pathways—clathrin and non-clathrin. 
In the clathrin trafficking pathway, clathrin coated vesicles are released from the 
plasma membrane and become an Early Endosome (EE). An EE can continue its 
trafficking into the cytosol and become a late endosome or it can merge with other 
vesicles and form a merged endosome. A merged endosome can either traffic to the 
Endosomal Recycling Center (ERC) embedded in the Golgi or the merged endosome 
   30
can traffic to the lysosomes along with late endosomes where the endosomal contents 
are degraded. 
Figure 6  Types of endocytic vesicles 
Endocytic describes a process in which cells take in materials from the extracellular 
matrix into the cytosol along with a small portion of their plasma membrane. 
Phagocytosis and pinocytosis are the two major types of endocytosis. In 
phagocytosis, structures like whole cells and cell debris are engulfed. Whereas in 
pinocytosis, smaller molecules are engulfed into the cytosol. There are four major 
types of pinocytosis: clathrin mediated, dynamin-dependent; caveolin mediated, 
dynamin-dependent; clathrin and caveolin independent, dynamin-dependent; and 
clathrin, caveolin, and dynamin-independent. Clathrin and caveolin are types of 
vesicle coats and dynamin is a small GTPase that releases the vesicles from the 
plasma membrane. 
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Abstract 
Although vesicular transport of the H-Ras protein from the Golgi to the plasma membrane is 
well-known, additional trafficking steps, both to, and from, the plasma membrane, have also 
been described. Notably, both vesicular and non-vesicular transport mechanisms have been 
proposed. The initial trafficking of H-Ras to the plasma membrane was therefore examined 
in more detail. In untreated cells, H-Ras appeared at the plasma membrane more rapidly than 
a protein carried by the conventional exocytic pathway, and no H-Ras was visible on Golgi 
membranes in >80% of the cells. H-Ras was still able to reach the plasma membrane when 
COP II-directed transport was disrupted by two different mutant forms of Sar1, when COP I-
mediated vesicular traffic from the ER to Golgi was inhibited with Brefeldin A, or when 
microtubules were disrupted by nocodazole. Although some H-Ras was present in the 
secretory pathway, protein that reached the membranes of the ER-Golgi intermediate 
compartment was unable to move further in the presence of nocodazole. These results 
identify an alternative mechanism for H-Ras trafficking that circumvents conventional COP 
I-, COP II-, and microtubule-dependent vesicular transport. Thus, H-Ras has two 
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simultaneous but distinct means of transport, and need not depend on vesicular trafficking for 
its delivery to the plasma membranes.  
Introduction 
The broad outlines of the biosynthetic transport of Ras proteins to the plasma membrane 
are known [1-3]. Mammalian H-Ras, N-Ras, and K-Ras and also yeast Ras proteins are 
initially cytosolic, become modified with a farnesyl isoprenoid, and are then escorted, 
perhaps by the farnesyl transferase itself [4,5], to the cytosolic face of the widely dispersed 
membranes of the endoplasmic reticulum.  There, farnesylated Ras proteins are further 
modified by an ER-resident prenyl-dependent protease (Rce1), and by a second ER-resident 
methyl transferase enzyme (Icmt). [6,7]. At this point the K-Ras4B protein is released from 
the surface of the ER and rapidly appears at the plasma membrane. [3,8,9]. No internal 
membrane or vesicular intermediates have been observed for this step, and the transport 
mechanism is currently unknown. [10]. In neural cells, calcium signals cause calmodulin to 
bind to plasma membrane-bound K-Ras4B and trigger its internalization through a protein-
mediated, cytoplasmic shuttle mechanism. [11]. Thus K-Ras4B, at least in neurons, appears 
to use non-vesicular means for both initial outward and signal-dependent, inward trafficking. 
For H-Ras, N-Ras and yeast Ras2, a second lipid modification can occur, in which a 
palmitoyl lipid is attached to additional cysteines near the farnesylated C-terminus. A two-
subunit protein acyl transferase enzyme that attaches palmitates to H-Ras and N-Ras in 
mammalian cells has only recently been identified, and may be located on ER and Golgi 
membranes. [12-14]. In yeast, a similar two-subunit enzyme (Erf2/Erf4) that modifies yeast 
Ras2 has been found on ER membranes. [15]. Another mammalian acyl transferase, 
Huntington interacting protein-14 (HIP-14), is distributed on ER/Golgi membranes and has 
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been reported to enhance vesicular trafficking of multiple acylated proteins. [16,17]. 
Additional palmitoyl transferase enzymes are likely to be located in the plasma membrane, 
because mutant yeast and mammalian Ras proteins that reach the plasma membrane without 
associating with ER or Golgi membranes can be palmitoylated. [18,19]. 
The movement of H-Ras from the cytosolic surface of the vast ER membrane network is 
the first step in its journey to the plasma membrane. Two recent reports have laid the 
framework of this path. These studies propose that non-palmitoylated (but farnesylated) H-
Ras distributes rapidly between cytosolic and transient, non-specific membrane-bound 
phases. Wherever H-Ras encounters an acyl transferase and is palmitoylated it becomes 
"kinetically trapped" on the membranes [20], and as a result, can then be retained on vesicles 
and moved onward via traditional vesicular means. [21,22]. Proteins that control vesicular 
trafficking at the sites where acyl transferases are found thus become relevant for H-Ras 
transport. However, the model currently does not address whether a farnesylated H-Ras will 
need a partner protein to mask its lipid group during its cytosolic phase. These possibilities 
give importance to understanding the steps that H-Ras takes as it makes its way from the ER 
to the plasma membrane. 
A great deal is known about vesicular trafficking from the ER to the Golgi. Formation of 
vesicles on the ER begins with assembly of a COP II complex of proteins around the site, 
termed an ER exit site (ERES), at which the newly cargo-loaded vesicle will form. [23-25]. 
The protein that initiates this event is the GTPase, Sar1. GTP-binding mutants of Sar1 disrupt 
this cycle, and inhibit COP II-mediated vesicle transport from ER to Golgi. [26]. In 
mammalian cells, the COP II vesicles that are released from the widely dispersed ERES then 
seem to merge into a perinuclear vesiculo-tubular center sometimes termed the ER-Golgi-
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intermediate compartment (ERGIC). From here, some vesicles move onward to the Golgi, 
while others return to the ER. [27]. 
COP I-coated vesicles mediate anterograde transport from the ERGIC to Golgi, and 
retrograde traffic from Golgi membranes to the ER. [28,29]. The fungal product Brefeldin A 
(BFA) prevents the COP I complex from binding to membranes. This causes collapse of the 
Golgi stacks, as the membranes and proteins of the Golgi rapidly drain backwards into the 
ER, and also impairs anterograde trafficking beyond the ERGIC. [30] Thus, BFA inhibits 
vesicular transport at a separate point and by a mechanism distinct from that of Sar1 mutants. 
BFA has been reported to partially inhibit transport of a chimeric GFP protein with a 
lipidated C-terminus derived from H-Ras. [3]. However, another study reported continued 
transport of both H-Ras and another GTPase, TC10, to the plasma membrane in BFA-treated 
cells. [31]. Thus, it is unresolved to what extent BFA-sensitive, conventional vesicular 
trafficking contributes to H-Ras transport. The yeast Ras2 protein (which is modified by both 
farnesyl isoprenoid and palmitoyl lipids) has been reported to use a non-conventional 
pathway for trafficking. [19].  
These precedents prompted us to examine the mechanisms by which mammalian H-Ras 
accesses the plasma membrane, with particular attention to the initial steps at its release from 
the ER. The results indicate that two distinct routes for H-Ras transport operate 
simultaneously, and that a non-conventional, COP I- and COP II-independent mechanism 
moves the bulk of H-Ras to the plasma membrane. Unexpectedly, when traditional vesicular 
trafficking is blocked, H-Ras that has entered that pathway appears unable to switch to the 
non-conventional pathway. This suggests that the choice of pathway, and mechanism of 
transport, is determined prior to ER disengagement. 
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Materials and Methods  
Mutants, Plasmids and Antibodies 
 - H-Raswt, H-RasQ61L, and GFP-H-Ras were expressed from pcDNA3 (Invitrogen). The 
cDNAs for YFP-GT46 and the monomeric GFP (mGFP) [32] were gifts from Anne 
Kenworthy (Vanderbilt), with permission of Roger Tsien (San Diego). The cDNAs for 
hemagluttinin (HA)-tagged Sar1T39N–HA and Sar1H79G-HA were gifts from Dr. Jennifer 
Lippincott-Schwartz (NIH). Anti-Ras rat monoclonal antibody 238 (Santa Cruz), anti-HA 
mouse monoclonal antibody (Covance), anti-giantin rabbit polyclonal antibody (Covance), 
anti-ERGIC-53 mouse monoclonal antibody (Alexis), and Alexa-Fluor conjugated secondary 
antibodies (Molecular Probe) were used for immuno-fluorescence. The anti-Ras rat 
monoclonal antibody was detected with a rat-specific secondary antibody. 
Cell Culture and transfection 
 NIH 3T3 cells and COS-7 cells were cultured at 10% CO2 in Dulbecco’s Modified 
Eagle’s Medium (GIBCO-BRL) supplemented with 10% calf serum (Hyclone Laboratories). 
Twenty-four hours before DNA transfection, cells were plated on pre-washed glass cover 
slips (Corning) in 12 well tissue culture plates at a density about 105-106 cells per well. 
Transfection was performed using Effectine reagent (GIBCO-BRL) as described by the 
manufacturer. For sequential DNA transfection, only Sar1 DNA was used for the first 
transfection, and after 18 hours a second round of transfection, with DNA for H-Ras, was 
performed. For Sar1 co-transfection, a DNA ratio of 2:1 (Sar1: other DNAs; w/w) was used. 
For all other co-transfections a 1:1 DNA ratio (w/w) was used. 
Counting cells 
 NIH 3T3 cells were co-transfected with cDNAs for YFP-GT46 and H-Ras, as indicated. 
After 18 hours, cells were fixed and viewed by epifluorescence (for GFP constructs) or 
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immuno-stained with antibody for H-Ras or giantin.  One hundred cells with YFP-GT46 (or 
giantin) visible in the perinuclear area were then counted, and the number of cells in which 
H-Ras was present only on plasma membrane or coincident with the perinuclar marker 
protein was noted. Two separate experiments were performed for each H-Ras form, and the 
data were analyzed using the GraphPad Prism software program. 
Brefeldin A, nocodazole and cycloheximide treatment 
At 6 hours after transfection, Brefeldin A (BFA, 5 μg/ml) was applied to the cells in 
regular medium. Cells were fixed and visualized by immuno-fluorescence at 30, 60 and 90 
minutes after BFA treatment. Where indicated, cells were treated with cycloheximide 
(50μg/ml) immediately after the transfection. After 6 hours the cycloheximide was washed 
out and fresh medium with either BFA or nocodazole (20μg/ml) was added. After 1.5 hours, 
cells were fixed for immuno-fluorescence.  For one experiment, cells were transfected and 
treated with cycloheximide for 6 hours, then were rinsed to wash out the cycloheximide, and 
nocodazole was applied for 4 hours. Then nocodazole was washed out, and cycloheximide 
was added to the medium again. After 2 more hours, cells were fixed and stained for 
immuno-fluorescence. 
Immuno-fluorescence imaging 
 NIH 3T3 and COS-7 cells were fixed with 4% formaldehyde in phosphate-buffered 
saline (PBS) at room temperature for 15 minutes. Cells were permeablized with 0.2% 
TritonX-100 on ice for 5 minutes and treated with 50mM NH4Cl in PBS for 15 minutes at 
room temperature. Non-specific binding was blocked using 1% fat-free milk in PBS for 15 
minutes, followed by primary antibody for 1 hour and secondary antibody for 1 hour at room 
temperature. Cover slips were mounted with VECTASHIELD and images were captured 
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with a Leica inverted fluorescence microscope (Model DIMER2) or Leica confocal TCS NT 
microscope system equipped with separate Argon-UV, Argon, and Krypton lasers and the 
appropriate filter sets for FITC, Texas Red and TRITC imaging. The contrast and signal 
strength of images were balanced and images were deconvolved and merged as indicated, 
using Improvision Open Lab and Adobe Photoshop software.  
Movies 
NIH 3T3 cells were cultured and transfected with GFP-H-Ras cDNA as described before. 
Cells were treated with cycloheximide (50μg/ml) immediately after the transfection. After 6 
hours the cycloheximide was washed out and fresh medium with BFA (5μg/ml) and HEPES 
(20μg/ml, pH 7.4) was added. Cells were thereafter kept at 37oC in a warmed chamber. After 
30 minutes of BFA treatment, images of a selected cell were taken at 90-second intervals for 
about 1 hour with a Leica inverted fluorescence microscope (Model DIRME2). Movies were 
created by Improvision Open Lab software. 
Results 
H-Ras proteins often show little accumulation in the Golgi 
Although previous reports clearly documented the presence of H-Ras on the ER and 
Golgi, most of those studies used GFP-H-Ras fusion proteins to produce bright signals when 
localized to a small area. [1,3]. When a non-tagged version of H-Ras was imaged, using an 
H-Ras antibody, many transfected NIH 3T3 cells showed H-Ras protein only on the plasma 
membrane, with no protein detectable on perinuclear membranes. This visual impression was 
quantified, by determining the proportion of cells that showed H-Ras immunofluorescence on 
Golgi membranes. To verify the location of the Golgi apparatus, a co-expressed YFP-GT46 
protein, which traffics through the conventional exocytic pathway [33], or giantin, a resident 
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cis-Golgi protein, were also imaged. At 18 hours after transfection, H-Ras was strongly 
visible on the plasma membrane in >95% of all transfected cells. YFP-GT46 was detectable 
at the plasma membrane, and also in an organized perinuclear area in >90% of the transfected 
cells (Table 1). One hundred cells that showed YFP-GT46 in the perinuclear area were then 
counted, and the presence and abundance of H-Ras on membranes that were coincident with 
the perinuclear YFP-GT46 was noted in each. The results verified the preliminary impression 
that H-Ras was frequently absent from internal membranes (Golgi or recycling center [34]), 
as ~85% of the transfected cells showed no H-Ras on organized internal membrane structures 
that were also marked by YFP-GT46. Roughly 10% of the cells showed some modest 
amount of internal H-Ras, while about 5% showed strong colocalization with perinuclear 
membranes containing YFP-GT46. The same experiment was performed using COS-7 cells, 
with similar results (Table 1). Thus, in both cell types, only a few of the transfected cells 
showed a strong H-Ras signal on internal membranes. 
To see if a GTP-bound, oncogenic form of H-Ras behaved similarly, an activated version, 
H-RasQ61L was expressed. Once more, in 85-95% of the transfected cells, there was very little 
H-RasQ61L that colocalized with YFP-GT46 in the perinuclear area, although the plasma 
membrane was illuminated (Fig. 1A; Table 1). Thus, both the native form and an oncogenic 
form of H-Ras displayed limited accumulation on internal membranes.  
To look more specifically at the Golgi, the experiment was repeated, using COS-7 cells 
and staining of the endogenous protein, giantin, to mark the cis-Golgi. Again, a large 
majority of the cells showed almost no H-RasQ61L on Golgi membranes (Fig. 1B; Table 1). A 
similar limitation in Golgi localization of H-Ras has been reported in CHO-K1 cells. [35].  
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In contrast, when GFP-H-Ras fusion proteins were examined, a larger portion (~70%) of 
transfected cells showed the GFP-H-Ras fusion proteins on Golgi membranes, and only 
~30% of the cells lacked any accumulation of H-Ras in the Golgi area (Table 1). This 
significant amount of GFP-H-Ras on Golgi membranes agrees with previous work using 
GFP-H-Ras proteins. [1]. To learn if this apparent influence of GFP on H-Ras localization 
might arise because of the tendency for the original versions of GFP to dimerize, a 
monomeric form of GFP was attached to H- RasQ61L and the steady-state distribution of this 
mGFP-H-RasQ61L was examined. In roughly half of the cells, mGFP-H-RasQ61L was visible 
on perinuclear membranes, compared to ~65% for the original GFP version. Meanwhile, the 
portion of cells in which no perinuclear fluorescence of mGFP-H-Ras was visible increased 
moderately, from ~35% for the original GFP-tagged version, up to about 50% with 
monomeric GFP version (Table 1). However, the mGFP-H-RasQ61L was still clearly different 
in its distribution from that of the untagged H-RasQ61L, in which <5% of the cells showed 
perinuclear fluorescence and >90% did not. These results suggest that, although GFP-H-Ras 
(or mGFP-H-Ras) proteins may be useful for documenting the presence of H-Ras at internal 
locations, they may not fully replicate normal usage of the transport pathways. 
Nascent H-Ras moves much faster than YFP-GT46 to the plasma membrane 
These results suggested two possibilities: a) in 85% of the cells the amount of H-Ras on 
Golgi membranes was low because vesicular transport was particularly efficient; or b) a 
significant amount of H-Ras might be able to access the plasma membrane without utilizing 
the exocytic pathway through the Golgi. 
To study trafficking efficiency, the initial movement of H-Ras was examined at early 
time points after the protein was synthesized. This avoided the complexity of possible 
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deacylation-based recycling of previously synthesized H-Ras between plasma and internal 
membranes. [21]. For this, cells were co-transfected with cDNAs for H-RasQ61L and YFP-
GT46 and then were placed immediately in medium containing cycloheximide for 6 hours, to 
allow the cDNAs to be transcribed, and the RNA for H-Ras to accumulate, but to prevent 
translation. Cycloheximide was then removed to produce a synchronous wave of H-Ras 
protein synthesis and trafficking. At various time points after cycloheximide removal, cells 
were fixed and imaged. Using this approach, both H-Ras and YFP-GT46 had been translated 
and accumulated in amounts sufficient to be visible within 50 minutes of removal of 
cycloheximide. At that time, both proteins were present only on the ER (Fig. 2, 50′). Twenty 
minutes later (70 minutes after cycloheximide removal) a strong signal of YFP-GT46 was 
present on well-organized perinuclear membranes in ~90% of the transfected cells (Fig. 2, 
GT46, 70′). Importantly, no visible YFP-GT46 had yet reached the plasma membrane. In 
contrast, H-Ras was already detectable on the cell surface, well ahead of YFP-GT46 (Fig. 2, 
H-Ras, 70′). By 90 minutes after cycloheximide removal, YFP-GT46 was present in the 
Golgi and, in some cells, on vesicles that appeared to be exiting the Golgi, but which were 
not yet at the cell surface (Fig. 2, GT46, 90′). At this time point, H-Ras was now easily 
visible at the plasma membrane (Fig. 2, H-Ras, 90′), although no H-Ras-containing vesicles 
were detected and fewer than half of the cells showed any H-Ras in the perinuclear area. 
After another 20 minutes, (110 minutes after cycloheximide removal), exocytic vesicles 
containing YFP-GT46 could be seen in most transfected cells. In some cells, these GT46-
containing vesicles had reached the cell surface, and the outline of these cells could now be 
barely seen (Fig. 2, GT46, 110′). 
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H-Ras was now present on plasma membrane and on both perinuclear membranes and 
individual “granules” inside the cell (Fig. 2, H-Ras, 110′). When the images were merged, 
many of the vesicles containing YFP-GT46 did not have H-Ras on them (Fig. 2, merge, 
110’). This result suggested that much of the H-Ras was not using YFP-GT46-containing 
vesicles for transportation to the plasma membrane. By 140 minutes after cycloheximide 
removal, large amounts of YFP-GT46 had reached the plasma membrane and many YFP-
GT46-containing vesicles enroute were obvious. Merged images of H-Ras and GT46 showed 
some vesicles that contained both H-Ras and YFP-GT46, although again, many contained 
only one of the proteins (Fig. 2, merge, 140′).  The colocalization of YFP-GT46 and H-Ras 
agrees with previous reports that (some) H-Ras can traffic from the Golgi to the plasma 
membrane on vesicles. [1,21,22].  
These results clearly showed that nascent H-Ras could reach the plasma membrane more 
rapidly than a protein carried on the traditional vesicular pathway, Furthermore, in many 
cells, there was no evidence that H-Ras transited internal membranes. This led us to test 
whether H-Ras could reach the plasma membrane if conventional vesicular transport was 
prevented.  
Neither Brefeldin A nor dominant negative Sar1 prevent H-Ras movement to 
the plasma membrane 
To test if H-Ras plasma membrane traffic required the presence or organization of the 
Golgi apparatus, brefeldin A was used to inhibit COP I-mediated vesicular transport and 
cause Golgi collapse. Cells were transfected with cDNAs for H-RasQ61L and YFP-GT46, and 
were immediately treated with cycloheximide. After allowing 6 hours for RNA synthesis, the 
cycloheximide was washed out to permit protein synthesis, but Brefeldin A (BFA) was also 
added. After an additional 90 minutes, the cells were fixed and imaged. As expected for a 
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transmembrane protein in the secretory pathway, YFP-GT46 was found in the ER after BFA 
treatment, and clearly outlined the ER membranes around the nucleus (Fig. 3A). No other 
internal membranes contained YFP-GT46, confirming that vesicular traffic had halted, and 
the Golgi apparatus had been absorbed into the ER. In contrast, H-RasQ61L continued to 
illuminate the plasma membrane in the presence of BFA (Fig. 3A). No organized, 
perinuclear structures that contained H-RasQ61L were visible, and the protein did not 
accumulate on the nuclear envelope. To determine if the activation state of the protein 
influenced whether H-Ras transport was BFA-insensitive, the experiments were repeated 
using the inactive, cellular form of H-Ras (H-Raswt). The results were similar to those with 
the activated form. BFA had no inhibitory effect on movement of H-Raswt to the plasma 
membrane (data not shown). 
Additional trials with a 3 hr exposure to BFA were performed to examine if H-Ras might 
begin to accumulate on ER membranes if given more time. Even with this longer treatment, 
both H-Raswt and H-RasQ61L continued to move to the plasma membrane (data not shown). 
Also, BFA added to cells for 4 hours at 18 hours after transfection caused no accumulation of 
H-Ras on internal membranes (data not shown). Additional experiments with H-RasQ61L 
expressed in COS-7 cells showed that H-RasQ61L movement to the plasma membrane was not 
prevented by BFA in this other cell type (data not shown). These results indicated that neither 
GDP-bound nor GTP-bound forms of H-Ras required physically distinct Golgi membranes or 
COP I-coated vesicles in order to travel to the cell surface. 
Although the results with BFA suggested that H-Ras might not require vesicular transport 
to reach the plasma membrane, these studies inhibited only the COP I side of this process. 
The necessity for H-Ras vesicular trafficking was tested in a second way, by preventing 
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assembly of the COP II complex, using mutants of the assembly regulator, Sar1. Cells were 
co-transfected with cDNAs for H-RasQ61L and a GDP-bound inhibitory form of Sar1 
(Sar1T39N-HA), and 24 hr later were fixed and imaged. The H-RasQ61L protein strongly 
outlined the plasma membrane of cells that over-expressed the Sar1 dominant-negative 
protein (Fig. 3B). There was no indication of accumulation of H-RasQ61L in the ER or around 
the nuclear envelope, nor any Golgi-like structures. This suggested indirectly that the 
Sar1T39N had successfully ablated the Golgi. A second, longer experiment was also performed 
to give the Sar1T39N more time to amass to levels that would certainly disrupt ER exit sites 
(ERES) before H-Ras was present. Even after 48 hr, in cells co-expressing Sar1T39N and H-
RasQ61L, the H-RasQ61L continued to mark the plasma membrane and showed no build-up in 
the ER (data not shown). In addition, a sequential transfection technique was developed to 
allow Sar1 more time to become functional before H-Ras was synthesized and began its 
trafficking. Cells were first transfected with cDNA for the Sar1T39N and allowed to express 
this protein for 18 hr. The cells were then transfected a second time with cDNA for H-
RasQ61L and after a further 24 hr, were fixed and imaged. All cells that expressed H-RasQ61L 
showed strong plasma membrane staining, including those that also co-expressed the 
previously synthesized Sar1T39N (Fig. 3B). In cells that expressed both Sar1T39N and H-
RasQ61L proteins, there was no Golgi-like staining of H-RasQ61L on internal membranes. In 
cells that expressed only H-RasQ61L or that had only low expression of Sar1T39N, there was 
again a mixture of cells displaying H-Ras on plasma membrane only, or having H-Ras on 
both plasma membrane and perinuclear membranes. H-RasQ61L did illuminate some scattered 
internal membranes that did not have the layered appearance of Golgi, and seemed to be 
fluid-filled pinosomes, with H-Ras-stained rims but dark interiors (Fig. 3B). Activation of H-
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Ras is known to strongly stimulate fluid-phase endocytosis [36], so these structures may be 
the recently reported H-RasQ61L-containing endocytic vesicles [35] that had been internalized 
after reaching the plasma membrane.  
To ensure that the Sar1T39N protein was functioning correctly, a similar experiment was 
performed using the YFP-GT46 protein. The mutant Sar1 prevented YFP-GT46 from 
trafficking to the plasma membrane and caused it to accumulate on internal ER and nuclear 
envelope membranes (Fig. 3B, lower row). This indicated that the amount of Sar1T39N that 
was expressed was sufficient to block transport of a protein in the traditional exocytic 
pathway.  Equivalent results were obtained with Sar1T39N and H-RasQ61L expression in COS-
7 cells (data not shown), indicating that H-Ras trafficking is Sar1-independent in other cell 
types. To disrupt exit site assembly at a separate step, a different, GTP-bound Sar1 mutant, 
Sar1H79G-HA, was employed. With either simultaneous or sequential transfection protocols, 
H-RasQ61L continued to reach the plasma membrane in cells that also expressed the Sar1H79G-
HA protein (data not shown). These results indicated that H-Ras did not need COP II vesicles 
in order to traffic to the plasma membrane.  
Structures that carry H-Ras do not show directed movement to the plasma 
membrane in BFA-treated cells 
The results to this point suggested that a great deal of H-Ras trafficking occurred via a 
pathway to the plasma membrane that was independent of the classical vesicular route 
through the Golgi. To examine this alternative pathway in more detail, the classical pathway 
was ablated with BFA, and a movie was recorded to study if any type of BFA-resistant 
vesicles carrying H-Ras protein could be seen moving to the plasma membrane. NIH 3T3 
cells were transfected with GFP-H-RasQ61L cDNA and treated with cycloheximide 
immediately after the transfection. After 6 hours, cycloheximide was washed out and BFA 
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was added to the medium. After another 30 minutes to allow protein synthesis, the culture 
dish was moved to a chamber held at 37 degrees, and movement of the newly synthesized 
GFP-H-RasQ61L was recorded. As had been seen in the earlier experiments with fixed cells, at 
40 minutes after the wash out of cycloheximide, detectable amounts of GFP-H-RasQ61L had 
already appeared in the cytosol and on ER membranes. The GFP-H-RasQ61L was also present 
on numerous, very small, granular structures within the cell. These granules were unlikely to 
be conventional vesicles as they did not arise from any organized perinuclear, Golgi-like 
center, and the previous experiments had shown that this time point was prior to the time at 
which (limited amounts of) H-Ras would be seen on conventional exocytic vesicles. The 
GFP-H-RasQ61L granules moved slowly, often inward (Fig. 4, insets), and had no specific 
direction towards the plasma membrane (Fig. 4 and supplemental movie). A few granules 
(two in the 8 cells that were imaged) did fuse with the plasma membrane and illuminate the 
membrane temporarily (data not shown). Notably, the GFP-tagged H-Ras protein could be 
seen on ruffles and plasma membrane of the BFA-treated cells. Thus, a GFP-tagged version 
of H-Ras could successfully access the plasma membrane during BFA exposure. This 
indicated that the GFP tag did not prevent this type of trafficking. As more GFP-H-Ras 
protein was synthesized after the removal of the cycloheximide, an increase in GFP-H-Ras 
fluorescence was noted in the perinuclear area. This area was not the Golgi, because it had 
been ablated by the BFA that was present. The identity of this region was examined below. 
The general absence of directed movement of the visible dots of GFP-H-RasQ61L, in addition 
to its COP I- and COP II- independence, suggested that the initial transport of GFP-H-
RasQ61L to the plasma membrane that occurred in BFA-treated cells might be non-vesicular.  
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Nocodazole does not prevent H-Ras movement to the plasma membrane 
To determine if transport of nascent H-Ras was also independent of microtubules that 
might support vesicular traffic, cells transfected with cDNA for H-RasQ61L were treated with 
cycloheximide for 6 hours, cycloheximide was removed and nocodazole was added for 90 
minutes. With this treatment length, nocodazole causes fragmentation of the Golgi into 
multiple individual Golgi mini-stacks throughout the cell. These stacks were visualized with 
antibody to the endogenous Golgi protein, giantin, which verified that the nocodazole 
treatment had successfully dispersed the Golgi (Fig. 5). To determine how effectively this 
nocodazole treatment inhibited transport of a protein in the traditional exocytic pathway, 
GT46 was examined. After a 4-hour exposure to nocodazole, GT46 was found, exclusively, 
on internal membranes (Fig. 5); no GT46 was visible on the plasma membrane. This 
indicated that this protocol for nocodazole treatment efficiently inhibited microtubule-
dependent vesicular transport during the experiment. Importantly, in cells in which 
microtubules had been depolymerized, H-RasQ61L was still able to reach the plasma 
membrane (Fig. 5). This indicated that a microtubule-independent mechanism could move 
H-Ras to the plasma membrane. These results complement previous work [22] that had 
shown that H-Ras that was already at the plasma membrane could reach the Golgi, when 
microtubules were depolymerized by acute application of nocodazole.  
Notably, in these nocodazole-treated cells, there was a prominent amount of H-Ras that 
was located on dispersed internal structures. These HRas-containing structures were often 
alongside of, but did not actually colocalize with, the giantin-marked Golgi mini-stacks (Fig. 
5, merge). This revealed that, although a significant amount of H-Ras reached the plasma 
membrane, nocodazole treatment caused some H-Ras to be retained internally, on structures 
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that were distinct from cis-Golgi membranes in the trafficking pathway. These results 
pointed to the possibility of simultaneous utilization of two parallel mechanisms for H-Ras 
transport. One route was the traditional, vesicular path, dependent upon microtubule 
integrity; the other, a pathway that did not require COP I or COP II vesicles or microtubules. 
Some H-Ras accumulates at the ERGIC when the classical pathway is blocked 
The identity of the non-Golgi structures that contained H-Ras in nocodazole-treated cells 
was examined. A clear candidate location was the series of membranes, often termed the ER-
Golgi intermediate compartment (ERGIC) [37,38], that bud off the widely dispersed ER exit 
sites and move toward the Golgi. Microtubule de-polymerization does not prevent traffic 
from ER to ERGIC, but does interrupt vesicular transport from ERGIC to Golgi. [38]. Thus, 
at steady-state the bulk of ERGIC membranes are located near the perinuclear cis-Golgi, but 
in nocodazole-treated cells, proteins in the ERGIC reside near the ERES and Golgi mini-
stacks. ERGIC membranes are also BFA-resistant, are maintained rather than absorbed 
during BFA exposure, and even accumulate in a perinuclear mass in cells treated for 
extended periods with BFA. [38]. Thus, both nocodazole and BFA cause proteins in the 
conventional trafficking pathway to accumulate in the ERGIC, although the ERGIC 
membranes are organized in spatially distinct ways by these drugs. 
To learn if some H-Ras accumulated on ERGIC membranes in cells in which vesicular 
transport was impaired, transfected COS-7 cells were treated with cycloheximide for 6 hours, 
then with nocodazole or BFA for 1.5 hours in the absence of cycloheximide, and finally, 
were fixed and stained. Antibody to the endogenous ERGIC-53 protein was used to mark the 
location of ERGIC membranes. In untreated cells, the ERGIC-53 protein was located on a 
cluster of perinuclear membranes (Fig. 6, control). The ERGIC-53-containing membranes 
   54
intertwined around the giantin-marked cis-Golgi (data not shown), making these structures 
difficult to resolve in untreated cells.  In the minority of untreated cells that showed H-Ras on 
perinuclear membranes, the newly synthesized H-RasQ61L protein showed substantial 
colocalization with the endogenous ERGIC-53 (Fig. 6, control).  
In agreement with previous reports, in nocodazole-treated cells, the ERGIC-53 antibody 
stained membranes that had dispersed throughout the cell body (Fig. 6, + Noc), while in 
BFA-treated cells, ERGIC-53 staining appeared on a cluster of perinuclear membranes (Fig. 
6, + BFA). In cells treated with either nocodazole or BFA, the internal sites where the H-
RasQ61L protein was located colocalized with the ERGIC-53 protein (Fig. 6).  Once again, H-
Ras was also present on the plasma membrane in these nocodazole- or BFA-treated cells. 
There was also a considerable amount of the newly synthesized H-Ras that was still cytosolic 
or on the widely dispersed membranes of the ER. These results indicated that some of the 
newly synthesized H-Ras had entered the traditional trafficking pathway and accumulated in 
the ERGIC when vesicular transport was impaired.  
H-Ras that is in the ERGIC does not access the alternate pathway in 
nocodazole-treated cells 
If H-Ras could move to the plasma membrane via a non-conventional mechanism that 
originated prior to the Golgi, it might enter this alternate pathway directly from the ER, 
shortly after interacting with the enzymes that remodel the C-terminus. Alternatively, it 
might aggregate at ER exit sites and move to the ERGIC via conventional means, but from 
there disengage and be routed to the cell surface. The proteins that might control H-Ras 
transport would likely differ at these two locations. The failure of inhibitory Sar1 proteins to 
prevent H-Ras plasma membrane access suggested that the alternate pathway did not require 
the proteins found at ER exit sites. Another experiment was designed to test if the H-Ras that 
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accumulated in the ERGIC upon nocodazole treatment could eventually access the plasma 
membrane. COS-7 cells were transfected and cycloheximide treated immediately. After 6 
hours, cycloheximide was washed out to generate synchronous production of nascent H-Ras 
proteins, and nocodazole was added at that same time to allow some of these nascent H-Ras 
proteins to get into, but to impair their exit from, the ERGIC. After 4 hours, when a 
detectable portion of H-Ras protein accumulated in the ERGIC, a second cycloheximide 
treatment was applied, to prevent synthesis of additional H-Ras, and the cells, still in the 
presence of nocodazole, were incubated a further two hours. Thus, only pre-existing H-Ras 
protein was in the ERGIC, and new protein could not move in. The prediction was that, if H-
Ras could be exported from ERGIC via the alternative pathway, it would disappear from the 
ERGIC, since there would be no new H-Ras supplied from the ER. However, this was not 
observed. H-Ras was still present in the membranes that aligned with ERGIC-53 even after 2 
more hours (Fig 7, + Noc Chase). In a control experiment, nocodazole was removed during 
the second cycloheximide exposure, to now allow vesicular traffic out of the ERGIC. During 
this nocodazole wash out, the organized, perinuclear structure of the ERGIC quickly re-
formed, and H-Ras was observed on many internal, vesicle-like structures that no longer co-
aligned with ERGIC-53 (Fig 7, - Noc Chase). This confirmed that the H-Ras that had 
become trapped during the nocodazole treatment had not been damaged and remained 
competent for transport. Thus H-Ras could rapidly leave the ERGIC if vesicular transport 
was available, but could leave only very slowly or not at all if that conventional mode of 
transport was impaired. This result suggests that the two modes of transport are separate, and 
that H-Ras that reaches the ERGIC can no longer access the alternate route. This supports the 
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possibility that this alternate pathway for H-Ras transport to the plasma membrane originates 
directly from the ER. 
Discussion 
The results here represent the first comprehensive look at modes of transport used to 
move newly synthesized H-Ras to the plasma membrane. Despite our expectations, 
conventional vesicular mechanisms could not account for most of the H-Ras that reached the 
cell surface. Previous work, although focused on the traditional exocytic pathway, had also 
noted that a significant amount of H-Ras reached the plasma membrane when traditional 
trafficking pathways were inhibited. [3]. Fluorescence photo-bleaching experiments had also 
indicated that the H-Ras protein moves from the ER to the Golgi too rapidly to be carried by 
vesicles. [22]. 
Those studies, combined with the evidence presented here, lead us to propose that a 
significant amount of H-Ras uses a non-classical pathway for transportation to the plasma 
membrane. This model proposes that H-Ras has two pathways by which it can reach the 
plasma membrane, and that in normal circumstances both routes are used simultaneously. In 
NIH 3T3 or COS-7 cells, this non-classical pathway appears to be the primary means for 
plasma membrane access. In yeast, strong genetic evidence supports the idea that the Ras2 
protein moves to the cell surface via a non-conventional pathway. [19,39]. This indicates that 
a non-classical pathway of Ras transport may be conserved in eukaryotes. 
This non-classical pathway appears to be initiated at the ER rather than at the Golgi. 
Comparison of the localizations of H-Ras and Sec13 on ER membranes suggests that very 
little H-Ras is present at conventional vesicle budding domains of ER export sites. [HZ, 
unpublished data). In addition, once H-Ras enters the conventional transport pathway and 
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reaches the ERGIC, it appears to have very limited access to this non-classical pathway. This 
suggests that the choice of pathway, and mechanism of transport, is determined prior to ER 
disengagement. H-Ras thus has two distinct means of transport, and, importantly, need not 
depend on vesicular trafficking for its delivery to the plasma membrane. 
Though the two different pathways for H-Ras traffic appear to separate at the ER, it is not 
yet known what initiates this divergence. One strong candidate for such a mechanism is 
palmitoylation. [39]. There is existing evidence that, as long as it is non-palmitoylated, 
farnesylated H-Ras is in a dynamic equilibrium between the cytosol and membranes. 
[20,22,40]. Current models propose that when H-Ras encounters a membrane-bound 
palmitoyl transferase and becomes palmitoylated, it can no longer disengage from that 
membrane. The location at which palmitoylation occurs then defines the point where the 
palmitoylated H-Ras can join the classical vesicular pathway. [21,22]. Our evidence, that 
some H-Ras is in the secretory pathway and can reach ERGIC membranes, but, in 
nocodazole-treated cells, appears unable to leave, provides independent support for this 
model. The data also bolster the recent report that a palmitoyl transferase may be located on 
ER membranes [13], and, suggest, additionally, that it may be located on perinuclear ERGIC 
membranes as well. Our model would propose that regulation of this enzyme’s activity might 
then adjust the amounts of H-Ras that enter each of the two transport pathways. If H-Ras 
fails to be palmitoylated on the ER, it may be able to use the non-classical pathway to move 
to the plasma membrane. Experiments with mono-palmitoylated H-Ras mutants are under 
way to test this prediction. [JM, unpublished data]. An additional prediction, suggested by 
the large amounts of H-Ras that associated stably with the plasma membrane when vesicular 
transport was inhibited, is that there are other palmitoyl transferases located at the plasma 
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membrane. There is already some evidence that supports the possibility of H-Ras 
palmitoylation on the plasma membrane. A novel H-Ras that is not farnesylated but that 
retains the native cysteines as sites for acylation, completely avoids the Golgi, yet is targeted 
to the plasma membrane and becomes palmitoylated. [18,41]. 
In both yeast and, shown here, mammalian cells, H-Ras transport can function in the 
apparent absence of traditional vesicles. Neither interruption of outward vesicular movement 
with nocodazole nor ablation of COP I or COP II vesicles provided any evidence for non-
traditional vesicles that might carry H-Ras to the plasma membrane. Thus, the data currently 
suggest that this non-classical pathway is non-vesicular. The potential lack of a vesicular 
membrane for interaction of the lipidated C-terminus of H-Ras poses a problem, as the 
hydrophobic farnesyl (and possibly, palmitoyl) group at the C-terminus would then be 
exposed to the aqueous phase. This situation would be thermodynamically unfavorable 
unless the lipid groups were able to fold back against the protein. There is currently no 
precedent for such a model. An alternative way to prevent exposure of the lipids would be for 
an escort or chaperone protein to interact with the C-terminus and mask the hydrophobic tail 
of H-Ras. There is also recent evidence that H-Ras can be found on intracellular particles 
termed “nanoparticles” or “rasosomes”, that could potentially serve a role in H-Ras transport. 
[42,43]. Whatever the mechanism, this non-conventional transport of H-Ras is efficient, and 
delivers H-Ras specifically to the plasma membrane. 
Several cancer therapies currently in clinical trials are designed to inhibit membrane 
binding of Ras proteins. [44]. Our findings that H-Ras may use two pathways to reach the 
plasma membrane suggests that there is more to learn before this therapeutic strategy will be 
successful. Of equal importance, the evidence that a significant amount of H-Ras may use 
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non-vesicular means for movement suggests that proteins that escort or regulate H-Ras 
trafficking from the ER should be sought. The assays developed in this work provide 
strategies that will be useful for searching for novel H-Ras partners. 
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Figure Legends 
Figure 1  H-Ras is not in the perinuclear area in many cells 
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NIH 3T3 or COS-7 cells were co-transfected with H-RasQ61L and YFP-GT46 DNAs or 
transfected with H-RasQ61L DNA alone. At 18 hours after transfection, cells were 
fixed and immuno-stained to show the location of the H-Ras protein. Epifluorescence 
of YFP-GT46 or immunostaining of giantin were used to mark the perinuclear/Golgi 
area. The strength of the HRas signal in the perinuclear area was assigned a value of 
“none”, “+” or “++”.  Scale bar shows 10μm. 
Figure 2  H-Ras moves faster than YFP-GT46 to the plasma membrane 
NIH-3T3 cells were co-transfected with H-RasQ61L and YFP-GT46 DNAs. 
Cycloheximide was added to the media immediately. Six hours later, that medium 
was removed and replaced with medium that did not contain cycloheximide. Cells 
were fixed at different time points after the removal of cycloheximide and stained 
with antibody to H-Ras. White arrowheads indicate protein that has accumulated in 
the perinuclear area; white arrows show the plasma membrane. The insets are 
magnified images of the area enclosed in the box; pink and green arrowheads show 
vesicles with only H-RasQ61L (red) or YFP-GT46 (green) respectively; yellow 
arrowhead shows one of the vesicles that has both H-RasQ61L and YFP-GT46. Scale 
bar shows 10μm. 
Figure 3  BFA or dominant negative Sar1 do not prevent H-Ras from reaching the 
plasma membrane 
A) NIH-3T3 cells were co-transfected with H-RasQ61L and YFP-GT46 DNAs. 
Cycloheximide was added immediately after the transfection and was removed 6 
hours later. Brefeldin A was added to the media upon the removal of cycloheximide 
and, 90 minutes later, cells were fixed and stained with H-Ras antibody. B) NIH-3T3 
cells were either co-transfected or sequentially transfected with HA-Sar1T39N and H-
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RasQ61L or HA-Sar1T39N and YFP-GT46 DNAs. At 18 hours after transfection, cells 
were fixed and stained with H-Ras antibody. Arrowheads show the nuclear envelope 
and arrows show the plasma membrane. Scale bars equal 10μm. 
Figure 4  Live cell imaging shows no obvious vesicular traffic of H-Ras to the plasma 
membrane when BFA is present 
NIH-3T3 cells were transfected with GFP-H-RasQ61L DNA. Cycloheximide was added to 
the media immediately after the transfection and was removed 6 hours later. BFA was 
added to the media upon the removal of cycloheximide and live cells were imaged at 
different time points after the addition. Arrowheads show the perinuclear area. The 
insets show a higher magnification of the boxed area, with arrows that indicate the 
stable position of an internal “granule” carrying GFP-H-RasQ61L. Scale bar shows 
10μm. 
Movie 1  NIH-3T3 cells were transfected with GFP-H-RasQ61L DNA  
Cycloheximide was added to the media immediately after the transfection and was 
removed 6 hours later. BFA was added to the media upon the removal of 
cycloheximide and live cells were imaged at 37 degrees starting approximately 30 
minutes later, when protein had been synthesized in amounts sufficient to be visible. 
Figure 5  H-Ras still reaches the plasma membrane when nocodazole is present  
NIH-3T3 cells were transfected with H-RasQ61L or YFP-GT46 cDNAs. Cycloheximide 
was added to the media immediately after the transfection and was removed 6 hours 
later. Nocodazole was added to the media upon the removal of cycloheximide and 
after 90 minutes (120 minutes for YFP-GT46, right panel, first row) cells were fixed 
and immuno-stained with antibody for giantin and, in the H-Ras-transfected cells (the 
left and middle columns), antibody for H-Ras. Arrows indicate the plasma membrane. 
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Merge panels are enlargements of the boxed areas, with arrowheads that indicate two 
separate structures, one containing H-RasQ61L or YFP-GT46 (green), the other 
containing giantin (red). Scale bar shows 10μm.  
Figure 6  When nocodazole or BFA is present, a portion of H-Ras accumulates in 
the ERGIC 
COS-7 cells were transfected with H-RasQ61L cDNA. Cycloheximide was added to the 
media immediately after the transfection and was removed 6 hours later. Nocodazole 
or BFA were added to the media upon the removal of cycloheximide and, after 90 
minutes, cells were fixed and stained with antibodies for H-Ras and ERGIC-53. 
Arrows show the plasma membrane; arrowheads show the colocalization of H-Ras 
and ERGIC-53. Scale bar shows 10μm. 
Figure 7  H-Ras does not leave the ERGIC in the presence of nocodazole. COS-7 cells 
were transfected with H-RasQ61L DNA 
Cycloheximide was added to the media immediately after the transfection and was 
removed 6 hours after the transfection. Nocodazole was added to the media upon the 
removal of cycloheximide and after 2 hours cycloheximide was added again to the 
media while nocodazole was either washed out (-Noc) or still kept in the media 
(+Noc). After another 2 hours, cells were fixed and immuno-stained. Arrows show 
the plasma membrane; arrowheads show the ERGIC membrane. Scale bar shows 
10μm. 
Table Legends 
Table 1  HRas perinuclear distribution is distinct from the pattern of a protein in the 
traditional vesicular trafficking pathway 
 NIH 3T3 cells and Cos-7 cells were co-transfected with YFP-GT46 and one of the H-Ras 
DNAs was indicated. After 18 hours, the cells were fixed and immuno-stained for HRas. 
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Approximately 100 cells were examined and the strength of the HRas signal in the 
perinuclear area was assigned values of “none”, “+”, or “++”. Values are the averages 
and standard deviations of the number of cells from two (HRas) or four (YFP-GT46) 
independent experiments. Monomeric GFP is abbreviated as mGFP and “N.d.” means not 
determined. 
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Figures 
 
Figure 1  H-Ras is not in the perinuclear area in many cells 
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Table1  HRas perinuclear distribution is distinct from the pattern of a protein in the 
traditional vesicular trafficking pathway 
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Figure 2  H-Ras moves faster than YFP-GT46 to the plasma membrane 
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Figure 3  BFA or dominant negative Sar1 do not prevent H-Ras from reaching the 
plasma membrane 
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Figure 4  Live cell imaging shows no obvious vesicular traffic of H-Ras to the plasma 
membrane when BFA is present 
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Figure 5  H-Ras still reaches the plasma membrane when nocodazole is present 
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Figure 6  When nocodazole or BFA is present, a portion of H-Ras accumulates in the 
ERGIC 
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Figure 7  H-Ras does not leave the ERGIC in the presence of nocodazole. COS-7 cells 
were transfected with H-RasQ61L DNA 
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Abstract 
Recent studies indicate that multiple exocytosis pathways are used by HRas to reach the 
plasma membrane in yeasts and mammals. When Ras is attached to GFP, more instances of 
vesicular trafficking are seen, but in the absence of GFP, the majority of Ras bypasses the 
Golgi on its way to the plasma membrane. In this study we have further established that GFP 
emphasizes the vesicular trafficking pathway in various polarized epithelial cell types, such 
as MDCK (Madine Canine Kidney Cells) and HeLa (Henrietta Lacks cells). To date, we have 
seen a Golgi-independent-trafficking mechanism used predominantly in NIH 3T3 cells and 
Cos-7 cells. To more clearly understand Golgi-independent trafficking mechanisms, we 
explore which properties of HRas are required for the non-vesicular trafficking pathway. We 
have found that all palmitate lipid modifications as well as the entire hypervariable region are 
needed for HRas localization at the plasma membrane via the Golgi-independent trafficking 
mechanism.  
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Introduction 
Ras is a member of the small GTPase family that plays an essential role in cellular function. 
It is often described as a molecular switch that exists in two states—GTP bound (active) and 
GDP bound (inactive). When it is activated, Ras is able to interact with multiple down stream 
effectors that ultimately result in cell proliferation, differentiation, and apoptosis. While the 
four major isoforms of Ras—HRas, NRas, KRas A, and KRas B—are highly conserved with 
each other in the conserved region, their isoforms differ in their hypervariable regions at the 
carboxy terminus (C-terminus). 
In order to become fully functional as a molecular switch, newly synthesized Ras goes 
through a series of posttranslational modifications. The posttranslational modification takes 
place at the final four residues of Ras often described as the CAAX box (C = cysteine = 
cys 186; AA = aliphatic amino acids; and X = any amino acid). To begin the posttranslational 
modification, C of the CAAX box is modified by the enzyme farnesyl transferase. Then the 
farnesylated Ras binds to the cytoplasmic leaflet of the Endoplasmic Reticulum (ER) where 
Ras Converting Enzyme 1 (RCE 1) cleaves the -AAX of the CAAX box. [1, 2]  The newly 
exposed cysteine is then modified by the Isoprenyl Cysteine Carboxy Methyl Transferase 
(Icmt; methyl transferase).[3-5] At this point KRas, with its positively charged polylysine 
residues, localizes to the plasma membrane by an unknown mechanism, but NRas and HRas 
require additional modifications before membrane localization. [2] The enzyme Palmitoyl 
Transferase attaches the palmitate lipid groups onto the cysteines just upstream of the CAAX 
box. NRas receives a single palmitate at position 181, whereas HRas receives double 
palmitates at positions 181 and 184. [6, 7] These palmitates serve as membrane anchors that 
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adhere Ras to the cytoplasmic leaflet of the plasma membrane where Ras acts as a molecular 
switch. [8-10] 
Early models show that in order for Ras to act as a molecular switch, it must be localized 
to the plasma membrane. [11] In fact, mutations that prevent Ras from localizing to the 
plasma membrane show significant decreases in Ras-mediated oncogenic activity. [12] On 
the other hand, Ras that is localized on endomembranous organelles, such as the 
Endoplasmic Reticulum (ER), is thought to be a protein that is in transit before it localizes to 
the plasma membrane via vesicles. The process by which Ras travels out to the plasma 
membrane in vesicles is known as the vesicular trafficking mechanism. For HRas, vesicular 
trafficking begins when palmitoylated Ras is released into the cytoplasmic leaflet of the ER. 
[1, 13] In the ER, vesicle formation begins when a small GTPase—Sec-related and Ras-
related protein 1 (Sar 1)—is activated by GTP binding. [14] Activation of Sar1 leads to 
aggregation of the COP II complex of proteins around the ER Exit Sites (ERES). [15-17] 
Before reaching the Golgi, COP II-coated vesicles will first merge into a vesiculo-tubular 
intermediate structure (ER-Golgi-Intermediate-Compartment, ERGIC). [18] From here, 
cargo-containing COP II vesicles continue their trafficking to the Golgi and, ultimately, to 
the plasma membrane.[19] In some cases, vesicles are transported back to the ER from 
Golgi, This kind of retrograde trafficking is regulated by the COP I complex. [19] 
An antifungal reagent, Brefeldin A (BFA), inhibits the COP I complex from binding to 
the ER membrane but allows retrograde trafficking to continue. Continued trafficking in one 
direction causes Golgi membranes and proteins to rapidly regress into the ER and ultimately 
results in the collapse of the Golgi. 
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Several interesting, recent studies show that even in the absence of Golgi, HRas 
anterograde trafficking to the plasma membrane continues, suggesting a Golgi-independent 
mode of trafficking for HRas. Some have even suggested the existence of nanoparticles or 
the possibility of Ras oligomer formation. [20, 21]  Further, this Golgi-independent 
mechanism seems to also be vesicle-independent. [22-24] Finally, a potassium-channel 
subunit, KchIP, and KRas also seem to localize to the plasma membrane in a Golgi-
independent manner. [25, 26] 
In this study, we examine the roles that palmitoylation may play in Golgi-independent 
and vesicle-independent trafficking. We also explore whether any of the non-palmitoylated 
residues upstream of the CAAX box are key players in Golgi-independent HRas trafficking. 
Materials and Methods 
DNA and plasmids 
HRas C181S, HRas C184S, and HRas Q61L were expressed in PcDNA3 plasmid 
(Invitrogen). GFP-HRas Q61L is expressed in pEGFP–C3 vector. GFP delta 17 and GFP 
delta 19 were gifts from Dr. Ian Prior. Briefly, for delta 17 mutants, 7 alanine residues were 
inserted just upstream of the CAAX box. ( HKLRKLNPPDESGPGCMSCKCVLS to 
HKLRKLNAAAAAAAGCMSCKCVLS). For delta 19 mutants, 7 alanine residues were inserted 
further upstream from the CAAX box (HKLRKLNPPDESGPGCMSCK to 
AAAAAAAPPDESGPGCMSCK). Both mutants were expressed in GFP-C1 vector. YFP-GT46, 
mGFP-HRas Q61L, and mGFP-HRas wildtype (wt) were gifts from Dr. Anne Kenworthy. 
Cell culture and transfection 
NIH3T3, HeLa, and Cos-7cells were cultured in 10% CO2 in Dulbecco’s Modified 
Eagle’s Medium (DMEM from GIBCO-BRL). DMEM also contained 10% calf serum 
(GIBCO). One percent each of sodium pyruvate (GIBCO), L-glutamine (GIBCO), antibiotics 
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(GIBCO), and Fungazone (Sigma) were added. MDCK cells were cultured at 10% CO2 in 
DMEM, which also contained 10% fetal bovine serum (GIBCO) and 1% each of 
L-glutamine, sodium pyruvate, antibiotics, and Fungazone. To seed the cells, pre-washed 
glass coverslips were placed in 12 well-tissue-culture plates and were coated with a mixture 
of polylysine and fibronectin for at least 2 hours at 37°C. Twenty-four hours before DNA 
transfection, NIH3T3 cells were placed on these coverslips at a density of approximately 
105–106 cells per well. 
Transfection was done using Effectene transfection reagent (Qiagen) following the 
manufacturer’s protocol. For experiments where double transfection was needed, DNA were 
combined (0.15µg of each type of DNA per well) before transfection. 
Cell counts 
NIH 3T3, HeLa, MDCK, and Cos-7 cells were co-transfected with YFP-GT46 and HRas wt 
or HRas Q61L mutant. YFP-GT46 is an artificial, secretory protein that consists of the 
Yellow Fluroescent Protein (YFP), the N-glycosylation site, the transmembrane domain of 
the LDL receptor, and the cytoplasmic tail of CD 46. After 24 hours, cells were immuno-
stained with HRas antibody. Approximately 150 cells expressing YFP-GT46 in the 
perinuclear region were counted. Of these same cells, whether HRas was present in the same 
perinuclear area were noted. At least two individual counts were performed and the data were 
analyzed using ABI Prism software. 
Brefeldin A, Nocodazole, and Cycloheximide treatments 
For cycloheximide treatments, NIH 3T3 cells were treated with cycloheximide (50μg/ml) 
immediately following the transfection. The cells were incubated at 37°C for 6 hours, then 
cycloheximide was washed out with phosphate buffered saline (PBS). Cells in complete 
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medium were then treated for 4 hours (unless otherwise noted) with either BFA (10 µg/ml) or 
nocodazole (20µg/ml). Cells were then fixed and stained for immunofluorescence. 
Immunofluorescence  
Following transfection and the pharmacological treatments described above, NIH 3T3 
cells were fixed with 4% paraformaldehyde in PBS at room temperature for 1 hour. Cells 
were then permeablized with either 100% methanol at -20°C for 1 minute or 0.2% Triton X-
100 on ice for 5 minutes. Cells were then quenched twice (15 minutes each) with 50mM 
NH4Cl in PBS before being blocked. For the blocking step, cells were incubated in blocking 
buffer (2% horse serum, 0.4% BSA in PBS) at room temperature for 30 minutes. 
Immediately after blocking, the cells were incubated in primary antibodies diluted in 
blocking buffer at room temperature for 1 hour (HRas 238 Rat monoclonal IgG. 1:400 
dilution, Santa Cruz; giantin anti-rabbit polyclonal antibody, 1:800, Covance; TRAP anti-
rabbit 1:500, Nicchita). Then the cells were incubated in secondary antibodies (Alexa-Fluor® 
donkey-anti-rat, 594 1:800, Alexa-Fluor® goat-anti rat 488 1:800, Alexa-Fluor®  goat anti-
rabbit 594, 1:800; all secondary antibodies were purchased from Molecular Probes) diluted in 
blocker solution for an additional hour in the dark. For phalloidin labeled experiments, the 
cells were incubated in Alexa-Fluor® 594-congugated phalloidin (Molecular Probes, 1;200 
dilution in blocking buffer) for 20 minutes in the dark. After labeling with secondary 
antibodies, the coverslips containing cells were washed in PBS and distilled water before 
being mounted on glass slides with mounting media (Vectashield). Finally, the coverslips 
were rimmed with nail polish. 
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Microscopy 
All cells were examined and photos were taken with Leica DMIRE2 microscope with a 
numerical aperture of 100x. Images were first captured in black and white, then colors were 
added using Open Lab 3.5.1 software. The images were then exported to Adobe Photoshop 7 
to equalize intensity of both images and then merged. Unless noted in the figure legends, all 
images were taken in Z-stack mode. 
Results 
GFP-HRas expression in multiple cell types  
HRas localizes on endomembranous structures such as the Golgi and the ER in addition 
to the plasma membrane. To study HRas localization, green fluorescent proteins (GFP) are 
often attached to the amino terminus of HRas to make a GFP-HRas—an HRas chimeric 
protein. As an HRas chimera, GFP acts as a reporter and indicates where its fusion partner is 
located, even on membrane structures. Although in these situations GFP is a great reporter, 
effects that the approximately 50 kDa GFP might have on HRas localization and trafficking 
patterns have not yet been closely examined because when GFP is expressed without fusion 
to HRas, GFP is evenly distributed in the cytosol and absent from membrane structures. 
When GFP is attached to the HRas N-terminus, GFP-HRas will localize at the plasma 
membrane and other endomembranes. In fact, our studies show that GFP-HRas emphasizes 
perinuclear accumulation of HRas more than their non-GFP tagged counterparts. (Chapter 2) 
When NIH 3T3 cells were transfected with GFP-HRas, there were frequently strong 
localizations at the plasma membrane and at the structure that appears to be Golgi near the 
nucleus. (Figure 1, Table 1) At first we entertained the possibility that these accumulations 
are directly related to GFP-HRas over-expression. In high concentrations, GFP has the ability 
to form dimers, so it was possible that the GFP of the GFP-HRas could bind with one another 
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to form dimers. Formation of GFP dimers might change the rate of HRas trafficking to the 
plasma membrane because of increases in the size of HRas. When monomeric GFP (mGFP), 
a GFP mutant that is unable to form dimers, is attached to HRas and expressed in NIH 3T3 
cells, even though mGFP-HRas was able to reach the plasma membrane, there was a 
decrease in the percentage of cells showing the perinuclear accumulation. On average, 60–
70% of cells expressing GFP-HRas61L showed Golgi-like accumulation near the nucleus. In 
contrast, monomeric GFP version of the same HRas (mGFP HRas Q61L) accumulated near 
the nucleus in only about 25% of the cells. Although mGFP significantly decreased HRas 
accumulation in the perinuclear area, mGFP HRas is still seen significantly more frequently 
in the perinuclear area than HRas Q61L (<10%) which does not contain any reporters. 
(Figure 1, Table 1) 
To identify the perinuclear structure in HRas-expressing cells, NIH 3T3 cells were co-
transfected with HRas and YFP-GT46, a artificial, secretory, chimeric protein that is known 
to use the conventional trafficking mechanism. YFP-GT46 consists of the yellow fluorescent 
protein (YFP), an N-glycosylation site, the transmembrane domain of LDL receptor, and the 
cytoplasmic tail of CD 46. [27] When we co-transfected NIH 3T3 cells with YFP-GT46, this 
protein marked the entire conventional trafficking pathway and the perinuclear Golgi region. 
At 24 hours after co-transfection, most of YFP-GT64 was localized at the perinuclear region 
as well as at the plasma membrane. To verify that these perinuclear regions are, in fact, 
Golgi, giantin (a Golgi-resident protein), was used as a marker to visualize the cis-Golgi 
structure. As expected, there were strong colocalizations between giantin and YFP-GT46. 
(data not shown) 
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Recently, Gomez et al. described restricted HRas accumulation at the Golgi apparatus in 
the absence of GFP tags in CHO-K1 cells. [28] To see if the lack of HRas accumulation at 
the Golgi is observable in other cell types, the experiments reported above were repeated 
with four cell types, MDCK, HeLa, NIH 3T3, and Cos-7. When expressed, GFP HRas also 
showed strong Golgi accumulation in MDCK and HeLa cells. When cells were co-
transfected with YFP GT 46 and untagged HRas, the majority of cells of all four cell types 
showed HRas only at the plasma membrane. (Figure 2; Table 2) 
We examined whether the GTP- or GDP-bound state of HRas changed its subcellular 
localization patterns. An oncogenic mutant form of HRas (HRas Q61L) or a cellular form of 
HRas (HRas wt) was co-transfected with YFP-GT46. Although YFP-GT46 showed strong 
accumulation both at the Golgi and at the plasma membrane as before, there were no 
significant differences between the oncogenic or cellular types of HRas colocalizing with 
perinuclear YFP-GT46. (Table 1, Table 2) These results suggest two interesting 
possibilities. First, GFP changes HRas trafficking by decreasing the rate of movement and 
decreasing HRas trafficking efficiency toward the plasma membrane through the Golgi. GFP 
dramatically slows the HRas trafficking mechanism. If GFP changes HRas trafficking 
efficiency and the rate of movement through the Golgi, it follows that all HRas must pass 
through the Golgi. 
However, a second possibility was considered: how does naturally occurring HRas traffic 
out to the plasma membrane in the absence of Golgi. In our previous study (Chapter 2), we 
observed that HRas trafficked out to the plasma membrane in a Golgi-independent manner, 
while GFP-tagged HRas prefers Golgi-dependent trafficking. In other words, non-GFP-
tagged HRas prefers the Golgi-independent trafficking mechanism more than GFP-tagged 
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HRas does. It is not yet known if more than one Golgi-independent trafficking mechanism 
exists. 
HRas plasma membrane localization with BFA 
To investigate these possibilities further, NIH 3T3 cells were co-transfected with HRas 
Q61L and YFP-GT46. To insure that only outward-bound HRas are visualized, cells were 
treated with cycloheximide, a pharmacological reagent that inhibits translation. If 
cycloheximide is added immediately after transfection, cells may accumulate HRas RNA, but 
no HRas protein will be translated or trafficked. To test whether Golgi is an essential 
component in HRas trafficking, YFP-GT46 and HRas Q61L transfected NIH 3T3 cells were 
treated with cycloheximide for 6 hours. Then they were washed with PBS and treated with 
Brefeldin A (BFA). BFA is a pharmacological reagent that collapses the Golgi and prevents 
vesicular transport. As expected, when treated with BFA, YFP-GT46 was absent from the 
plasma membrane in NIH 3T3 cells (Figure 5). YFP-GT46 proteins were predominantly 
located on the internal membranes and on the circumference of the nucleus. This is consistent 
with proteins located on the ER. 
On the other hand, most HRas Q61L was localized only at the plasma membrane. 
(Figure 3) In our previous study (Chapter 2), we noticed that HRas can reach the plasma 
membrane much faster than YFP-GT46 even when protein trafficking to the plasma 
membrane was synchronized (HRas = 20 minutes; YFP GT46= 2 hours). Even the small 
punctate structures in transit in the cytosol showed very little, if any, colocalization between 
HRas and YFP-GT46.  
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Mono-palmitoylated HRas does not accumulate in the Golgi  
It has been well established that HRas palmitoylation is essential for its plasma 
membrane localization. Even though some isoforms of Ras are not dependent on 
palmitoylation for plasma membrane localization (e.g., KRas), further study was needed to 
determine whether 1) mono-palmitoylated HRas is still able localize to the plasma membrane 
and 2) Golgi-independent exocytosis is available to HRas with one palmitate. Roy et al.. 
described mono-palmitoylated HRas being localized at the plasma membrane as well as at 
the Golgi apparatus. [29] To confirm these findings, we co-transfected HRas with either 
C181S or C184S and with YFP-GT 46. As expected, approximately 98% of the cells 
expressing YFP-GT46, showed very strong Golgi and plasma membrane localizations. In 
addition to the study done by Hancock et al., very few (<10%) NIH 3T3 cells with HRas 
C181S or C184S (Figure 4) showed strong Golgi localization even though both mutants 
illuminated the plasma membrane very clearly. (Figure 5, Figure 6) It is likely that this 
discrepancy between our findings and other published data may be due to the attachment of 
GFP on the N-terminus of the mono-palmitoylated HRas proteins used in other studies. As 
previously mentioned, adding GFP to HRas enhances protein accumulation in the Golgi and 
thus emphasizes the usage of Golgi-dependent trafficking mechanism. 
Palmitoylation requirements for Golgi-independent trafficking 
To further investigate whether the Golgi-independent trafficking mechanism is available 
to mono-palmitoylated HRas, NIH 3T3 cells were co-transfected with YFP-GT46 and either 
C181S HRas or C184S HRas. Immediately following the transfection, cells were exposed to 
cycloheximide for 6 hours to synchronize protein trafficking then they were treated with 
BFA to collapse the Golgi. To our surprise, both HRas C181S and HRas C184S failed to 
localize to the plasma membrane (Figure 3), but HRas Q61L reached the plasma membrane 
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as expected. (Figure 5; Figure 6) We also noted that neither HRas Q61L, HRas C181S, or 
HRas C184S colocalized with YFP-GT46 when vesicles in transit were examined. To 
consider the possibility that these HRas mutants retreated back into the ER in the absence of 
Golgi, the experiments were repeated and cells were immuno-labeled with an ER-resident 
marker (α trap). Even in the regions near the nucleus where the ER is most densely packed, 
no colocalization between HRas palmitoylation mutants and ER-resident protein was 
observed. In the presence of BFA, both mutants appear to be mostly cytosolic or in tiny 
punctate structures. (Figure 5) 
Because mono-palmitoylated HRas was clearly absent from the plasma membrane but 
not retained in the ER, we repeated the experiment using nocodazole, which destroys the 
microtubular tracks, to see if mono-palmitoylated HRas were trapped in the vesicles. Once 
formed, vesicles usually travel along the microtubular tracks to move within a cell and to 
deliver cargo proteins to the plasma membrane. New tracks of microtubules are constantly 
being synthesized while old tracks are being destroyed. An overall net growth of 
microtubules occurs when GTP-bound tubulins are attached to the terminal GDP-bound 
tubulin. When GTP hydrolysis is much faster than the addition of new tubulins, microtubules 
begin to shrink and are eventually destroyed. Nocodazole, a pharmacological reagent, is 
commonly used to depolymerize microtubules in these ways. 
When HRas C181S or HRas C184S mutants were co-expressed in NIH 3T3 cells along 
with YFP-GT46, all of the constructs were easily visible on the plasma membrane, and only 
YFP-GT46 was aggregated in the Golgi region. However, when the experiment was repeated 
and cells were treated with cycloheximide and nocodazole, neither mutant illuminated the 
plasma membrane. It seems that when vesicular trafficking is inhibited, HRas C181S and 
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HRas C184S are largely cytosolic or in small clusters much like the ones observed during 
BFA treatments. (Figure 6) Likewise, both BFA and nocodazole treatments disperse YFP-
GT46 around the nuclear envelop as well as small, dot-like structures in the cytosol, but they 
are not co-aligned to HRas dots. 
Non-palmitoylated residues and HRas plasma membrane localization 
The trafficking experiments reported here that were conducted with mono-palmitoylated 
HRas demonstrate that mono-palmitoylation alone is insufficient to localize HRas to the 
plasma membrane through Golgi-independent pathways. However, not only are each of the 
final 10 amino acid residues of HRas sufficiently lipid-modified to reach the plasma 
membrane, HRas can do so through the Golgi-independent mechanisms. To investigate 
whether non-palmitoylated residues between the two palmitate groups are needed for Golgi-
independent trafficking, we conducted an experiment with a new HRas mutant—HRas 
CDQCE. As the name indicates, the HRas CDQCE mutant has the C–terminus amino acid 
sequence —CDQCECVLS, as opposed to cellular HRas which has the sequence —CMSCKCVLS. 
This mutant contains all of the lipid modification sites but the residues in between the 
palmitate groups have been changed. When the CDQCE mutant was transfected into the NIH 
3T3 cells, there was a small accumulation of HRas in the Golgi, but the HRas CDQCE 
proteins were largely absent from the plasma membrane. (Figure 7) To eliminate the 
possibility that this mutant localizes to the plasma membrane at a much slower pace than 
their cellular counterparts, proteins were synthesized and trafficked for up to 48 hours. Even 
at 48 hours post-transfection, HRas CDQCE was unable to reach the plasma membrane, 
whereas HRas wt was able to reach the plasma membrane in less than one hour. We also 
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noted that the trafficking of and localization (i.e. internal) of GTP-bound HRas 61L CDQCE 
mutant was similar to that of the wt GDP bound form (data not shown).  
Conservation of the amino acids further upstream of the CAAX box is also 
required for Golgi-independent HRas trafficking 
After having observed that each of the terminal 10 amino acids seem to contribute to 
HRas trafficking and plasma membrane localization, we expanded the study to explore how 
other parts of the hypervariable region serve as determining factors for HRas trafficking and 
localization. To address this question, we obtained two additional HRas mutants from Dr. Ian 
Prior’s lab. The first of the two mutants, GFP delta 17, contains alanines that were substituted 
for residues 166 through 172 (—HKLRKLNAAAAAAAGCMSCKCVLS). Likewise, the second 
mutant, GFP delta 19, also contains seven alanine substitutions that span from residue 173 
through residue 189. (Figure 8) When each of these mutants was expressed in NIH 3T3 
cells, they both showed a very strong localization of HRas at the plasma membrane and at the 
Golgi, like HRas wt or HRas Q61L. This perinuclear accumulation was expected as both 
proteins are GFP chimeras. 
To see whether these alanine mutants reach the plasma membrane through a Golgi-
independent mechanism, transfected cell were first treated with cycloheximide and BFA, 
then co-immuno-labeled with giantin. As expected, giantin-labeled Golgi structures were 
completely destroyed in the presence of BFA. Because both of the alanine mutants contain 
the final 10 amino acids in the HRas tail, it seemed reasonable that both the GFP delta 17 and 
the GFP delta 19 mutants would exhibit trafficking behavior that is similar to HRas 61 and 
GFP HRas tail. However, it seemed that neither the GFP delta 17 nor the GFP delta 19 
mutants were able to reach the plasma membrane in the presence of BFA, much like HRas 
C181S and HRas C184S constructs. On rare occasions, some transfected cells did show 
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minute amounts of alanine mutants on plasma membranes, but these were only apparent on 
cellular ruffles. To confirm that the delta mutants did not localize at the plasma membrane, 
experiments were repeated and GFP delta 17 and GFP delta 19 mutants were co-immuno-
labeled with Alexa-Fluor® 594-conjugated phalloidin, a toxin found in a specific type of 
mushroom that binds to the F-actin and clearly indicates plasma membranes. As expected, 
the delta 17 and delta 19 proteins did not show any colocalization with phalloidin in NIH 3T3 
cells. (Figure 9) 
Discussion 
Although HRas uses the classical, Golgi-dependent pathway, previous research suggests the 
existence of an alternative trafficking mechanism for HRas. Furthermore, it seems that this 
alternative mechanism does not use either the Golgi or vesicles as the primary mode of 
intracellular trafficking. Based on these earlier findings, in this study we attempted to gain 
further insights into the Golgi-independent trafficking. 
Golgi-independent trafficking exists in multiple cell types 
Golgi-dependent and Golgi-independent trafficking mechanisms occur across multiple 
cell types, including NIH 3T3, Cos-7, MDCK and HeLa. Although the degree of emphasis on 
the classical trafficking pathway is slightly less in MDCK than other cell types, it does not 
lessen the observation that the presence of GFP affects protein trafficking. These results 
imply the general existence of the Golgi-independent mechanism.  
Palmitoylation is required for Golgi-independent trafficking mechanism 
With the importance of the Golgi independent mechanism already established, this study 
was expanded toward exploring which properties of HRas might act as contributing factor(s) 
in selecting trafficking mechanisms in the ER. Because farnesylation, the first step in HRas 
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modification, occurs in the cytosol after which the proteins are recruited to the ER. Further, 
because trafficking selection appears to happen in the ER, we postulated that palmitoylation 
is a key element in HRas trafficking. Our data show that while single palmitoylation at either 
position 181 or 184 is sufficient to localize HRas to the plasma membrane, palmitoylation of 
both cysteines is required for HRas to travel via Golgi-independent, non-vesicular 
exocytosis. 
Residues between the lipid moieties are important in HRas trafficking 
Our previous data demonstrate that the HRas tail—the final 10 HRas amino acid 
residues—are sufficient to locate GFP to the plasma membrane. The HRas tail can use both 
the classical vesicular and the newly identified non-vesicular mechanisms to reach plasma 
membranes. To explore precisely which residues in the HRas c-terminus participate in 
trafficking mechanism selection, amino acids placed between the two palmitate groups were 
mutated from —CMCKCVLS (HRas wt or HRas 61L) to —CDQCECVLS (HRas CDQCE). HRas 
CDQCE never reached the plasma membrane even when proteins were expressed for up to 
48 hours, which indicates that the CAAX box, the lipid modified cysteines, and the 
surrounding residues are factors in proper HRas localization and trafficking. 
Conservation of HRas hypervariable region and Golgi-independent trafficking 
The HRas hypervariable region spans from residue 166 to residue 189. In this study, we 
asked how much of the hypervariable region must be conserved in order for HRas to use a 
Golgi-independent mechanism to reach the plasma membrane. To answer this question, GFP 
delta 17 and GFP delta 19 constructs were obtained. In the GFP delta 17 construct, 7 alanines 
were substituted for residues 173 to 181, and in the GFP delta 19 construct, 7 alanines were 
substituted for residues 166 to 172. Although both mutants can easily reach the plasma 
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membrane when unperturbed, they are unable to traffic to the plasma membrane in the 
presence of either BFA or nocodazole. 
These results indicate that conservation of the amino acids in the hypervariable region is 
important for HRas localization and trafficking. More specifically, at least one modified 
cysteine, the CAAX box, and amino acids surrounding the palmitoylated cysteines seem to 
be factors in HRas trafficking to the plasma membrane. This is important because non-lipid-
modified amino acids in the hypervariable region have been largely ignored. 
Concluding remarks 
Results presented here support the idea that HRas can use a Golgi-independent 
mechanism to reach the plasma membrane. However, this mechanism is slightly problematic 
for HRas because of its lipid modifications. In the Golgi-independent mechanism, a fully 
modified HRas must leave the endomembrane and travel across the cytosol in order to reach 
the plasma membrane, but lipid groups are highly hydrophobic and, as such, are 
thermodynamically unfavorable for exposure to the aqueous phase of the cytosol. 
HRas may overcome this problem in one or more of three possible ways. First, the lipid 
groups within an HRas molecule may fold inward to be shielded from the cytosol. However, 
there is currrently no evidence that support this model. Alternatively, HRas can travel in 
small particles called “rasosomes” [20], with a chaperone or an escort protein. An escort or 
chaperone protein might be able to protect the lipid moieties until HRas reaches the plasma 
membrane. Finally, it may be possible that HRas proteins can form oligomers with one 
another. In forming an oligomer, HRas lipid groups might be oriented inward and thereby 
shielded from the cytosol. 
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We have shown that conservation of the HRas hypervariable region is important for 
Golgi-independent trafficking. Further we have shown that the addition of GFP greatly 
enhances the Golgi-dependent trafficking mechanism. Based on data presented here, the 
formation of oligomers or the binding of chaperone or escort proteins seem most likely. 
Although additional studies are required, it is tempting to speculate that the hypervariable 
region serves as a recognition sequence for chaperone binding and that the GFP tag prevents 
oligomers or chaperone/escort protein complexes from forming. 
Whatever the actual mechanism might be, information presented in this study could be 
useful in developing future cancer therapies. Currently, treatments for cancer focus on HRas 
membrane localization, Golgi-mediated trafficking, and mutations in the switch regions. 
However, further research into the HRas hypervariable region and the inhibition of non-
vesicular trafficking could lead to effective cancer treatments. 
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Figure Legends 
All scale bars represent 10μm. White arrowheads indicate the plasma membrane and blue 
arrowheads indicate the Golgi unless otherwise noted. 
Figure 1  GFP-HRas Q61L and mGFP-HRas Q61Laccumulates in the Golgi area 
A) NIH 3T3 cells were transfected with GFP-HRas Q16L (green) for 24 hours then co-
immuno-labeled with giantin antibody (red). 
B) NIH 3T3 cells were transfected with mGFP-HRas Q61L (green) for 24 hours then co-
immuno-labeled with giantin antibody (red). 
Figure 2  GFP-HRas Q61L expression in multiple cell types 
A) NIH 3T3 cells were transfected with GFP-HRas Q16L (green) for 24 hours then co-
immuno-labeled with giantin antibody (red). 
B) HeLa cells were transfected with GFP-HRas Q16L (green) for 24 hours then co-
immuno-labeled with giantin antibody (red). 
C) MDCK cells were transfected with GFP-HRas Q16L (green) for 24 hours then co-
immuno-labeled with giantin antibody (red). 
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D) Cos-7 cells were transfected with GFP-HRas Q16L (green) for 24 hours then co-
immuno-labeled with giantin antibody (red). 
Figure 3  GFP-HRas Q61L utilizes Golgi-independent, microtubule-independent 
exocytosis 
All cells were transfected with GFP-HRas Q16L (green), then immediately treated with 
cycloheximide for 6 hours. 
A) After the cycloheximide treatment, GFP-HRas Q61L-expressing NIH 3T3 cells were 
incubated in media for 4 hours. 
B) After the cycloheximide treatment, GFP-HRas Q61L-expressing NIH 3T3 cells were 
incubated in BFA for 4 hours. 
C) After the cycloheximide treatment, GFP-HRas Q61L-expressing NIH 3T3 cells were 
incubated in nocodazole for 4 hours. 
D) After the cycloheximide treatment, GFP-HRas Q61L-expressing NIH 3T3 cells were 
incubated in media for 4 hours. 
E) After the cycloheximide treatment, GFP-HRas Q61L-expressing NIH 3T3 cells were 
incubated in BFA for 4 hours. 
F) After the cycloheximide treatment, GFP-HRas Q61L-expressing NIH 3T3 cells were 
incubated in nocodazole for 4 hours. 
Figure 4  HRas mono-palmitoylated mutants 
HRas Q61L contains two palmitoylation sites (blue) at positions 181 and 184 and a 
farnesylation site at 186 (red). HRas C181S mutants contain one palmitoylation site at 
position 184 and a farnesylation site at position 186. Cysteine 181 has been mutated 
from cysteine to serine (orange). For HRas C184S mutant, cysteine at position 184 
has been mutated to serine. 
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Figure 5  Mono-palmitoylated HRas does not utilize Golgi-independent, microtubule-
independent exocytosis 
A) YFP-GT46 was expressed in NIH 3T3 cells for 28 hours. The yellow arrowhead 
shows the Golgi accumulation and the white arrowhead shows the plasma membrane 
localization. 
B) 18 hours after transfection,YFP-GT46-expressing NIH 3T3 cells were treated with 
cycloheximide for 6 hours, then the cells were treated with nocodazole for an 
additional 4 hours before fixation. 
C) 18 hours after transfection,YFP-GT46-expressing NIH 3T3 cells were treated with 
cycloheximide for 6 hours, then the cells were incubated in BFA for an additional 4 
hours before fixation. 
D) HRas C181S NIH 3T3 cells 28 hours after transfection. The white arrowhead shows 
the plasma membrane localization. 
E) 18 hours after transfection, HRas C181S-expressing NIH 3T3 cells were treated with 
cycloheximide for 6 hours, then the cells were treated with nocodazole for an 
additional 4 hours before fixation. 
F) 18 hours after transfection, HRas C181S-expressing NIH 3T3 cells were treated with 
cycloheximide for 6 hours. Then the cells were treated with BFA for an additional 4 
hours before fixation. 
G) HRas C184S-expressing NIH 3T3 cells 28 hours after transfection. The white 
arrowhead shows the plasma membrane localization 
H) 18 hours after transfection, HRas C184S-expressing NIH 3T3 cells were treated with 
the cycloheximide for 6 hours, then the cells were treated with nocodazole for an 
additional 4 hours before fixation. 
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I) 18 hours after transfection, HRas C184S-expressing NIH 3T3 cells were treated with 
cycloheximide for 6 hours, then the cells were treated with BFA for an additional 4 
hours before fixation. 
Figure 6  Mono-palmitoylated HRas does not retreat back into ER in the presence of 
BFA 
A) NIH 3T3 cells were transfected with HRas C181S mutant for 18 hours, then treated 
with BFA for additional 3.5 hours. Cells were co-immuno-labeled for HRas (green) 
and trap (red). 
B) Merged image of HRas C181S (green) and ER (red). 
C) NIH 3T3 cells were transfected with HRas C184S mutant for 18 hours, then were 
treated with BFA for an additional 4 hours. Cells were co-immuno-labeled for HRas 
(green) and trap (red). 
D) Merged image of HRas (green) C184S and trap (red). 
Figure 7  HRas CDQCE mutant does not localize to the plasma membrane 
A) NIH 3T3 cells were transfected with HRas Q61L for 24 hours then immuo-labeled. 
The red arrowhead indicates the Golgi and the white arrowhead indicates the plasma 
membrane. 
B) NIH 3T3 cells were transfected with HRas CDQCE WT for 24 hours then immuo-
labeled. 
Figure 8  HRas alanine mutants 
HRas Q61L contains two palmitoylation sites (blue) at positions 181 and 184 and a 
farnesylation site at 186 (red). The HRas delta 17 mutant contains all of the lipid 
modification sites but has 7 alanine substitutions (orange) far upstream from the 
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CAAX box. HRas delta 19 also has all of the lipid modification sites but its alanine 
substitutions (orange) are immediately upstream of the CAAX box. 
Figure 9  HRas alanine mutants do not utilize the Golgi-independent, microtubule-
independent exocytosis mechanism. 
A) HRas delta 17 in NIH 3T3 cells 24 hours after transfection. 
B) HRas delta 19 in NIH 3T3 cells 24 hours after transfection. 
C) NIH 3T3 cells were transfected with HRas delta 17 mutant, then immediately treated 
with the cyclohexoimide for 6 hours. The cells were then treated with BFA for an 
additional 4 hours before fixation. 
D) NIH 3T3 cells were transfected with HRas delta 19 mutant, then immediately treated 
with the cyclohexoimide for 6 hours. The cells were then treated with BFA for 
additional 4 hours before fixation. 
E) NIH 3T3 cells were transfected with HRas delta 17 mutant, then immediately treated 
with the cyclohexoimide for 6 hours. The cells were then treated with nocodazole for 
an additional 4 hours before fixation. 
E) NIH 3T3 cells were transfected with HRas delta 19 mutant, then immediately treated 
with the cyclohexoimide for 6 hours. The cells were then treated with nocodazole for 
an additional 4 hours before fixation. 
Table Legends 
Table 1  HRas perinuclear distribution is distinct from the pattern of a protein in the 
classical vesicular trafficking pathway in NIH 3T3 and Cos-7 cells 
NIH 3T3 cells and Cos-7 cells were co-transfected with YFP-GT46 and one of the H-Ras 
DNAs was indicated. After 18 hours, the cells were fixed and immuno-stained for 
HRas. Approximately 100 cells were examined and the strength of the HRas signal in 
the perinuclear area was assigned values of “none”, “+”, or “++”. Values are the 
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averages and standard deviations of the number of cells from two (HRas) or four 
(YFP-GT46) independent experiments. Monomeric GFP is abbreviated as mGFP and 
N.d. means not determined. 
Table 2  HRas perinuclear distribution is distinct from the pattern of a protein in the 
classical vesicular trafficking pathway in MDCK and HeLa cells 
MDCK cells, and HeLa cells were co-transfected with YFP-GT46 and one of the H-Ras 
DNAs was indicated. After 18 hours, the cells were fixed and immuno-stained for 
HRas. Approximately 100 cells were examined and the strength of the HRas signal in 
the perinuclear area was assigned values of “none”, “+”, or “++”. Values are the 
averages and standard deviations of the number of cells from two (HRas) or four 
(YFP-GT46) independent experiments. Monomeric GFP is abbreviated as mGFP and 
“N.d.” means not determined. 
Figures 
 
Figure 1  GFP-HRas Q61L and mGFP-HRas Q61L accumulate in the Golgi area 
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Figure 2  GFP-HRas Q61L expression in multiple cell types 
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Table 1  HRas perinuclear distribution is distinct from the pattern of a protein in the 
classical vesicular trafficking pathway in NIH 3T3 and Cos-7 cells. 
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Table 2 HRas perinuclear distribution is distinct from the pattern of a protein in the 
classical vesicular trafficking pathway in MDCK and HeLa cells. 
 
 
mGFP-H-RasQ61L
GFP-H-RasQ61L
GFP-H-Raswt
H-Ras Q61L
H-Raswt
YFP-GT46
HeLa
n.dn.dn.dn.dn.dn.d
48 ± 77 ± 145 ± 854 ± 818 ± 535 ± 4
22 ± 57 ± 372 ± 477 ± 810 ± 714 ± 1
91 ± 12 ± 17 ± 298 ± 01 ± 11 ± 1
88 ± 34 ± 25 ± 191 ± 34 ± 25 ± 1
9 ± 31 ± 290 ± 430 ± 026 ± 1245 ± 12
None  + ++None +++Fluorescence in
perinuclear area
MDCK
Cell Type
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Figure 3  GFP-HRas Q61L utilizes Golgi-independent, microtubule-independent 
exocytosis 
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Figure 4  HRas mono-palmitoylated mutants 
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Figure 5  Mono-palmitoylated HRas does not utilize Golgi-independent, microtubule-
independent exocytosis 
A
IHG
FED
CB
   106
 
Figure 6  Mono-palmitoylated HRas does not retreat back into ER in the presence of 
BFA 
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Figure 7  HRas CDQCE mutant does not localize to the plasma membrane 
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Figure 8  HRas alanine mutants 
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Figure 9  HRas alanine mutants do not utilize the Golgi-independent, microtubule-
independent exocytosis mechanism 
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Abstract 
H-Ras has often been sighted on endocytic vesicles, and, recently, on recycling endosomes, 
but the class of endosomes to which it bound has remained uncharacterized. The aim of this 
study was to identify those pathway(s), and to determine if endosomal H-Ras could bind 
GTP or was inactive. The results found that ectopically expressed, constitutively active H-
Ras61L or normal H-Ras, in either basal or EGF-stimulated NIH 3T3 cells, were absent from 
endosomes of the clathrin-associated pathway. Instead, both forms of H-Ras were present on 
endosomes of the clathrin-independent, Arf6-associated pathway and in the endosomal-
recycling center. In contrast, the Ras effector, Raf-1, was distributed primarily on EEA1-
containing endosomes of the clathrin-dependent path. K-Ras4B-V12 and chimeric green 
fluorescent proteins with either H-Ras or K-Ras4B C-termini were also present on Arf6-
associated vesicles. These results identify a specific class of constitutive endosomal vesicles 
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that can bind Ras proteins. This information provides a new mechanism through which 
membrane-bound H-Ras can localize on intracellular membranes.  
Introduction 
Although the site of Ras signaling is widely depicted as the plasma membrane, Ras 
proteins have now been shown to be distributed on, and to produce significant signals from, 
internal membranes [1-3]. The means by which Ras proteins localize to these internal sites 
are varied. In neurons, calcium signals trigger Ca++/calmodulin binding to KRas4B and cause 
the release of the KRas/calmodulin complex from the plasma membrane [4]. This cytosolic 
complex is subsequently targeted to Golgi and recycling endosomes [5]. For H-Ras, some of 
the newly synthesized protein is delivered from the ER to Golgi membranes, apparently by 
non-vesicular means, and eventually boards outward-bound vesicles within the cytoplasm [6, 
7]. Recent work indicates that if palmitoylated H-Ras that is already at the plasma membrane 
becomes de-palmitoylated, it is released into the cytosol, and can be captured on internal 
membranes, from which it can then re-join the biosynthetic pathway [8]. This deacylation-
controlled internalization appears to be non-vesicular. However, H-Ras has repeatedly been 
found on vesicles with all the characteristics of endosomes [9-11], including new 
observations of H-Ras on membranes of the pericentriolar endocytic recycling compartment 
[12]. A small portion of H-Ras can also become ubiquitinated, a modification that stabilizes 
its association with endosomes but seems to decrease its association with Golgi membranes 
[13]. Thus it is unclear whether H-Ras that reaches the plasma membrane must await 
depalmitoylation before it can re-enter the cell and bind to internal membranes or whether a 
membrane-bound form of H-Ras can traverse the cytosol and serve as a source for 
intracellular signaling. 
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A clear identity for the endosomes to which H-Ras binds has not been reported. There is 
even the possibility that more than one type of endosomal pathway might be utilized, as the 
distribution of H-Ras in the plasma membrane is reported to vary. The inactive form of H-
Ras is included in raft-like lipid microdomains, while GTP-bound forms inhabit the more 
general lipid bilayer [14]. Endocytic pathways also show preferences for one type of domain 
or the other [15]. A previous study has shown that a Rab5- and dynamin-regulated pathway 
of endocytosis and recycling is required for signaling by the Ras effector, Raf-1 [16]. 
Additional studies report that both Rab5 and Rab11 regulate H-Ras internalization [12]. 
However, Rab5 is found on endosomal membranes and sorting endosomes that are derived 
from both clathrin-mediated and clathrin-independent pathways [12, 17], and thus does not 
define a specific class of endosomes. Expression of the constitutively active Rab5-Q79L 
protein causes some H-Ras to accumulate on enlarged endosomes, but, notably, not Raf-1 
[18]. Thus, a portion of H-Ras can be internalized, but the internalized population appears to 
disengage from this effector. Raf-1 itself has also been observed on endosomes, colocalizing 
with EEA1, an early endosomal marker for the clathrin-mediated pathway [10]. Other studies 
report that blocking clathrin-mediated endocytosis with a dominant, mutant form of epsin or 
AP180 does not prevent accumulation of H-Ras on intracellular membranes [2, 8]. In 
addition, in earlier electron microscopy studies, H-Ras was notably absent from clathrin-
coated pits or flat arrays on the plasma membrane [14, 19, 20]. Although these studies 
suggest that H-Ras can leave the plasma membrane and enter an endocytic pathway, they do 
not provide a clear identity for that pathway, or answer whether activated H-Ras can 
maintain its GTP-bound state while on such endosomes. 
   113
Several pathways for clathrin-independent endosomal entry of proteins have been 
described [15, 17, 21-24]. One of these is a pathway that serves as an entry route for the class 
I major histocompatibility complex protein (MHC-I), IL-2 receptor α subunit, the beta-1 
subunit of integrins, and the Src tyrosine kinase [25-27]. This pathway is identifiable by the 
presence of Arf6. Arf6 is a member of the Arf and Arl subfamily of small GTPases that 
participate in vesicular trafficking [28]. The Arf6 protein is located on the plasma membrane, 
endosomes, and tubular-vesicular recycling membranes [29]. Several studies suggest that 
Arf6-associated vesicles converge on the endosomal recycling center (ERC) [30], where they 
mingle with endosomes that are derived independently from clathrin-mediated endocytosis 
[26, 31]. Arf6-associated vesicles also participate in a recycling pathway that returns proteins 
to the plasma membrane [32, 33]. 
The studies reported here examined what type of endosomes could bind H-Ras, whether 
binding differed between inactive or active forms, and if activation changed the type of 
endosome to which H-Ras was bound. The results build a new mechanistic link between 
Arf6 and H-Ras that reaches from the plasma membrane to the perinuclear endosomal 
recycling center. 
Materials and methods 
Plasmids, cell culture, and DNA transfection  
The H-Ras and ExtRas DNAs in the pcDNA3 vector were described previously [34]. 
GFP-H-Ras-61Q, GFP-KRas4B-G12V, GFP-ExtRas61L, GFP-ExtRas-61Q, and GFP-H-
Ras-61L were constructed using the pcDNA3 versions as PCR templates and transferred to 
the pEGFP-C3 vector (Clontech Labs). GFP-RBD contains residues 51-131 of Raf-1 [2] that 
were transferred to pEGFP-C3 from a cDNA for a GST-RBD that was obtained from the 
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laboratory of C. Der (UNC). GFP-H-tail was constructed by attaching the bases encoding the 
10 C-terminal amino acids of H-Ras (GCMCKCVLS), a termination codon, and a Bam H1 
restriction enzyme site to pEGFP-C3 by PCR. Arf6-67Q-GFP (Arf6-WT, wild type) and 
Arf6-Q67L-GFP are in the pEGFP-N1 vector; Arf6-67Q-HA and Arf6-Q67L-HA each with 
a C-terminal hemagluttinin (HA) epitope tag, are in pXS vectors. Dr. J.G. Donaldson, 
National Institute of Health generously provided all the Arf6 constructs and the GFP-K-tail 
plasmid.  
NIH 3T3 cells were cultured at 37°C and 10% CO2 in Dulbecco’s modified Eagle’s 
medium supplemented with 10% calf serum plus penicillin, streptomycin, glutamine and 
sodium pyruvate. For immunofluorescence and immuno-isolation, NIH 3T3 cells were 
transfected with Effectene (Qiagen) according to the manufacturer’s instructions and used 
after 24 hours or as mentioned in the results. The H-Ras61L or H-RasWT (HRas cellular 
form, wild-type) stable cell lines have the H-Ras61L or H-RasWT DNAs expressed from the 
pZIPneo vector; the GFP-H-Ras61L stable cell line has the GFP-H-Ras61L DNA expressed 
from the pEGFP-C3 vector. Cells treated with EGF (Gibco BRL) were cultured in the same 
media described above and incubated with 5 or 10 ng/ml of EGF at 37°C for the time as 
indicated, followed by washing with phosphate-buffered saline and fixation. 
Antibodies 
Antibodies used for immunoblotting included mouse monoclonal anti-Ras (BD 
Bioscience 610010), mouse monoclonal anti-c-Raf (BD Bioscience 61051), rabbit polyclonal 
anti-hemagluttinin (Covance PRB-101P), mouse monoclonal anti-GFP (Roche 1814460) and 
rabbit polyclonal anti-EEA1 (ABR P1-063). For immunofluorescence, rat monoclonal anti-
Ras (sc-34), rabbit polyclonal anti-c-Raf-1 (sc-227), and rabbit polyclonal anti-clathrin heavy 
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chain (sc-9069) were from Santa Cruz Biotechnology. Mouse monoclonal antibody (W6/32) 
to human MHC-I protein was from Leinco Technologies (#H263). The same EEA1 antibody 
or mouse anti-hemagluttinin (Covance PRB-101R) were used for both immuno-isolation and 
immunofluorescence. Murine monoclonal anti-Ras (Quality Biotech LA069) and the above 
rat monoclonal anti-Ras antibody are also used for immuno-isolation. Goat anti-rat IgG 
coupled to Alexa Fluor 488, goat anti-mouse IgG coupled to Alexa Fluor 594, goat anti-
rabbit IgG coupled to Alexa Fluor 594, donkey anti-rat IgG coupled to Alexa Fluor 594, and 
transferrin from human serum coupled to Alexa Fluor 594 are from Molecular Probes. 
Live cell labeling with transferrin or MHC-I antibody 
To mark early endosomes of the clathrin-dependent pathway, cells were transfected and 
incubated for 18 hours, then cycloheximide (10 µg/ml) was added for 5.25 hours, to allow 
time for previously synthesized protein to vacate Golgi membranes. Cells were then chilled 
for 45 minutes at 4°C in a cold room in medium containing 50 mM HEPES, pH 7.4 buffer, 
cycloheximide (10 µg/ml), and AlexaFluor-transferrin (Molecular Probes, 10 µg/ml). Finally, 
the cold medium was removed and pre-warmed (37°C) medium containing 50 mM HEPES, 
pH 7.4 was added and cells were incubated at 37°C in a water bath for 1 minute before 
fixation with cold 4% paraformaldehyde and processing for immunofluorescence. 
For marking the endosomal recycling center (ERC), cells were transfected with various 
cDNAs, incubated for 18 hours, and then treated for 5.25 hours with cycloheximide (10 
µg/ml). Alexa-Fluor transferrin (10 μg/ml) was then added for 45 minutes. Cells were 
washed, fixed and processed for immunofluorescence. 
To monitor MHC-I internalization, HeLa cells were transfected and incubated for 18 
hours, then cycloheximide (10 µg/ml) was added for 5.5 hours, to allow time for newly 
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synthesized H-Ras proteins to vacate Golgi membranes. Cycloheximide-containing media 
with MHC-I antibody (200µg/ml) was equilibrated to 37o C and then added to the above cells 
for 30 min at 37o C.  At the end of incubation, cell surface-associated antibodies were 
removed by rinsing the cells in low pH solution (0.5% acetic acid, 0.5M NaCl, pH 3.0) for 30 
seconds [26].  Cells were fixed with 4% formaldehyde in phosphate-buffered saline (PBS) 
for 10 minutes, permeabilized, and stained in blocking buffer (2% horse serum, 0.4% bovine 
serum albumin and 0.2% saponin in PBS, pH 7.4) [26, 35]. The internalized antibodies were 
visualized with the appropriate fluorochrome-labeled secondary antibody in the above 
blocking buffer. 
Immuno-isolation of membranes 
Twenty-four hours after transfection, cells were scraped into 300 μl homogenization 
buffer (3 mM imidazole, pH 7.4, 1 mM Na3VO4, 5 mM MgCl2, 1% Protease Inhibitor 
Cocktail (Sigma), and 5% sucrose) and homogenized with 15 strokes in a Dounce 
homogenizer followed by 20 passages through a 26-gauge needle. The nuclei and unbroken 
cells were removed by centrifugation at 1300 x g (4 °C) for 10 min. This post-nuclear 
supernatant (PNS) was pre-cleared by incubation for 1 hour at 4°C with protein G- or protein 
A-agarose beads (Invitrogen). Beads were removed and the supernatant then incubated with 
mouse monoclonal anti-HA antibody or a mixture of mouse and rat monoclonal anti-H-Ras 
antibodies or rabbit EEA1 antibody overnight. The following day fresh protein G agarose 
beads (or protein A beads for rabbit EEA1 antibody) were added for 2 hours at 4°C. The 
beads were washed 3 times in cold homogenization buffer and boiled in SDS-PAGE sample 
buffer. Proteins present in the membranes were separated by SDS-PAGE and detected on 
   117
immunoblots with the indicated antibodies. 95% of the sample was loaded in the IP lane, and 
5% in the PNS lane. 
Immunoblotting  
Samples collected by immuno-isolation were separated by SDS-PAGE. Proteins were 
transferred to polyvinylidene difluoride (PVDF) membranes (Pall Life Science) and then 
incubated in blocking buffer (Vector Labs 10x casein diluted to 1x) in TTBS [0.15 mol/L 
NaCl, 0.05 mol/L Tris-HCl, 0.05% Tween-20, pH 7.4]) for 20 minutes at room temperature. 
PVDF membranes were washed in TTBS, incubated with primary antibodies overnight at 
4°C. The proteins of interest were detected using horseradish peroxidase-conjugated goat 
anti-mouse or goat anti-rabbit secondary antibodies and an enhanced chemiluminescence kit 
from Pierce. 
Immunofluorescence and preparation of sonicated membrane fragments 
NIH 3T3 cells were plated on coverslips coated with 100 μg/ml poly-L-lysine (Sigma) 
and 500 μg/ml fibronectin (Sigma) and transfected with DNA. After 24 hours (or as 
mentioned in the results), cells were fixed with fresh 4% formaldehyde in phosphate-buffered 
saline, pH 7.4, at room temperature for 1 hour then permeabilized with -20°C methanol and 
quenched with 50 mM ammonium chloride in phosphate-buffered saline. The fixed cells 
were incubated with blocking buffer (2% horse serum and 0.4% bovine serum albumin in 
phosphate-buffered saline, pH 7.4) then sequentially with primary and secondary antibodies 
diluted in blocking buffer. Experiments to produce adherent plasma membrane fragments 
were carried out exactly as described previously [36]. The slips were mounted in Vectashield 
mounting medium (Vector Laboratories). For experiments imaging adherent membrane 
fragments, cells were analyzed using a 63X oil immersion lens on a Nikon Eclipse E800 
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microscope with Spot RT digital camera. All the confocal images were taken with a Leica 
TCS-NT confocal system with a 63X oil immersion lens with an aperture adjustable from 
1.32 to 0.6, using an argon laser (488 nm excitation) and a krypton laser (568 nm excitation). 
Other images were taken with Leica DMIRE2 microscope using a 100X oil immersion lens 
with an aperture adjustable from 1.3 to 0.6 and Q Imaging Retiga 1300 camera. Images were 
exported to Adobe Photoshop 7.0 or, for the images taken with the Leica DMIRE2 
microscope; images were taken in black and white, processed in Openlab3.5.1, displayed in 
colors and then exported to Adobe Photoshop 7.0 to equalize image intensity prior to 
merging. For some experiments, as indicated in the figure legends, a series of z-stack images 
were acquired using a motorized stage on the Leica DMIRE2 microscope. These images 
were processed using Openlab’s nearest neighbor deconvolution module and processed as 
above. 
Results 
H-Ras does not utilize the clathrin-dependent pathway 
The previous report of dynamin sensitivity of H-Ras triggered Raf-1 signaling [16] 
suggested that the dynamin-sensitive, clathrin-dependent pathway might mediate H-Ras 
endocytosis. To specifically inspect plasma membranes for possible H-Ras and clathrin 
colocalization, adherent basal plasma membranes of transfected NIH 3T3 cells were prepared 
by sonication, fixed, and examined by indirect immunofluorescence [36]. However, neither 
the activated H-Ras61L (Fig. 1A) nor the transfected cellular form of H-Ras (H-Ras-WT; 
data not shown) overlapped with clathrin heavy chain.  
Another marker of a later step in the clathrin-dependent pathway, the early endosome 
antigen-1 protein (EEA1), was used to determine if H-Ras was present in early endosomal 
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vesicles that had already lost their clathrin coat. Upon examination of EEA1-positive vesicles 
in intact cells, no overlap of H-Ras-WT and EEA1 was detected (Fig. 1B). On adherent 
fragments of basal membranes from sonicated cells, the population of EEA1-positive vesicles 
was more clearly resolved, but again no H-Ras (this time the activated form, H-Ras61L) was 
present in these vesicles (Fig. 1C). Because EEA1 marks early endosomal vesicles 
specifically, these results indicated that neither an oncogenic nor the normal form of H-Ras 
were present on early endosomes derived from the clathrin-dependent pathway. 
Because the experiments with H-Ras61L used a permanently activated, mutant form of 
H-Ras, we also tested if H-Ras-WT that became transiently GTP-bound after EGF 
stimulation now joined the clathrin-dependent pathway. This was a relevant question, as the 
serum-activated form of H-Ras is reported to shift from raft-like lipid microdomains, to a 
more general membrane distribution from which clathrin-mediated internalization might 
occur [14]. However, after stimulation of cells for 10 minutes with a moderate, 10 ng/ml, 
dose of EGF [37], no co-alignment of the EEA1 marker of early endosomes and H-Ras-WT 
was detected (Fig. 1D).  
As an additional test, a fluorescent derivative of transferrin was added to live cells to 
enable tracking of the first minutes of clathrin-mediated endocytosis. For these experiments, 
a cycloheximide pre-treatment was included to avoid imaging newly synthesized H-Ras on 
Golgi-derived vesicles that might mingle with the endocytic vesicles. Cells were then chilled 
and incubated with transferrin, so as to label, but prevent internalization of transferrin 
receptors. Cells were warmed briefly (1 minute) to allow internalization to re-start. Although 
H-Ras-positive vesicles were present in the re-warmed cells, the transferrin-containing early 
endosomes did not overlap with GFP-H-Ras61L (Fig. 1E). Thus, although H-Ras was present 
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on vesicles, it was notably absent from endosomes associated with these characteristic steps 
of the clathrin-dependent endocytic route. 
To supplement the previous imaging results, we used a biochemical approach to examine 
if H-Ras in its GTP-bound form might be present on EEA1-containing endosomes. Using an 
antibody to EEA1 and a detergent-free protocol for immuno-isolation of membrane 
fragments and vesicles [10], the presence of H-Ras and endogenous Raf-1 on EEA1-
containing endosomes was assessed. In agreement with the imaging results, neither cellular 
H-Ras, nor activated H-Ras61L (Fig. 1F) could be detected on the captured EEA1-containing 
membranes.  
Thus, by multiple techniques, we found no evidence of H-Ras on endocytic vesicles that 
were derived from the clathrin-dependent pathway. 
In spite of this absence, endogenous Raf-1 was easily observed in these EEA1 antibody-
captured endosomes (Fig. 1F). This ability to capture a protein associated with EEA1-
containing membranes verified that the membrane isolation protocol was successful, and thus 
validated the absence of H-Ras on those membranes. This result confirmed previous work 
that Raf-1 could be found on EEA1-containing early endosomes [10]. All these studies 
indicated that endocytic vesicles to which H-Ras was bound had not entered the cells via a 
clathrin-mediated pathway. 
Endosomes associated with Arf6 bind H-Ras 
A prominent class of non-clathrin plasma membrane structures is comprised of caveolae. 
However, the ability of caveolae to internalize (as “caveosomes”) is generally thought to be 
restricted to special situations such as viral infection [38]. H-Ras, although present on 
membranes with a low buoyant density similar to that of caveolae, is largely absent from 
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these structures [14, 36]. Thus another class of non-caveolar, clathrin-independent 
endosomes for binding H-Ras was sought. 
An additional type of clathrin-independent endosomes are those which arise from the 
constitutive pathway by which the endogenous major histocompatibility complex I (MHC-I) 
is internalized [30]. To examine this pathway, endosomal vesicles containing MHC-I were 
identified by applying an antibody that recognizes an external epitope of human MHC-I to 
live HeLa cells. In addition, to further diminish the signal from endogenous MHC-I and 
transfected H-Ras that were within the biosynthetic pathway, cycloheximide was added to 
the transfected cells for the final 6 hours before fixation. Anti-MHC-I antibody was added to 
the culture medium for the last 30 minutes to label MHC-I at the cell surface. Cells were then 
briefly washed with mild acid, to remove MHC-I antibody that had not entered the cell, were 
fixed, and then stained with antibody for the transfected H-Ras protein [35, 39]. The resulting 
images showed multiple vesicular structures that held both H-Ras and endogenous MHC-I 
protein, as well as other vesicles that held only a single protein (Fig. 2A).  
MHC-I is reported to traffic through a pathway that is associated with the Arf6 small 
GTPase [40, 41]. The extent of colocalization of externally labeled MHC-I with an expressed 
Arf6-Q67L tagged with GFP was therefore examined. Similar to the study with H-Ras and 
MHC-I, there were multiple vesicles that contained both MHC-I and Arf6, and others that 
held only a single protein (Fig. 2B). These results implied that H-Ras should be present on 
vesicles on which Arf6 was located. To test this prediction, NIH 3T3 cells were co-
transfected with H-Ras-WT and a GFP-tagged version of the cellular form of Arf6 (Arf-WT-
GFP), and were examined by fluorescence microscopy. H-Ras-WT was observed on the 
plasma membrane, as expected, and also on both small endosomes and larger, apparently 
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fluid-filled, pinosomes that were also populated by Arf6-WT-GFP (Fig. 2C). Pinosome 
structures are often associated with Arf6 [42]. At high resolution, the Arf6 and H-Ras 
proteins appeared to inhabit distinct domains of many of the larger endosomes, producing a 
beaded appearance in cross-section (Fig. 2D). The constitutively active H-Ras61L was also 
present on Arf6-WT-associated endosomes (data not shown). These results agree with the 
previous finding that endogenous Ras proteins can be found on endosomes regardless of their 
activation state [10]. Complex cellular changes that affect endocytosis accompany 
transformation caused by long-term expression of activated H-Ras61L [9]. To learn if these 
changes included altered H-Ras61L binding to Arf6-associated endosomes, Arf6 was 
expressed in a stable cell line harboring H-Ras61L. In the transformed cells, oncogenic H-
Ras61L was found on endosomes coated with Arf6 (data not shown).  
The results indicated that endosomes that contained Arf6 could bind H-Ras in both the 
GDP- and GTP-bound states. This data provides a complement for the earlier biochemical 
experiments that indicated that neither H-Ras-WT nor H-Ras61L nor EGF-stimulated H-Ras-
GTP bound clathrin-dependent endosomes. 
To examine if Arf6 activation changed the ability of H-Ras to bind these endosomes, an 
Arf6 protein that favors the GTP-bound form (Arf6-Q67L) was used. The Arf6-Q67L protein 
supports the early steps of endosome formation in a normal fashion, but the inability of the 
protein to hydrolyze its bound GTP prevents the nascent endosomes from further progress, 
leading to an endocytic cul-de-sac and formation of multiple, enlarged endosomes [29]. In 
cells co-transfected with Arf6-Q67L-GFP and H-Ras61L, the H-Ras61L protein brightly 
outlined the distinctive groups of large endosomes that were also positive for Arf6-Q67L-
   123
GFP (Fig. 2E). Thus, H-Ras could also bind to endosomes in which the Arf6 protein was 
GTP-bound. 
To further characterize these endosomes, cells were transfected with a hemagluttinin 
(HA)-tagged version of Arf6-Q67L-HA along with GFP-H-Ras61L so that Arf6-containing 
membranes could be immuno-isolated using HA antibody. On detergent-free fragments of 
Arf6-HA-containing membranes that were isolated with anti-HA antibody, GFP-H-Ras61L 
was present (Fig. 2F). A reverse experiment, using H-Ras-directed antibody capture, showed 
that Arf6-Q67L-GFP could also be detected on H-Ras-containing membrane fragments (Fig. 
2G). In addition, a control experiment was performed, in which anti-HA antibody-directed 
membrane isolation was performed using cells that expressed H-Ras but that had no Arf6-
HA to capture. The resulting sample contained no H-Ras (Fig. 2H).  This showed that the 
presence of H-Ras in the sample required Arf6, and was not the result of incomplete 
membrane washing or non-specific binding of H-Ras to the HA antibody.  
EGF and H-Ras activation on Arf6 endosomes 
Given the constitutive nature of endocytosis via the Arf6-associated pathway an 
important issue was whether binding to these endosomes would result in rapid down 
regulation of H-Ras GTP binding. This question had not been answered by the previous 
experiment with H-Ras61L, because H-Ras61L GTP hydrolysis is impaired. This experiment 
required a cell to simultaneously express 3 proteins: Arf6, H-Ras-WT, and GFP-RBD (a 
GFP-tagged version of the Ras binding domain of Raf-1) to bind to and report the location of 
the GTP-bound form of H-Ras. To accomplish this with only two color filters, the activated 
Arf6-Q67L was used so that its presence could be detected by the distinctive clustering of 
endosomes it produced, rather than by staining. The triply transfected cells were then either 
   124
left untreated or were exposed to a low concentration of EGF for varying times before 
fixation and imaging. 
In untreated cells, the GDP-bound H-Ras-WT protein outlined the plasma membrane and 
clustered endosomes as before, but the GFP-RBD did not, and was instead nearby in the 
cytosol (Fig. 3A). This is the appropriate location for GFP-RBD in an unstimulated cell. 
After 5 minutes of exposure of the cells to EGF, GFP-RBD could now be seen both at the 
plasma membrane and on many H-Ras-WT-coated enlarged endosomes (Fig. 3B). Notably, 
within this short time frame, no significant binding of GFP-RBD to perinuclear membranes 
that might be Golgi was observed [43]. This indicated that H-Ras-WT could become GTP-
bound at the plasma membrane and on Arf6-associated vesicles that were already internal or 
that entered the cell during the 5 minutes of EGF exposure. 
Previous studies had shown that total H-Ras GTP binding remained elevated for several 
minutes after EGF stimulation, and returned to baseline within about one-half hour [11]. 
Similarly, in this experiment, after 10 minutes of exposure to EGF, GFP-RBD remained 
visible on both the plasma membrane and on many Arf6-Q67L vesicle membranes (Fig. 3C). 
Thus, during EGF stimulation, H-Ras continued to associate with, and retained GTP while 
bound to, Arf6 vesicles. There was no indication that endosomal H-Ras lost GTP more 
rapidly than H-Ras at the plasma membrane. After 30 minutes of EGF exposure, GFP-RBD 
binding to the Arf6 vesicles did decline, indicating that H-Ras GTP binding had dropped 
(data not shown). These results indicated that binding of H-Ras to vesicles of the Arf6-
associated endocytic pathway is neither a method for rapid “down regulation” of H-Ras 
activity nor a mechanism to prolong H-Ras GTP binding. 
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Very little Raf-1 binds to H-Ras61L on Arf6 endosomes 
The initial studies described above had indicated that although endosomes that contained 
EEA1 did not bind H-Ras, they did bind the H-Ras effector protein, Raf-1. The finding that 
GTP-bound H-Ras was present on Arf6-associated vesicles raised the question of whether 
some Raf-1 might also be present with H-Ras-GTP on Arf6-coated vesicles. It was necessary 
to use immunofluorescence to examine Arf6 endosomes specifically, rather than membrane 
immuno-isolation, because Arf6 is present on both the plasma membrane (where Raf-1 is 
known to associate with active H-Ras) and on endosomal membranes. Cells were co-
transfected with DNAs for Arf6-Q67L (to generate visibly identifiable endosomes) and H-
Ras61L, then were stained with antibodies for endogenous Raf-1. As before, the 
characteristic vesicles and clustered Arf6-Q67L endosomes were brightly rimmed with GFP-
H-Ras61L (Fig. 4A). However, the Raf-1 antibody did not illuminate those clustered 
endosomes (Fig. 4B), and in only a few spots did endogenous Raf-1 and H-Ras61L 
colocalize on endosomes. (Fig. 4C) A second experiment examined whether endosomes that 
displayed transfected Arf6-Q67L-GFP could bind Raf-1. Once again, there was no alignment 
(Fig. 4D). These results suggested, unexpectedly, that endosomal H-Ras, although in the 
GTP-bound form, bound very little Raf-1. Further experiments are planned to learn if 
endosomal Raf-1 is completely separate from endosomal H-Ras-GTP.  
H-Ras is present in the perinuclear endosomal recycling center 
Although some H-Ras is present on Golgi membranes, recent studies have found that H-
Ras persists in the perinuclear area despite clearing the H-Ras biosynthetic pathway by 
exposing cells to cycloheximide [7, 8]. Our own studies (see below) confirmed that even 
after prolonged interruption of biosynthesis, H-Ras was present (i.e., either retained or 
continuously replaced) on perinuclear membranes. The contribution of endosomal pathways, 
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and in particular the perinuclear endosomal recycling center (ERC), to the internal pool of H-
Ras was investigated.  
In order to specifically identify the ERC and to distinguish it from Golgi membranes, 
transferrin, a protein known to enter the ERC, was used. In cells pre-treated with 
cycloheximide for 6 hours, live-cell uptake of AlexaFluor-transferrin for 45 minutes at 37°C 
produced a strong perinuclear accumulation, along with numerous peripheral vesicles that 
were entering or recycling to the plasma membrane (Fig. 5A). In these cycloheximide-treated 
cells, the previously synthesized H-Ras61L that was located on internal membranes 
colocalized entirely with the perinuclear concentration of AlexaFluor-transferrin (Fig. 5A). 
Transfected H-RasWT also co-aligned well with the transferrin-marked ERC (data not 
shown).  This indicated that the internal membranes populated by previously synthesized H-
Ras were predominantly those of the ERC, and that, with this protocol, very little H-Ras was 
located on Golgi membranes. This data supported the recent report that H-Ras is associated 
with Rab11-positive vesicles in the recycling center [12]. Notably, at the periphery of the 
cell, the previously synthesized GFP-H-Ras61L was present in small vesicles that were 
separate from those that contained AlexaFluor-transferrin (Fig. 5B). This corroborated the 
results shown above, which indicated that H-Ras61L could bind vesicles that were separate 
from those that carried transferrin. The ERC region was too densely packed with vesicles to 
determine if the H-Ras-containing vesicles simply intermingled or actually merged with 
transferrin-containing vesicles. These results indicated that, in addition to endosomal 
membranes and membranes of the Golgi, H-Ras could distribute to a third type of internal 
membrane -- the membranes of the ERC. 
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KRas4B and ExtRas binding to Arf6 endosomes differs from H-Ras 
The route of the outward, biosynthetic trafficking of the non-palmitoylated KRas4B 
protein is unknown, but appears to differ from the vesicular mechanism of H-Ras trafficking 
from the Golgi. We therefore examined if these two Ras proteins also differed in either 
endocytosis or recycling. Activated GFP-KRas4B-G12V protein was clearly seen on the 
plasma membrane and on Arf6-Q67L-enlarged endosomes (Fig. 6A). This result indicated 
that activated KRas4B could also bind Arf6-associated vesicles, and was not excluded from 
this pathway. However, in cells loaded with Alexa Fluor-transferrin (without Arf6-Q67L), 
activated KRas4B was not present in the ERC (Fig. 6B). Thus, KRas4B differed from H-Ras 
and did not bind either ERC or Golgi membranes.  
To learn more about the properties that were responsible for the binding of H-Ras to Arf6 
endosomes, a mutant H-Ras protein with C-terminal characteristics of both H-Ras 
(palmitates) and KRas4B (lysine residues), was examined [34]. This protein (ExtRas) is a 
mutant of H-Ras with a C-terminal extension of 6 lysines that act to prevent attachment of 
farnesyl. Because of its lack of farnesylation, ExtRas also fails to undergo proteolysis or 
methylation, and does not interact with ER or Golgi membranes where these modifications 
take place [34, 44]. In addition, ExtRas shows no evidence of binding to exocytic vesicles, 
but does associate with the plasma membrane and become palmitoylated [34]. Interestingly, 
ExtRas differed from H-Ras and KRas4B, and was not detectable on Arf6-WT endosomes 
(Fig. 6C). Furthermore, ExtRas61L did not colocalize with AlexaFluor-transferrin in the 
ERC (Fig. 6D). This was an important control because, although endocytosis via Arf6-
associated vesicles can occur continuously, binding to these endosomes was neither universal 
nor inevitable for a palmitate-modified H-Ras protein. 
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The C-terminal domain of H-Ras or KRas4B proteins can target GFP to the 
Arf6 endocytic pathway  
Because both GDP-bound and GTP-bound forms of H-Ras were found on Arf6-
associated vesicles, it appeared that the Switch I and Switch II regions of the protein (which 
differ between the GDP vs GTP state) were not likely to be determinants of endocytosis. To 
study the structural requirements for endocytosis more directly, a GFP chimera, having only 
the last ten C-terminal residues of H-Ras was tested. Identical GFP-H-tail proteins have 
previously been shown to be correctly modified with farnesyl and palmitoyl lipids, and to be 
targeted to raft-like areas of the plasma membrane [20]. This GFP-H-tail protein also bound 
Arf6-Q67L endosomes (Fig. 7A). A second chimeric version of GFP, GFP-K-tail, with the 
last twenty residues of KRas4B, also bound Arf6-Q67L endosomes (Fig. 7B). These results 
mirrored the ability of the full-length H-Ras and KRas4B proteins to bind Arf6-Q67L 
endosomes. This indicated that the farnesylated C-termini of Ras proteins, with either 
palmitates or multiple lysine residues, were sufficient for binding to Arf6-coated endosomes.  
Discussion 
The studies here provide two notable findings—the absence of H-Ras from clathrin-
dependent endosomes, and the identity of a second class of vesicles that do bind H-Ras. 
Cellular, growth factor stimulated, and oncogenic forms of H-Ras bind clathrin-independent 
endosomes that contain the Arf6 protein. These endosomes are separate from, and in addition 
to, vesicles of the biosynthetic pathway. Also, Arf6 endosomes provide a second mechanism 
of internal localization for a membrane-bound form of H-Ras that is distinct from the 
deacylation-controlled cycle between the cell surface, cytosol and internal membranes. 
Several other clathrin-independent endocytic routes are rapidly being defined [15, 24, 45, 
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46]. It will be important to learn if H-Ras also utilizes these pathways, or only the Arf6-
associated route.  
Both active and inactive forms of H-Ras were found on the Arf6 endosomes. The 
nucleotide-independence of H-Ras endosome binding is consistent with previous reports [10] 
and with the constitutive nature of Arf6-mediated endocytosis [25, 47, 48]. Internal 
relocation via deacylation/re-acylation also operates for both GDP- and GTP-bound forms of 
H-Ras [7, 8], but interestingly, palmitate turn-over is accelerated when H-Ras is in the GTP-
bound form [36]. Arf6 endocytosis can also be regulated, and it remains to be seen how 
stimulation of Arf6-associated endocytosis [25, 40, 42] affects H-Ras-GTP that may be on 
those endosomes, and whether H-Ras signaling is influenced through this physical relocation. 
Although the plasma membrane is widely viewed as the static, final destination for Ras 
proteins, this report adds support to the idea that the amount of Ras at the plasma membrane 
is dynamic and continuously adjustable, both through deacylation and by endocytosis. 
Properties that influence binding of Ras proteins to Arf6-associated vesicles 
Our results show that the seven, C-terminal residues of H-Ras, and the accompanying 
farnesyl, methyl, and palmitoyl groups, play an important role in endosome binding, just as 
they also do for association with Golgi membranes [6, 8]. The H-Ras protein that is found on 
Arf6-associated vesicles is likely to be palmitoylated, as it continues to bind strongly to 
membranes. However, palmitoylation cannot be the sole determinant for Arf6-based 
endocytosis, because the ExtRas protein is palmitoylated on C-terminal cysteines, and it 
failed to enter endosomes.  
Because the GFP-H-tail protein resides in low-density (“raft”) membrane microdomains 
[49], its internalization probably takes place from these domains. The GFP-K-tail protein and 
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the full-length KRas4B-G12V protein, which reside outside of the raft-like domains [20] 
were also observed on Arf6-Q67L endosomes. These results are consistent with reports that 
Arf6-associated endosomes can internalize proteins from both types of domains [26]. 
The role of endosomes in H-Ras signaling 
The separation of H-Ras from the clathrin-dependent pathway has special importance for 
interactions of H-Ras with its effector, Raf-1. Both in this work and in studies with insulin 
stimulated- [10], or angiotensin-stimulated cells [50], activated Raf-1 has been found 
primarily on endosomes derived from the clathrin-dependent pathway. The presence of Raf-1 
on EEA1-containing endosomes is also consistent with the report that H-Ras-stimulated Raf-
1 signaling is decreased by a dominant negative dynamin mutant [16]. Combined with the H-
Ras results of these studies, these reports suggest that H-Ras-triggered Raf-1 signals can 
occur on classical early endosomes, without H-Ras being present. This possibility is also 
consistent with the findings that H-Ras:Raf interactions at the plasma membrane are actually 
quite brief [51].  
In contrast, only a very small amount of Raf-1 was found on Arf6-associated vesicles that 
contained H-Ras-GTP. Furthermore, Arf6-associated endosomes also bind other signaling 
proteins, such as Src and Rac [26, 40]. This suggests that signals arising from endosomal H-
Ras may differ from those of H-Ras on the plasma membrane. There is already precedent for 
selective association of nucleotide exchange factors (GEFs), effectors, and GTPase activating 
proteins (GAPs) with H-Ras that is present on Golgi membranes [1, 43].  
These studies also reveal a new challenge for studies that wish to measure H-Ras 
signaling from internal sites -- the presence of H-Ras in the perinuclear recycling center. 
Because the endocytic recycling center is often embedded within or near the Golgi, it may be 
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necessary to distinguish H-Ras on ERC membranes from newly synthesized or re-acylated 
H-Ras on Golgi membranes [8]. 
Ras signaling pathways have previously been linked functionally with Arf6. H-Ras 
stimulates phosphatidylinositol 3-kinase activity, which leads to recruitment and activation of 
the Arf6 nucleotide exchange factor, ARNO [30]. Reciprocally, inhibition of the extracellular 
signal-regulated kinases (ERKs) that are downstream of Ras proteins, specifically impedes 
Arf6-mediated, but not clathrin-mediated, endocytosis [52]. Arf6 and H-Ras collaborate in 
vesicular transport, through co-stimulation of phospholipase D activity needed for vesicle 
budding [53]. Both Arf6 and H-Ras proteins are also central to the pinocytosis and 
membrane ruffling that are caused by growth factors. The studies reported here provide the 
physical foundation that will allow the reciprocal interactions of Arf6 and H-Ras, and the 
impact of those interactions on signaling, to be unraveled. 
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Figure Legends 
Figure 1  H-Ras is absent from early endocytic vesicles of the clathrin-dependent 
pathway. 
All scale bars in this figure = 5 µm. 
A) Merged images of adherent membrane fragment from sonicated cell expressing H-
Ras61L. Cells were fixed, stained with antibodies to H-Ras (green) and clathrin heavy 
chain (red), and with fluorescent secondary antibodies, and were examined by 
indirect immunofluorescence microscopy. 
B) NIH 3T3 cells stably expressing H-RasWT cDNA were fixed and stained with 
antibodies to H-Ras (green) and EEA1 (red). Vertical z-stack images of each color 
were deconvolved and merged.  
C) Merged images of adherent membrane fragment from sonicated cell expressing H-
Ras61L. Cells were fixed and stained directly with antibodies to H-Ras (green) and 
EEA1 (red) and with fluorescent secondary antibodies. 
D) NIH 3T3 cells stably expressing H-RasWT were treated with 10 ng/ml of EGF for 10 
minutes before fixation and stained with antibodies to H-Ras (green) and EEA1 (red) 
and with fluorescent secondary antibodies. Vertical z-stack images of each color were 
deconvolved then merged. Inset is a higher magnification of the boxed area, to show 
separation of EEA-1 and H-Ras (arrowheads). 
E) Merged images of Alexa-Fluor transferrin (red, arrowheads) and GFP-H-Ras61L 
(green, arrows) in a cell transfected and grown for 18 hours, then treated with 
cycloheximide for 6 hours, chilled and exposed to transferrin, then warmed for 1 
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minute before fixation. Vertical z-stack images of each color were deconvolved 
before merging. 
F) Membranes from the post-nuclear supernatant (PNS) in NIH 3T3 cells stably 
expressing HRas-WT or H-Ras 61L were captured with EEA1 antibody (IP). Proteins 
were separated by SDS-PAGE and identified by immunoblotting with indicated 
antibodies. 95% of the sample was loaded in the IP lane, and 5% in the PNS lane. 
Figure 2  H-Ras is present on endosomal membranes that contain MHC-I and Arf6 
A) HeLa cells were transfected with cDNA for GFP-H-Ras61L, incubated for 18 hours, 
and then treated with cycloheximide for 6 hours.  During the last 30 minutes, anti-
MHC-I monoclonal antibody was added to the culture medium.  Cells were washed 
for 30 seconds with mild acid to remove surface-bound antibody, then were fixed, 
and stained with mouse secondary antibody (red). Vertical z-stack images of each 
color were deconvolved. Arrowheads indicate positions of several vesicles containing 
the internalized MHCI and GFP-HRas61L (green). 
B) HeLa cells were transfected with cDNA for Arf6-Q67L-GFP (green), incubated for 
18 hours then treated with cycloheximide for 6 hours.  During the last 30 minutes, 
anti-MHC-I was added to the culture medium.  Cells were washed briefly with mild 
acid, fixed, incubated with mouse secondary antibody (red) to detect the anti-MHC-I, 
and imaged. Vertical z-stack images of each color were deconvolved and merged. 
C) Confocal image of transfected H-RasWT (red) on endosomes in cell expressing Arf6-
WT-GFP (green). Scale bar = 10 µm. Cells were stained with appropriate primary and 
secondary antibodies and were examined by indirect immunofluorescence 
microscopy. 
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(D) Enlargement of merged H-Ras (red) and GFP (green) images, from another cell, to 
show the beaded appearance (arrow) of Arf6 and H-Ras on the endosome membrane. 
Scale bar = 5 µm. 
E) Confocal images of a cell transfected with cDNAs encoding activated H-Ras61L 
(red) and Arf6-Q67L-GFP (green). Scale bar = 10 µm. 
F) Cells were co-transfected with cDNAs encoding GFP-H-Ras61L and Arf6-Q67L-HA. 
Membrane fragments from the post-nuclear supernatant (PNS) were captured with 
anti-HA antibody (IP). Proteins present in the membranes were separated by SDS-
PAGE and detected on immunoblots with anti-HA (for Arf6) and anti-GFP (for GFP-
H-Ras). Asterisk (*) shows position of antibody heavy chain from the antibody used 
for immunoprecipitation. 
G) Cells stably expressing H-Ras61L were transfected with cDNA encoding Arf6-Q67L-
GFP. Membranes from the post-nuclear supernatant (PNS) were captured with anti-
Ras antibody (IP). Proteins present in the membranes were separated by SDS-PAGE 
and detected on immunoblots with anti-Ras and anti-GFP (for Arf-GFP) antibodies. 
H) Anti-HA antibody isolation performed on membrane fragments from the post-nuclear 
supernatant (PNS) of cells expressing H-Ras-61L?-GFP? (IP). Proteins present in the 
sample were separated by SDS-PAGE and detected on immunoblots with anti-GFP 
(for GFP-H-Ras). Asterisk (*) shows position of antibody heavy chain from the 
antibody used for immunoprecipitation. 
Figure 3  EGF exposure results in GFP-RBD recruitment to enlarged endosomes in 
cells expressing H-RasWT and Arf6-Q67L 
Confocal images of cells transfected with cDNAs encoding Arf6-Q67L-HA (unstained), 
cellular H-Ras (red), and the Ras-binding domain from Raf kinase (GFP-RBD, green) 
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to detect GTP-bound H-Ras. At 24 hours after transfection, cells were exposed to 
EGF for the indicated times, fixed, and stained with anti-H-Ras. Arrows indicate H-
Ras or GFP-RBD on plasma membrane; arrowheads indicate H-Ras or GFP-RBD on 
enlarged endosomes that result from expression of Arf6-Q67L. Scale bars = 10 µm. 
A) Control cell that was transfected with all three cDNAs, but not untreated with EGF. 
B) Transfected cell treated with 5 ng/ml EGF for 5 minutes. 
C) Transfected cell treated with 5 ng/ml EGF for 10 minutes. The chevron indicates lack 
of GFP-RBD on some endosomes after 10 minutes exposure to EGF.  
Figure 4  Raf-1 is present on Arf6-containing endosomes 
All scale bars in this figure = 10 µm. 
A) Merged images of H-Ras61L-GFP (green) and endogenous Raf-1 (red) in a cell also 
expressing Arf6-Q67L-HA (unstained). Cells were transfected, then fixed and stained 
with antibody to Raf-1. Arrowheads indicate points where Raf-1 is present on rim of 
enlarged endosomes with H-Ras61L. Vertical z-stack images of each color were 
deconvolved then merged. 
B) NIH 3T3 cells stably expressing H Ras61L were transfected with cDNAs for 
Arf6-Q67L-GFP (green) and Raf1- myc (red). Cells were fixed and stained with 
anti-myc antibody. Vertical Z-stack images of each color were deconvolved.  
C) Cells stably expressing GFP-H-Ras (green) were transfected with cDNAs for 
Raf1-myc (red) and the cellular form Arf6-WT-HA (unstained), fixed, and stained 
with anti-myc antibody. Vertical Z-stack images of each color were deconvolved. 
Arrowheads indicate endosomes with GFP-H-Ras61L and Raf1-myc. 
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D) Cells were transfected with cDNAs  for Arf6-Q67L-GFP (green) and Raf1-myc (red), 
then were fixed and stained with myc antibody. Vertical Z-stack images of each color 
were deconvolved. Raf-myc is absent (cheveron)on Arf6-coated endosomes indicated 
in the right panel (arrowhead) 
Figure 5  H-Ras is present in the perinuclear endosomal recycling center 
All scale bars in this figure = 10 µm. 
A) Confocal images of cell transfected with cDNA for H-Ras61L, treated with 
cycloheximide for 6 hr, exposed to AlexaFluor-transferrin (red) for 45 min, then fixed 
and stained with antibody against H-Ras (green). Arrowheads indicate perinuclear 
accumulation of H-Ras61L or transferrin. 
B) Cell treated as in (A). Boxed area is enlarged at right to show separate vesicles 
(arrowheads) of red and green. 
Figure 6  Endocytosis of KRas4B and ExtRas differs from H-Ras 
All scale bars in this figure = 10 µm. 
A) Confocal images of cell expressing GFP-KRas4B-12V (green) and Arf6-Q67L-HA 
(red) on enlarged endosomes (arrowheads). Cell was transfected with cDNAs for 
GFP-KRas4B-12V and Arf6-Q67L-HA, fixed, and stained with anti-HA antibody. 
B) Merged confocal images of a cell expressing GFP-KRas4B-12V (green) and exposed 
to AlexaFluor-transferrin (red) for 45 minutes, then fixed. Chevron indicates 
perinuclear accumulation of transferrin, but not KRas4B in the endosomal recycling 
center. 
C) Confocal images showing ExtRasWT (red) is present on plasma membrane but not on 
Arf6-WT-GFP enlarged endosomes (green). Chevrons in left panel indicate absence 
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of ExtRas on Arf6-WT-coated endosomes (arrowheads) that can be seen in right 
panel. 
D) Merged confocal images of a cell expressing ExtRas61L (green) after exposure to 
AlexaFluor-transferrin (red) for 45 minutes. Cell then was fixed and stained with 
antibody to H-Ras. Chevron indicates perinuclear accumulation of transferrin, but not 
ExtRas61L, in the endosomal recycling center. 
Figure 7  C-terminal residues of H-Ras or KRas4B proteins can target GFP to the Arf6 
endocytic pathway 
All scale bars in this figure = 10 µm. 
A) Merged images of a cell expressing GFP-H-tail (green) and Arf6-Q67L-HA (red). 
B) Merged images of GFP-K-tail (green) on Arf6-Q67L-HA (red) endosomes.  
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Figures 
Figure 1  H-Ras is absent from early endocytic vesicles of the clathrin-dependent 
pathway 
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Figure 2  H-Ras is present on endosomal membranes that contain MHC-I and Arf6 
 
Fi
gu
re
 2
  H
-R
as
 is
 p
re
se
nt
 o
n 
en
do
so
m
al
 m
em
br
an
es
 th
at
 c
on
ta
in
 M
H
C
-I 
an
d 
A
rf
6 
   145
 
Figure 3  EGF exposure results in GFP-RBD recruitment to enlarged endosomes in 
cells expressing H-RasWT and Arf6-Q67L 
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Figure 4  Raf-1 is present on Arf6-containing endosomes 
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Figure 5  H-Ras is present in the perinuclear endosomal recycling center 
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Figure 6  Endocytosis of KRas4B and ExtRas differs from H-Ras 
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Figure 7  C-terminal residues of H-Ras or KRas4B proteins can target GFP to the Arf6 
endocytic pathway 
B
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Chapter 5 
General Conclusions 
This dissertation describes intracellular trafficking and signal transduction of Ras, a 
member of a small family of G proteins. Ras is activated when it is bound to GTP and 
deactivated when it is bound to GDP. [1, 2] Within the Ras family, there are four major 
isoforms of Ras—NRas, KRas A, KRas B and HRas. Although more than 85% of the 
isoforms are conserved with one another, the isoforms differ from each other in their 
hypervariable region. (Figure 1) [3] 
At the molecular level, by activating its downstream signaling effectors such as RAF and 
PI3K, (Figure 2) [4] Ras functions as a molecular switch that conveys information from the 
extracellular environment to the intracellular environment. 
At a cellular level, Ras activation results in cell proliferation, differentiation, and 
apoptosis depending on the cell type in which Ras is activated. [2] 
Ras posttranslational modifications 
Before Ras can function as a molecular switch, it must first be posttranslationally modified at 
the carboxy terminus. The four amino acids at the carboxy terminus of Ras are often 
described as the CAAX box (C = cysteine, AA = aliphatic amino acid, X = any amino acid). 
Ras posttranslational modifications begin when the cysteine of the CAAX box gains a 
farnesyl lipid group. [5] For KRas, no additional modification is required, but for NRas and 
HRas, further modifications are needed. For example, NRas obtains a single palmitate group 
on cysteine 184 just upstream of the CAAX box, whereas HRas gains palmitates on both 
cysteine 181 and cysteine 184. (Figure 3) Once these modification processes are complete, 
Ras traffics to the plasma membrane and activates its signal transduction cascade that can 
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cause cells to proliferate, differentiate, or die. When the signal transduction cascade is 
constitutively activated, cells can become cancerous. 
The results of the experiments conducted as part of the research reported in the three, 
related articles (chapter 2, 3, and 4 of this dissertation) seem to show that Ras can use the 
plasma membrane and membranes of subcellular organelles as signaling platforms. Recent 
studies demonstrate that signal transduction cascades initiated from endomembranes are 
distinct from one another and from the signal transduction cascade initiated from the plasma 
membrane. This dissertation focuses primarily on trafficking and signaling of HRas even 
though various isoforms of Ras and Ras mutants were used in the experiments reported here. 
Ras intracellular trafficking 
Typically, following the posttranslational modification, NRas and HRas traffic via 
vesicular exocytosis to the plasma membrane. This mode of trafficking begins at the 
Endoplasmic Reticulum (ER) where Ras proteins aggregate toward the ER exit sites. ER exit 
sites are identifiable by accumulations of Coat Protein Complex II (COP II) that are activated 
by ARF1 and Sar1. Once Ras is tethered on the outside of the vesicles, Ras passes through 
the ERGIC, an intermediate, vesiculo-tububular structure, before arriving at the Golgi. [6, 7] 
While some ER-resident proteins have an opportunity to return to the ER via Coat Protein 
Complex I (COP I) coated vesicles, most Ras proteins will continue to travel toward the 
plasma membrane via vesicles and microtubules. [8-10] (Figure 4) 
Although vesicular exocytosis has been described as its primary trafficking mechanism, 
our own findings suggests that Ras traffic via a mechanism that is both Golgi- and vesicle-
independent. While both traditional and the alternative trafficking mechanisms seem to 
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function simultaneously, the majority of the HRas proteins show a strong preference toward 
the alternative trafficking mechanism. 
After Ras activates its signal transduction cascade from the plasma membrane, it can 
either be transiently removed from the plasma membrane by losing its palmitate groups or 
Ras can be more permanently removed by endocytosis. [11-13] There are several different 
vesicular endocytosis mechanisms but Ras typically utilizes a clathrin-independent, 
ARF6-mediated endocytosis. [14, 15] (Figure 5) 
Summary of the Studies 
With the general objective of understanding HRas intracellular trafficking and signal 
transduction cascades in mind, the three publications in this dissertation report examinations 
of HRas endocytosis, exocytosis, and amino acid conservation. These publications are 
summarized here. 
HRas does not need COP I- or COP II-dependent vesicular transport to reach 
the plasma membrane 
This manuscript focuses on HRas exocytosis from the ER to the plasma membrane. 
When HRas was transiently expressed in cells, many did not show the perinuclear 
accumulation that is consistent with Golgi. This was particularly noticeable in HRas that 
were not attached to GFP. Traditional belief dictates that once HRas has been 
posttranslationally modified, it will pass through the ER, then ERGIC, and then the Golgi 
before reaching the plasma membrane via vesicles and microtubule tracks. However, in the 
experiments reported here, the majority of HRas did not accumulate in the Golgi, a finding 
that opens up the possibility of alternative trafficking mechanisms for HRas that are not 
dependent on theGolgi or vesicles. 
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The results seem to indicate that there is, indeed, a Golgi-independent trafficking 
mechanism that is Brefeldin A-insensitive and Sar1-dominant-negative insensitive. Brefeldin 
A (BFA) is a pharmacological reagent that blocks the COP I complex of proteins from 
aggregating, so if exposure to BFA is prolonged, all of the Golgi vesicles retrograde to ER 
and the Golgi eventually disappears. Neither interruption of outward vesicular movement 
with nocodazole nor ablation of COPI or COPII vesicles provided any evidence of non-
traditional vesicles that might carry H-Ras to the plasma membrane. Thus, the data currently 
suggest that this non-classical pathway is non-vesicular. A similar mechanism also occurs 
when Sar1 dominant negative is expressed. Nocodazole, a pharmacological reagent that 
hinders the polymerization/depolymerization cycle of microtubules, was used to verify that 
the Golgi-independent trafficking mechanism is also vesicle-independent.  
Further examination revealed that the Golgi-independent mechanism is also nocodazole 
insensitive, implying that the Golgi-independent trafficking mechanism is also microtubule-
independent. In addition, because vesicles travel along the microtubule tracks, it can also be 
assumed that the Golgi-independent trafficking is non-vesicular. In addition, we 
demonstrated that the Golgi-independent trafficking pathway begins at the ER. Newly 
synthesized HRas located in the ERGIC were not released into the cytosol and trafficked to 
the plasma membrane in the presence of BFA and nocodazole. This suggests that HRas 
proteins in ERGIC are already committed to a vesicular trafficking mechanism. If HRas is 
somewhere before ERGIC, this place is mostly likely to be ER. In terms of their trafficking 
behavior, there were no observable differences between the constitutively active form of 
HRas and cellular form of HRas, which suggests that the activational state of HRas does not 
play a role in HRas trafficking. 
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Golgi-independent trafficking requires conservation of the HRas hypervariable 
region 
This manuscript discusses the properties of HRas that are needed for HRas to utilize the 
non-vesicular, Golgi-independent trafficking mechanism by first establishing that the non-
vesicular trafficking mechanism is available in various types of polarized epithelial cells and 
then showing that the presence of a GFP tag changes normal trafficking preferences for 
HRas. In Chapter 2 we reported that the 10 terminal amino acids of HRas are sufficient to 
enable the to use of the alternative trafficking mechanism to reach the plasma membrane. In 
Chapter 3 we investigated whether palmitoylation is a key property needed in order to utilize 
non-vesicular trafficking. Mono-palmitoylated HRas mutants with substitutions at either 
position 181 or 184 reached the plasma membrane with ease, but used a vesicular trafficking 
mechanism.  
This manuscript also discusses how non-palmitoylated residues in the HRas C-terminus 
are important for protein trafficking and localization. When an HRas mutant that retained all 
of the posttranslational modification sites but the residues in between the two palmitates were 
mutated (HRas CDQCECVLS), HRas was unable to reach the plasma membrane. 
The residues that are far upstream of the CAAX box are also important for HRas 
trafficking. In delta 17 and delta 19 mutants, alanine substitutions were made for the residues 
173–181 and 166–172 respectively. These mutants, like HRas C181S and HRas C184S, were 
able to reach the plasma membrane, but they did not localize to the plasma membrane when 
cells were treated with either BFA or nocodazole. Taken together these results show that 
every residue within the HRas hypervariable region plays a role in either HRas trafficking or 
membrane localization. 
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Internalization of HRas via ARF6-associated endosomal pathway 
This manuscript reports on an investigation of the mechanisms by which HRas and KRas 
are removed from the plasma membrane and trafficked to the Endosomal Recycling Center 
(ERC). Although there are many different types of endocytosis, traditional thought has been 
that HRas and KRas endocytosis occurs predominantly through clathrin-coated vesicles. 
In this study, however, Ras endocytosis was mediated by ADP Ribosylation Factor 6 
(ARF 6 mediated) instead of being clathrin mediated. This study also suggests that the 
activational state of Ras does not affect ARF6-mediated Ras endocytosis, but that Ras 
located on ARF6 endosomes can be activated by one of its upstream regulators, Epidermal 
Growth Factor (EGF). 
When stimulated with EGF, Ras actively localizes to ARF6-coated vesicles and recruits 
Ras Binding Domain of RAF (GFP-RBD). However, a full-length RAF was never visualized 
with HRas on ARF6 coated vesicles, which indicates that Ras is unable to complete its signal 
transduction while in transit through the Mitogen Activated Protein Kinase (MAPK) 
pathway. 
We also examined properties of Ras to understand the requirements for Ras to use the 
ARF6-mediated endocytosis pathway. Our study suggests that both HRas and KRas are able 
to use the ARF6-coated vesicles for endocytosis. Furthermore, the 10 terminal amino acids of 
HRas and the 10 terminal amino acids of KRas 4B each contain sufficient localization signals 
to locate green fluorescence protein (GFP) to vesicular membranes. In other words, the 
cysteines for palmitoylation of HRas and the polylysine residues of KRas are localization 
signals. An interesting finding is that when these two are cut and ligated, they form HRas 
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Ext, which does not use ARF6 vesicles for endocytosis, which suggests that farnesylation of 
cysteine 186 at the CAAX box serves as a trafficking signal during endocytosis. 
Ras in transit on ARF6 vesicles might be able to activate a signal transduction cascade, 
but apparently would not be able to complete the signal transduction and elicit a biological 
response such as cell proliferation. 
Regardless of the endocytosis mechanism, ERC, a circular structure embedded within the 
Golgi, appears to be the final destination for most inward-bound vesicles. Both KRas 4B and 
HRas, but not HRas Ext, were observed in the ERC. HRas Ext lacks the farnesylation 
cysteine, which implies that farnesylation is an important property that dictates Ras 
endocytosis and recycling. 
Biological Implications 
In United States, cancer is the second most common cause of death, and each year 
thousands of new cases are diagnosed. It has been estimated that up to 30% of all cancers are 
caused by mutations in Ras. [16] At a cellular level, Ras activation causes cell proliferation, 
differentiation, and apoptosis. The specificity of the cellular response depends on the 
activated Ras isoform and tissue type. [3] Until recently, it has been thought that the plasma 
membrane is the only platform from which Ras can activate its signal transduction. Now, 
however, research results presented here and elsewhere suggests that Ras can signal from 
various endomembrane platforms which differ from those that are activated at the plasma 
membrane. 
Recent advances in medical science and technology have yielded many new approaches 
to cancer therapies, particularly with regard to the ability of Ras to complete signal 
transduction cascades during endocytosis and in terms of the ability of Ras to complete 
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exocytosis both without the need for COP I or COP II and in a Golgi- and vesicle-
independent manner. These findings suggest possibilities for increasing the effectiveness of 
those cancer therapies, especially in devising novel therapies for cancers that are driven by 
understanding and exploiting Ras lipid modifications, vesicular trafficking to the plasma 
membrane, and signal transduction cascades. 
Suggestions for Future Research 
The possibilities for future research based on the findings reported here can be considered in 
two categories, experiments that would support the research through control groups and 
experiments that would extend the research into new areas. 
Additional control experiments 
In this section, I suggest the following six possibilities for repeating the research reported 
here to enhance the robustness of the research. 
• Would delta 17 and delta 19 alanine substitutions change the overall Ras-mediated 
biological responses? 
• How does dominant negative Ras also use Arf-6-mediated endocytosis? 
• Do Ras accumulate on the ARF6 vesicles when the ERK signaling cascade is 
inhibited? 
• Does palmitoyl transferase recognize the CDQCE mutant as Ras and attach 
palmitates? 
• What effect does the overall charges of amino acids have on Ras trafficking? 
Specifically, because DQ–E amino acid substitutions give Ras proteins an overall 
negative charge, would a mutant with a neutral charge change trafficking or 
membrane localization behavior? 
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• Are there differences in NRas trafficking patterns as compared with HRas trafficking 
patterns? Because palmitoylation is the driving force behind determining Ras 
trafficking behavior, and despite the fact that C184S HRas mimics NRas, do HRas 
and NRas differ in their hypervariable regions, and, if so, how? 
Experiments that extend the research 
The following seven research questions are by no means inclusive, but seem like logical 
routes toward extend our understanding of Ras trafficking and signal transduction. 
• What are the possibilities for Ras non-vesicular endocytosis? 
• Does NRas use Arf-6 vesicles in endocytosis? 
• What is the exact trafficking mechanism behind the Ras acylation cycle? 
• To what extent is the Ras hypervariable region conservation required during 
endocytosis? 
• What is the mechanism behind KRas trafficking and how does it compare with HRas 
Golgi-independent exocytosis? 
• Can Ras form dimers and oligomers with itself or with chaperones and/or escorts 
during exocytosis and endocytosis? 
• What, if any, roles do the conserved domains of Ras play intracellular trafficking and 
signal transduction? 
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Figure Legends 
Figure 1  Ras domains 
Structurally Ras proteins are divided into conserved domains and hypervariable regions. 
The conserved domain begins at the N-terminus and extends to residue 165. This 
domain is well conserved all Ras isoforms. Within the conserved domain there are 
two switch regions (switch 1 and switch 2) where GTP/GDP exchange occurs. 
Mutations in the switch regions can result in constitutively active or dominant 
negative mutants. The hypervariable region begins at the residue 166 and ends at the 
C-terminus. This region is posttranslationally modified with lipid groups. KRas 4 B 
acquires a farnesyl group at the CAAX box, whereas KRas A and NRas acquire an 
additional palmitate just upstream. HRas acquires two palmitates in addition to the 
farnesyl. 
Figure 2  Ras-mediated MAPK signal transduction pathway 
The best studied Ras-mediated signal transduction is the Mitogen Activating Protein 
Kinase Pathway (MAPK). To begin the signal transduction cascade by activating Ras, 
a GEF exchanges a GDP for a GTP, then the Ras downstream effectors RAF, MEK 
and ERK activated by addition of phosphate  groups. Activation of this signal cascade 
leads to cell proliferation, differentiation, and apoptosis. After initiating the MAPK 
signal transduction pathway, Ras becomes inactive by exchanging its GTP for a GDP. 
This exchange is facilitated by GAP enzymes. 
Figure 3  HRas C-terminus modifications 
A newly synthesized HRas must be posttranslationally modified at the C-terminus before 
acting as a molecular switch. HRas posttranslational modification begins with the 
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addition of a farnesyl group at the C of the CAAX box by the farnesyl transferase. 
Then the —AAX of the CAAX box is cleaved by the Ras Converting Enzyme 1 
(RCE 1), and the newly exposed C-terminus is methylated by the Isoprenyl cystein 
Carboxy Methyl Transferase (Icmt). Finally, two additional palmitates are added to 
the upstream cysteines by palmitoyl transferase and complete HRas C-terminus 
modifications. 
Figure 4  Ras exocytosis 
A newly made Ras protein is located in the cytosol. Ras posttranslational modification 
begins with addition of a farnesyl group by the farnesyl transferase. This lipid 
modification kinetically traps HRas on the cytosolic surface of the ER membrane. 
Here the CAAX box is cleaved and two palmitates are added, so HRas 
posttranslational modification is complete. A mature HRas can move out to the 
plasma membrane by a vesicular trafficking mechanism, which includes passage 
through ERGIC and Golgi. Ras can also traffic to the plasma membrane directly from 
ER in a non-vesicular trafficking mechanism. KRas, which only contains a farnesyl 
group, localizes to the plasma membrane from ER in an unknown trafficking 
mechanism. 
Figure 5  Endocytic vesicle trafficking 
There are two major endocytic vesicle trafficking pathways—clathrin and non-clathrin. 
In the clathrin trafficking pathway, clathrin coated vesicles are released from the 
plasma membrane and becomes an Early Endosome (EE). An EE can continue its 
trafficking into the cytosol and become a late endosome or it can merge with other 
vesicles and form a merged endosome. A merged endosome can either traffic to the 
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Endosomal Recycling Center (ERC) embedded in the Golgi or the merged endosome 
can traffic to the lysosmes along with late endosomes where the endosomal contents 
are degraded. 
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Figure 5 Ras endocytosis 
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Appendix 
The CD-Rom that accompanies this dissertation contains a Windows Media Player movie 
file (.mwv) that shows GFP HRas Q61L granules moving intracellularly as described in 
“HRas Does Not Need COP I or COP II-Dependent Vesicular Transport to Reach the Plasma 
Membrane.” (dissertation Chapter 2)  
These are the system requirements for playing this file: 
Windows systems require Windows NT®4.0 or later, Windows 98 or later and Windows 
Media Player 6.4 or later, Netscape Navigator 7.0 or later, or Microsoft Internet Explorer 5.0 
or later. 
Apple Macintosh systems require Apple Mac OS X or later, Windows Media Player for 
Mac OS X, or Internet explorer 5.2.2 or later. 
For a free download of Windows Media Player for Mac or other platforms, visit 
http://www.microsoft.com/windows/windowsmedia/download 
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